

# **Highlights In This Issue...**

Comprehensive Error Rate Testing (CERT) This Quarter's "A Physician's Focus" Topic	3
CMS Posts Correct Coding Initiative Edits On Intern Providers Can Now View CCI Code Pairs Online	
Medicare Covered Drugs Quarterly Pricing Update	20
Physical Therapy/Occupational Therapy Changes to Code List for Therapy Services	26
Home Health Consolidated Billing Annual Update of HCPCS Codes Used for Home Health Consolidated Billing Enforcement	
Skilled Nursing Facility Consolidated Billing 2004 Annual Update for Skilled Nursing Facility Consolidated Billing	39
HIPAA – The Health Insurance Portability and Accountability Act Contingency Plan for Health Insurance Portability and Accountability Act Transaction and Code Sets	43
Connecticut Medical Review Comprehensive Data Analysis; New, Revised, and Retired LMRPs	46
Florida Medical Review Comprehensive Data Analysis; New, Revised, and Retired LMRPs	61

### Features

Connecticut and Florida	Connecticut Only
A Physician's Focus	Medical Review
Coverage/Reimbursement 10 General Information 30 HIPAA and EMC 43	Claims

To receive quick, automatic notification when new publications and other To receive quice, automate nonreading men ducations and other items of interest are posted to our provider education Web sites, subscribe to our FCSO eNews mailing list. It's very easy to do; go to *www.connecticutmedicare.com* or *www.floridamedicare.com*, click on the "Join our Electronic Mailing List FCSO eNews" bar and follow the prompts. The FCSO eNews is sent at least every other week, more frequently as required.





The *Medicare B Update!* should be shared with all health care practitioners and managerial members of the provider/supplier staff. Publications issued beginning in 1997 are available at no cost from our provider education Web sites: www.connecticutmedicare.com and www.floridamedicare.com.

Routing Suggestions:

- Physician/Provider
  - Office Manager
- Billing/Vendor

- Nursing Staff
- Other

# TABLE OF CONTENTS

#### A Physician's Focus

#### About the Update!

About the Connecticut and Florida Medicare B Update! 4 Advance Beneficiary Notices (ABNs)
Claims Addition of Three New Diagnosis Codes to be Effective
as Part of the October 1, 2003, ICD-9-CM Update 6
CMS Posts Correct Coding Initiative Edits On Internet . 6
HMO Claims Are Returned as Unprocessable 6
Health Professional Shortage Areas7
Jurisdictional Pricing Requirement for New Place of

- Service (POS) Codes ...... 8 Requirements for Medicare Hearings-Reminder to
- Providers ......8 "Split-Split" Care—Clarification of Date of Service Requirement ......9
- Timeframe Filing Provision on Reconsiderations and Appeals-Reminder to Providers ......9 Timely Claim Filing Guidelines for All Medicare

#### Claims – Florida Only Invali

d or Inappropriate Modifiers	

### Coverage/Reimbursement

#### Medicare Physician Fee Schedule (MPFS)/ Healthcare Common Procedure Coding System (HCPCS)

care Common Procedure Coding System (HCPCS)
Medicare Physician Fee Schedule Payment Policy
Indicators 10
Ambulance
Adjustment to the Rural Mileage Payment Rate for
Ground Ambulance Services
Payment Policy When More Than One Patient Is
Onboard an Ambulance
Medicare Covered Drugs—Quarterly Pricing Update 20
Durable Medical Equipment
New Requirements - Physician's Order and Certifi-
cates of Medical Necessity (CMNs)
End-stage Renal Disease (ESRD)
MCM Updates Pertaining to Dialysis Services—
Correction to Effective Date
Immunizations
2003 Allowances for Administration of Influenza
Virus, Pneumococcal Pneumonia, and
Hepatitis B Vaccines
New Diagnosis Code for Influenza Virus Vaccine
Claims
Payment Amount for the Influenza Virus Vaccine 22
Pneumococcal Pneumonia Vaccine (PPV)
PaymentIncrease Effective October 1, 2003 23
Laboratory/Pathology
Guidelines for Medicare Part B Laboratory Testing . 23
Changes to the Laboratory National Coverage Deter-
mination Edit Software for January 1, 2004
Fecal Leukocyte Examination Under a ĆLIA Certificate for
Provider-Performed Microscopy24
Fecal Leukocyte Examination Under a CLIA Certificate for
Provider-Performed Microscopy (PPM) Procedures
During 2003
New CLIA Waived Tests
Diagnosis Code for Screening Pap Smear and Pelvic
Examination Services—Effective Date
Laboratory Services Not Covered by Medicare 26
Physical Therapy/Occupational Therapy
Changes to Code List for Therapy Services
Radiology
Billing Mammography with CAD Codes
New Modifiers for Transportation of Portable X-Ray
Equipment
Surgery
National Coverage Determination—Implantable
Automatic Defibrillators
Processing and Payment of Incomplete Screening
Colonoscopies
Other Services and Procedures
Coverage of Hyperbaric Oxygen (HBO) Therapy for the
Treatment of Diabetic Wounds of the Lower
Extremities—Clarification

Coverage/Reimbursement – I	Florida Only
2003 Carrier-Priced Codes for Florida-	Correction 15

### Conoral Information

General Information
Fraud, Waste, and Abuse
Office of Inspector General Special Advisory Bulletin,
April 2003—Contractual Joint Ventures
New England Benefit Integrity Support Center Selected
as New Program Safeguards Contractor for
Connecticut
Financial Services
Overpayment Interest Rate
Home Health Consolidated Billing
Correction to Quarterly Update of HCPCS Codes
Used for Home Health Consolidated Billing
Enforcement
Annual Update of HCPCS Codes Used for Home
Health Consolidated Billing Enforcement 34
Managed Care (Medicare+Choice)
Dilling Instructions for Claims for Ventricular Assist
Billing Instructions for Claims for Ventricular Assist
Devices for Beneficiaries in a Medicare+Choice
Plan
Medicare Secondary Payer (MSP)
Clarification of Policy for the Medicare Secondary Payer
Working Aged Provision
Provider Enrollment
What's New from Enrollment
Skilled Nursing Facility (SNF) Consolidated Billing (CB)
Guidelines for Skilled Nursing Facility (SNF) Consoli-
dated Billing
2004 Annual Update for Skilled Nursing Facility
Consolidated Billing 39
General Information
2004 Holiday Schedule 39
Interactive Voice Response Unit Operating Guide
(Connecticut)
(Florida) 40
The New Online CMS Manual System Announcement 41
HIPAA – The Health Insurance Portability

# and Accountability Act

Contingency Plan for Health Insurance Portability and
Accountability Act Transaction and Code Sets 43
Medicare Electronic Data Interchange (EDI) Enroll-
ments 43
HIPAA Privacy Medical Records 44

### **Connecticut Medical Review**

Medical Review Table of Contents	46
Advance Notice Statement	46
Comprehensive Data Analysis	47
Local Medical Review Policy (New)	49
Local Medical Review Policy (Revised)	54
Local Medical Review Policy (Retired)	59
Corrections	59

#### **Connecticut Educational Resources**

Free Medicare Part B Evaluation and Management 

### **Florida Medical Review**

Medical Review Table of Contents	61
Advance Notice Statement	61
Comprehensive Data Analysis	62
Local Medical Review Policy (New)	
Local Medical Review Policy (Revised)	70
Local Medical Review Policy (Retired)	77
Corrections	77

#### **Florida Educational Resources**

Medicare at the Movies ..... 78 Medicare Education & Training Event Registration Form 79

#### Order Form – 2004 Part B Materials ...... 80 Index to Connecticut and Florida Medicare B Update! for

### 

Florida	89

# Medicare B Update!

Vol. 2, No. 1 FirstQuarter 2004

Publications Staff Bill Angel Kimberly McCaw Millie C. Pérez

The Medicare B Update! is published quarterly by the Medicare Publications Department of First Coast Service Options, Inc., to provide timely and useful information to Medicare Part B providers in Connecticut and Florida.

Questions concerning this publication or its contents may be directed in writing to:

Medicare Part B Publications PO Box 45270 Jacksonville, FL 32232-5270

CPT codes, descriptors, and other data only are copyright 2002 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS apply. No fee schedules, basic units, relative values, or related listings are included in CPT. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for data contained or not contained herein.

ICD-9-CM codes and their descriptions used in this publication are copyright© 2003 under the Uniform Copyright Convention. All rights reserved.

#### Third party Web sites:

This document contains references to sites operated by third parties. Such references are provided for your convenience only. FCSO does not control such sites, and is not responsible for their content. The inclusion of these references within this document does not suggest any endorsement of the material on such sites or any association with their operators.

# **A** Physician's Focus

### Comprehensive Error Rate Testing (CERT)

First Coast Service Options. Inc. (FCSO) is a traditional Medicare contractor with claims processing responsibility as a carrier (Medicare Part B) in Connecticut and Florida, and as a fiscal intermediary (Medicare Part A) in Florida. Other Medicare contractors that pay claims include the durable medical equipment regional carriers (DMERC) and the regional home health and hospice intermediaries (RHHI). The Centers for Medicare & Medicaid Services (CMS) also utilizes contractors that do not have direct claims processing responsibility such as quality improvement organizations (QIO) and program safeguards contractors (PSC). PSCs focus on certain aspects of the Medicare program such as specific types of medical review and fraud detection and prevention. One PSC, AdvanceMed of Richmond, Virginia, has responsibility for CERT- the comprehensive error rate testing program.



Error rates are not new to the Medicare program. The Office of the Inspector General (OIG) has been reporting error rates based on medical reviews for services during 1996-2002. A national error rate has been reported based on a sample of claims paid by contractors during part of a given year. The paid claims of 50 beneficiaries were reviewed for selected contractors. Some 5,000-8,000 claims were reviewed yearly. The error rates reported ranged from 13.8% in 1996 to 6.3% in 2002.

The CERT will produce several error rates based on medical reviews done by the CERT contractor for services performed in 2001 forward. Because of the different methodology and definitions, comparison to previously reported OIG rates will not be valid. A much larger sample, approximately 200 claims processed monthly by each contractor, will be requested from physicians and providers in the respective contractor's jurisdiction. Eventually, some 200,000 paid or denied claims will be assessed per year, and all contractors that pay claims will be included in the process. Several error rates will be reported, including:

- paid claims error rate (dollars paid incorrectly / total dollars paid),
- *claims processing error rate* ([claim lines paid incorrectly + claim lines denied incorrectly] / total claim lines processed), and
- provider compliance rate (dollar value of claims submitted correctly / dollar value of total claims submitted).

The findings will be used to develop and supplement programs and processes directed at improving claims processing and provider billing practices. The goal is to pay claims correctly.

A major problem noted in preliminary reports is the failure of physician offices and other providers to respond to requests for medical records. FCSO data from AdvanceMed shows 30-75% of line item errors are due to failure to submit documentation. If you do not provide documentation, AdvanceMed will determine that your claim was paid in error and the contractor will request a refund for that claim. If you submit the documentation and an error is noted, you are only liable for the amount in error and no further assessment or audit will be done. Documentation will only be requested on previously processed claims.

The CERT program may take a few years to develop benchmarks. However, CERT will have the most benefit for the Medicare program if physicians and providers submit documentation when requested. If one or more of your claims are sampled, a letter from AdvanceMed will provide the details regarding the needed information and the name of a contact person. The CERT Web site *is www.psccert.org*. FCSO looks forward to using the CERT program to improve payment of claims for physicians and providers.

James J. Corcoran, MD, MPH

FCSO Chief Medical Director James.Corcoran@fcso.com

Third party Web sites. This document contains references to sites operated by third parties. Such references are provided for your convenience only. BCBSF and/or FCSO do not control such sites, and are not responsible for their content. The inclusion of these references within this document does not suggest any endorsement of the material on such sites or any association with their operators.

# The FCSO Medicare B Update!

# About the Connecticut and Florida Medicare B Update!

The *Medicare B Update!* is a comprehensive magazine published quarterly by First Coast Service Options, Inc. (FCSO) for all Part B providers in Connecticut and Florida. In accordance with notification requirements established by the Centers for Medicare & Medicaid Services, approximate delivery dates for fiscal year 2004 are:

Publication Name	Publication Date	Effective Date of Changes
First Quarter 2004	Mid-November 2003	January 1, 2004
Second Quarter 2004	Mid-February 2004	April 1, 2004
Third Quarter 2004	Mid-May 2004	July 1, 2004
Fourth Quarter 2004	Mid-August 2004	October 1, 2004

Important notifications that require communication in between these dates will be posted to the FCSO Medicare provider education Web sites, *www.connecticutmedicare.com* and *www.floridamedicare.com*. In some cases, additional unscheduled special issues may be published.

### Who Receives the Update?

Anyone may view, print, or download the *Update!* from our provider education Web site(s). Providers who cannot obtain it from the Internet are required to register with us to receive a complimentary hardcopy (please see the hardcopy registration form in the Third Quarter 2003 issue).

Distribution of the *Update!* in hardcopy format is limited to individual providers and professional association (PA) groups who have billed at least one Part B claim to either Connecticut or Florida Medicare for processing during the twelve months prior to the release of each issue. Providers meeting these criteria are eligible to receive a complimentary copy of that issue, *if a technical barrier exists that prevents them from obtaining it from the Internet and they have returned a completed hardcopy registration form to us.* 

For additional copies, providers may purchase a separate annual subscription for \$70. All issues published since 1997 may be downloaded from the Internet, free of charge.

FCSO Medicare Part B uses the same mailing address for *all* correspondence, and cannot designate that the *Update!* be sent to a specific person/department within a provider's office. To ensure continued receipt of all Medicare correspondence, providers must keep their addresses current with the Medicare Provider Registration department.

### **Clear Identification of State-Specific Content**

Each article in the combined publication clearly indicates whether the topic is applicable to both Connecticut and Florida, Connecticut only, or Florida only. Articles common to both states appear at the beginning of the publication. Within common articles, references to phone numbers, addresses, reimbursement amounts, past publications, etc., are state-specific as appropriate. Content specific to Connecticut is next, followed by content specific to Florida. Connecticut and Florida local medical review policy (LMRP) summaries are maintained in separate sections.

### **Publication Format**

The Update! is arranged into four distinct sections. Following the table of contents, a letter from the Carrier Medical Director, and an administrative information section, the Update! begins with content applicable to both states, as noted above. Within this section, information is categorized under claims, coverage/reimbursement, electronic media claims, or general information. Information in these sections is categorized as follows. The claims section provides claim submission requirements and tips, plus correspondence (appeals and hearings) information. The coverage/reimbursement section discusses specific CPT and HCPCS procedure codes. It is arranged by specialty categories (not specialties). For example, "Mental Health" would present coverage information of interest to psychiatrists, clinical psychologists, and clinical social workers, rather than listing articles separately under individual provider specialties. Also presented in this section are changes to the Medicare physician fee schedule, and other pricing issues. The section pertaining to electronic media claim (EMC) submission also includes information pertaining to the Health Insurance Portability and Accountability Act (HIPAA). The general information section includes fraud and abuse, provider registration, and Medicare Secondary Payer topics, plus additional topics not included elsewhere.

The two state-specific sections may include some or all of the above topics, dependent upon information being applicable to one site but not the other. **Local medical review** and **comprehensive data analysis** will *always* be state-specific, as will the **educational resources** section.

**Indexes** to the year's previous issues of the *Update!* plus important **addresses**, **phone numbers**, and **Web sites** are listed for each state in the back of the publication.

# The *Medicare B Update!* Represents Formal Notice of Coverage Policies

Articles included in each *Update!* represent formal notice that specific coverage policies either have or will take effect on the date given. Providers who receive each issue are expected to read, understand, and abide by the policies outlined in this document to ensure compliance

# Advance Beneficiary Notices (ABNs)

Medicare Part B allows coverage for services and items deemed medically reasonable and necessary for treatment and diagnosis of the patient. For some services, to ensure that payment is made only for medically necessary services or items, coverage may be limited based on one or more of the following factors (this list is not inclusive):

- Coverage for a service or item may be allowed only for specific diagnoses/conditions. Always code to the highest level of specificity.
- Coverage for a service or item may be allowed only when documentation supports the medical need for the service or item.
- Coverage for a service or item may be allowed only when its frequency is within the accepted standards of medical practice (i.e., a specified number of services in a specified timeframe for which the service may be covered).

If the provider believes that the service or item may not be covered as medically reasonable and necessary, the patient must be given an acceptable advance notice of Medicare's possible denial of payment if the provider does not want to accept financial responsibility for the service or item. ABNs advise beneficiaries, before items or services actually are furnished, when Medicare is likely to deny payment. ABNs allow beneficiaries to make informed consumer decisions about receiving items or services for which they may have to pay out-ofpocket, and to be more active participants in their own health care treatment decisions. An ABN must meet the following requirements:

- The ABN must be on an approved Form CMS-R-131 (see the following section, "New Patient Liability Notice").
- The ABN must be given in writing, in advance of furnishing the service or item.
- The ABN must include the patient's name, date(s) and description of the service or item, and the reason(s) why the service or item may not be considered medically reasonable and necessary (e.g., the service is not covered based on the patient's diagnosis, the frequency of the service was in excess of accepted standards of medical practice, etc.).

with Medicare coverage and payment guidelines. **The** date the *Update!* is posted to the Web site is considered the notice date, in the event there is a dispute over whether a provider received advance notice regarding coverage of a specific service and the financial liability for it.

- The notice must be signed and dated by the patient, indicating the patient assumes financial responsibility for the service if payment is denied as being not medically reasonable and necessary for reason(s) indicated on the ABN. The signature of the provider of service is not required.
- The ABN should be maintained with the patient's medical record.

### **New Patient Liability Notice**

Form CMS-R-131 is the new approved ABN, *required for services provided on or after January 1, 2003.* Form CMS-R-131 was developed as part of the Centers for Medicare & Medicaid Services' (CMS) Beneficiary Notices Initiative (BNI), and was approved by OMB (Office of Management and Budget) on June 18, 2002. The new ABNs are designed to be more beneficiary-friendly, more readable and understandable, with patient options more clearly defined.

There are two ABN forms - the General Use form (CMS-R-131G) and the Laboratory Tests form (CMS-R-131L). Both are standard forms that *may not be modi-fied*; however, both contain customizable boxes for the individual requirements of users, following the guidance in CMS Program Memorandum (PM) AB-02-114.

Reproducible copies of Form CMS-R-131 ABNs (in English and Spanish) and other BNI information may be found on CMS's BNI Web site at *www.cms.hhs.gov/medicare/bni*.

### **ABN Modifiers**

When a patient is notified in advance that a service or item may be denied as not medically necessary, the provider must annotate this information on the claim (for both paper and electronic claims) by reporting modifier **GA** (waiver of liability statement on file) or **GZ** (item or service expected to be denied as not reasonable and necessary) with the service or item.

Failure to report modifier **GA** in cases where an appropriate advance notice was given to the patient may result in the provider having to assume financial responsibility for the denied service or item.

Modifier **GZ** may be used in cases where a signed ABN is *not* obtained from the patient; however, when modifier **GZ** is billed, the provider assumes financial responsibility if the service or item is denied.

*Third party Web sites.* This document contains references to sites operated by third parties. Such references are provided for your convenience only. BCBSF and/or FCSO do not control such sites, and are not responsible for their content. The inclusion of these references within this document does not suggest any endorsement of the material on such sites or any association with their operators.

## ABOUT THE UPDATE!

# CLAIMS

# Addition of Three New Diagnosis Codes to be Effective as Part of the October 1, 2003, ICD-9-CM Update

The National Center for Health Statistics (NCHS) has added three new diagnosis codes to annual update to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), effective for services rendered on or after October 1, 2003. The new codes are:

079.82	SARS-associated coronavirus
480.3	Pneumonia due to SARS-associated
	coronavirus
V01.82	Exposure to SARS-associated
	coronavirus

The CMS Web site, http://www.cms.hhs.gov/ medlearn/icd9code.asp, has been updated with the new ICD-9-CM diagnosis codes. If you wish to have an updated full diagnostic addendum and index when it is completed, you must download it from the NCHS Web site at www.cdc.gov/nchs/icd9.htm. The NCHS Web site will be updated shortly with the new codes.

Source: CMS Transmittal AB-03-129, CR 2842

Third party Web sites. This document contains references to sites operated by third parties. Such references are provided for your convenience only. BCBSF and/or FCSO do not control such sites, and are not responsible for their content. The inclusion of these references within this document does not suggest any endorsement of the material on such sites or any association with their operators.

# **CMS Posts Correct Coding Initiative Edits On Internet**

The Centers for Medicare & Medicaid Services (CMS) has now made it easier for physicians and other providers to bill properly and be paid promptly for their services to Medicare beneficiaries. CMS has posted on its Web site the automated edits used to identify questionable claims and adjust payments to reflect what would have been paid if the claim had been filed correctly. The edits, known as the National Correct Coding Initiative (NCCI), identify pairs of services that normally should not be billed by the same physician for the same patient on the same day. The NCCI also promotes uniformity among the contractors that process Medicare claims in interpreting Medicare payment policies.

While the NCCI is one of the cornerstones of CMS' efforts to ensure that Medicare and beneficiaries do not pay twice for the same service or for duplicative services, CMS believes physicians should have easy access to the edits CMS uses to identify incorrect claims.

The NCCI includes two types of edits. One set – the comprehensive/component edits – identifies code pairs that should not be billed together because one service inherently includes the other. The other – the mutually exclusive edits – identifies code pairs that, for clinical reasons, are unlikely to be performed on the same patient on the same day. For example, a mutually exclusive edit might identify two different types of testing that yield equivalent results.

Until today, the NCCI edits have been available to physicians and other providers on a paid subscription basis, but now they are available to anyone with a personal computer.

The NCCI edits will be posted as a spreadsheet that will allow users to sort by procedural code and by effective date. A "Find" feature will allow users to look for a specific code. The edit files are indexed by procedural code ranges for easy navigation. The new Web page also includes links to documents that explain the edits: the NCCI Policy Manual for Part B Medicare Carriers, Medicare Carriers Manual, and the NCCI Question and Answer page.

CMS developed the NCCI to promote national correct coding by physicians and other providers and to ensure appropriate payments for Medicare services. The coding policies developed are based on coding conventions defined in the American Medical Association's *CPT* (*Current Procedural Terminology*) manual, national and local policies and edits, coding guidelines developed by national medical specialty societies, analysis of standard medical and surgical practice, and review of current coding practice. The NCCI is updated quarterly.

The NCCI edits are posted at *http://cms.hhs.gov/ physicians/cciedits/default.asp.* 

# HMO Claims Are Returned as Unprocessable

It is the responsibility of the beneficiary and his or her provider to ensure that claims are sent to the correct insurer. FCSO does not forward claims submitted to us incorrectly on behalf of beneficiaries who are members of a Health Maintenance Organization (HMO) to the HMO; such claims are returned as unprocessable. As a reminder, claims returned as unprocessable are not afforded appeal rights.

# Claims for Services Furnished to a Beneficiary Who is a Member of an HMO for only a Portion of the Claim

Medicare carriers sometimes receive claims when the beneficiary is a member of an HMO that include services furnished when the beneficiary *was* a member, and services furnished when the beneficiary *was not* a member of an HMO. In such cases, the non-member portion of the claim is processed; the HMO portion is returned as unprocessable with instructions for the service provider to submit a claim to the beneficiary's HMO for those services.

Source: CMS Transmittal 1792, CR 2473; MCM 4267.1

## **Health Professional Shortage Areas**

Physicians are eligible for a 10% bonus when they render service(s) in certain medically underserved areas. These areas, known as Health Professional Shortage Areas (HPSAs), may cover an entire county or a portion of a county or city, and are designated as either rural or urban HPSAs. HPSA designations are made by the Division of Shortage Designation (DSD) of the Public Health Service (PHS).

The incentive payments are based on 10% of the paid amount for both assigned and nonassigned claims for services performed by the physician. The incentive payment is not made on a claim-by-claim basis; rather, payments are issued quarterly.

### Eligibility

A physician is eligible for the HPSA incentive payment *when services are furnished in an area designated as a HPSA*, regardless of where the physician's office is located. For example, a physician's office may be located in an area not designated as a HPSA; however, the physician may treat a patient in a nursing facility located in a HPSA. In this instance, the physician would be eligible for the HPSA incentive payment. Likewise, the physician's office may be in a HPSA; however, the physician may treat a patient in his/ her home that is not located in a HPSA. In this case, the physician is *not* eligible for the HPSA incentive payment.

Only physicians are eligible for the HPSA incentive payments. The following degrees/credentials are considered physicians eligible for the incentive payments: M.D., D.O., D.C., D.P.M., D.D.S., and O.D.

### **Claims Filing Requirements**

To report services furnished in a HPSA, one of the following procedure code modifiers should be reported with the service:

QBPhysician service rendered in a rural HPSAQUPhysician service rendered in an urban HPSA

In addition, item 32 of Form CMS-1500 (or electronic equivalent) must be completed when either the QB or QU modifiers is billed. The physical location where the service was furnished must be indicated, if it is other than the patient's home.

### **Appeal of HPSA Incentive Payments**

The incentive payments do not include remittance advice notices; only a list of the claims to which the incentive payment applies is provided with the payment. As a result, physicians have not been provided with an opportunity to challenge the amounts of their HPSA incentive payments on nonassigned claims or to challenge nonassigned claims where incentive has not been paid. CMS has provided clarification of these issues:

entis has provided charmenton of these issues.

- In cases where a physician is not satisfied with the amount of the incentive payment on either assigned or nonassigned claims, he or she may request a review of the incentive payment. The review request must be made within 60 days of the date when the incentive payment was issued.
- In cases where an incentive payment was not made on a claim (assigned or nonassigned), but the physician believes that one should have been made, he or she

may request a reopening of that particular claim. The request must be within one year of the claim payment.

**Note**: If the physician is unsure of the date a nonassigned claim was *processed*, the request for reopening may be made within one year of the date the claim was *submitted*, to ensure the request for the reopening is made within the one-year time limit.

### **Geographic HPSA Designations**

The following are counties/area names/parts designated as geographic HPSAs (and therefore eligible for the HPSA bonus payment), as of July 3, 2003.

### Connecticut

Fairfield/
 Southwest Brid

Southwest Bridgeport/ Census tracts (C.T.) 0712.00, 0706.00, 0705.00, 0702.00, 7070.00, 0704.00, 0710.00, 0708.00, 0711.00, 0703.00, 0709.00 Central/East Bridgeport/ C.T. 0744.00, 0738.00, 0713.00, 0714.00, 0742.00, 0741.00, 0743.00, 0715.00, 0735.00, 0740.00, 0717.00, 0736.00, 0716.00, 0739.00 Central Norwalk/ C.T. 0440.00, 0441.00, 0444.00, 0445.00

Hartford/ North Central Hartford/ C.T. 5044.00, 5014.00, 5022.00, 5020.00, 5009.00, 5037.00, 5017.00, 5012.00, 5034.00, 5031.00, 5033.00, 5035.00, 5040.00, 5005.00, 5039.00, 5042.00, 5041.00, 5018.00, 5016.00, 5008.00, 5036.00, 5038.00, 5032.00, 5011.00, 5021.00, 5016.00, 5013.00, 5015.00, 5010.00 Charter Oak Terrace/Rice Heights/ C.T. 5030.00, 5049.00, 5028.00, 5019.00, 5046.00, 5003.00, 5029.00, 5002.00, 5001.00, 5027.00, 5004.00, 5045.00, 5043.00

- New Haven/ Fair Haven/ C.T. 1421.00, 1423.00, 1424.00, 1426.01, 1426.02, 1425.00, 1422.00
- New London/ Central Groton/ C.T. 7028.00, 7027.00, 7023.00, 7022, 00, 7025.00

### Florida

- Bradford
- Clay/
  - Keystone Heights division
- Dixie
  - Escambia / Atmore (AL/FL)/ C.T. 0039.00, 0038.00, and 0040.00
- Gadsden
- Glades
- Hardee
- Hendry/
  - Labelle/ C.T. 9604.00, 9603.00
- Holmes
- Lafayette
- Madison
- Martin/
  - Indiantown/
  - Indiantown division
- Sumter
- Suwannee
- Wakulla
- Walton
- Washington

### FLORIDA ONLY

### **Invalid or Inappropriate Modifiers**

Effective for claims processed on or after November 3, 2003, billing invalid or inappropriate modifiers will result in Claims being **returned as unprocessable**. This applies to the following scenarios:

- 1. modifier invalid
- 2. discontinued modifier submitted after date of discontinuance
- 3. new modifier submitted before implementation date
- 4. incorrect or inappropriate procedure-to-modifier combination
- 5. modifier required but not submitted

The examples below are common errors that will cause claims to be returned as unprocessable:

- Modifier billed more than once for the same line item (e.g., 71020 26 26; 80061 QW QW). This is an invalid procedure-to-modifier combination.
- Claims submitted with '00' in the modifier field; this is not a valid modifier.
   (Note to providers who bill electronically: if your billing software or vendor is 'zero-filling' the modifier fields when no modifier is to be indicated, this must be corrected.)
- Modifier Q1 is an old modifier that was once used generally by podiatrists; it was discontinued effective September 30, 1997, yet continues to be billed.
- Use of modifier 26 with procedure codes that are professional services by description, e.g., *CPT 93010* (*Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only*), or use of modifier TC with codes that are technical-only, e.g., *93012 (Telephonic transmission of post-symptom electrocardiogram rhythm strip(s), 24-hour attended monitoring, per 30 day period of time; tracing only*) [emphasis added].
- Spaces between modifier fields and/or in the modifier field, which causes the modifier to appear as a one-digit (and, therefore, invalid) modifier.

For more information regarding unprocessable claims, please refer to the Fourth Quarter 2002 *Medicare B Update!* (pages 6-11). As a reminder, claims returned as unprocessable must be corrected and resubmitted. Since such claims were not accepted, no appeal rights exist.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Jurisdictional Pricing Requirement for New Place of Service (POS) Codes

Information concerning new POS codes was published in the Fourth Quarter 2003 *Medicare B Update!* (pages 57-61). Since then, it has come to our attention that several of the new POS codes are subject to jurisdictional pricing rules. The new POS codes affected are:

- 13 Assisted Living Facility
- 14 Group Home
- 49 Independent Clinic
- 57 Non-residential Substance Abuse Treatment Facility

For these POS, providers *must* enter the name and complete address of the facility where the services were performed in Item 32 of Form CMS-1500 or electronic equivalent. A complete address includes the ZIP code. The ZIP code allows carriers to determine the correct pricing locality for claims payment purposes. Claims received without a name and complete address in Item 32 will be considered incomplete and will be returned as unprocessable. Claims returned as unprocessable are not afforded appeal rights; such claims must be corrected and resubmitted.

# Requirements for Medicare Hearings—Reminder to Providers

To help reduce the number of hearing requests dismissed each month, and to handle your requests quicker, please remember that a request for a Medicare hearing (Part A or Part B) *must* meet a number of requirements before the request can be accepted:

- the service at issue must have been reviewed (appealed),
- the hearing request must be made within six months of the date of the review determination, and
- the amount in controversy must be at least \$100.00.

Under the aggregation rules, claims may be combined to meet the amount in controversy requirement. When requesting a hearing officer hearing the provider **must** clearly state that he/she is aggregating claims to meet the amount in controversy requirement **and** the provider must specify in the appeal request the specific claims that are being aggregated. If the request for the hearing officer hearing does not specifically state that the claims are being aggregated, and/or does not list the specific claims being aggregated, each claim will be treated as an individual request for a hearing; those that do not meet the amount in controversy requirement will be dismissed.

## "Split-Split" Care—Clarification of Date of Service Requirement

We published an article pertaining to billing for "split-split" care in the Fourth Quarter 2003 *Medicare B Update!* (pages 13-14). The CMS Form-1500 examples provided on page 14 incorrectly indicated a 2-digit year in the date(s) of service field (item 24A) – the year of service must be billed as a 4-digit date (i.e., 2003 instead of 03). The examples also provided dates in month/day format in item 19; however, CMS Form-1500 requirements specify use of a 6- or 8-digit date. The article text and balance of the examples remain accurate. We apologize for any inconvenience this may have caused.

# Timeframe Filing Provision on Reconsiderations and Appeals— Reminder to Providers

Droviders and beneficiaries who disagree with Medicare's initial determination have the right to request a review. A

**F** request for an appeal must be submitted in writing within 120 days from the date of the initial Medicare notice. Section 1869(a)(3)(C) of the Social Security Act eliminates the distinction between the 60-day time limit for requesting a Part A reconsideration and the 180-day time limit for requesting a Part B review by creating a 120-day time limit for filing requests for appeal of all Medicare initial determinations. On October 1, 2002, the Centers for Medicare & Medicaid Services (CMS) implemented the uniform 120-day timeframe for requesting a reconsideration or appeal of and initial determination on a Medicare Part A or B claim.

Requests for an appeal of a Medicare Part B claim processed by the Connecticut Medicare carrier must be submitted to:

Attention: Appeals First Coast Service Options, Inc. Medicare Part B Claim Review P. O. Box C 1016 Meriden CT 06450-1016

Requests for an appeal of a Medicare Part B claim processed by the Florida Medicare carrier must be submitted to:

First Coast Service Options, Inc. Medicare Part B Claim Review P. O. Box 2360 Jacksonville, FL 32231-0018

CMS recognizes that making the transition to a shorter timeframe for Part B appeal requests may prove difficult in situations where appellants need to obtain documentation from other sources in order to file an appeal.

In order to alleviate any hardship associated with the possible need to gather documentation faster than in the past, Medicare may grant an extension of up to 60 days in the 120-day filing deadline for appeals of Part B claims, provided that the appeal request includes a credible explanation from the beneficiary, physician, or supplier that the time was needed to gather the necessary supporting records. Without a credible explanation the extension will not be granted and these appeals will be considered untimely.

# **Timely Claim Filing Guidelines for All Medicare Providers**

All Medicare claims must be submitted to the contractor within the established timeliness parameters. For timeliness purposes, services furnished in the last quarter of the calendar year are considered furnished in the following calendar year. The time parameters are:

### Dates of Service

### Last Filing Date

by December 31, 2003 by December 31, 2004 by January 3, 2006\* by January 2, 2007\*

October	1,	2001	_	September	30,	2002
October	1,	2002	_	September	30,	2003
October	1,	2003	_	September	30,	2004
October	1,	2004	_	September	30,	2005

\*If December 31 falls on a federal nonworking day, the last filing date is extended to the next succeeding workday. A federal nonworking day is considered a Saturday, Sunday, legal holiday, or a day declared by statute or executive order as a nonworking day for federal employees.

Claims must be submitted complete and free of errors. Any claim filed with invalid or incomplete information, and returned as unprocessable, is not protected from the timely filing guidelines.

# Coverage/Reimbursement

Medicare Physician Fee Schedule (MPFS)/ Healthcare Common Procedure Coding System (HCPCS)

# Medicare Physician Fee Schedule Payment Policy Indicators

We published an article in the Fourth Quarter 2003 *Medicare B Update!* (page 18) announcing CMS' new online Medicare physician fee schedule look-up, which is available on the CMS Web site at *http://cms.hhs.gov/physicians/mpfsapp/step0.asp.* 

The information that follows provides definitions of the national policy indicators for each procedure code (and modifier, where applicable) on the Medicare physician fee schedule database (MPFSDB).

### Procedure Code/Modifier (procmod)

The *CPT* or HCPCS procedure code and, where applicable, procedure code modifier.

### Code Status (status)

Provides the fee schedule status of each code.

- A Active code. These codes are separately paid under the physician fee schedule if covered. There will be relative value units (RVUs) and payment amounts for codes with this status. The presence of an "A" indicator does not mean that Medicare has made a national coverage determination regarding the service; carriers remain responsible for coverage decisions in the absence of a national Medicare policy.
- **B** Payment for covered services are always bundled into payment for other services not specified. There will be no RVUs or payment amounts for these codes and no separate payment is ever made. When these services are covered, payment for them is subsumed by the payment for the services to which they are incident (an example is a telephone call from a hospital nurse regarding care of a patient).
- C Carriers price the code. Carriers will establish RVUs and payment amounts for these services, generally on an individual case basis following review of documentation such as an operative report.
- **D** Deleted/discontinued codes. These codes are deleted effective with the beginning of the year and are always subject to a 90-day grace period.
- **E** Excluded from physician fee schedule by regulation. These codes are for items and/or services that the Centers for Medicare & Medicaid Services (CMS) chose to exclude from the fee schedule payment by regulation. No RVUs or payment amounts are shown

and no payment may be made under the fee schedule for these codes. Payment for them, when covered, continues under reasonable charge procedures.

- **F** Deleted/discontinued codes. (Code not subject to a 90 day grace period.) These codes are deleted effective with the beginning of the year and are never subject to a grace period. This indicator was effective with the 2002 fee schedule as of January 1, 2002.
- **G** Not valid for Medicare purposes. Medicare uses another code for reporting of, and payment for, these services. (Code subject to a 90-day grace period.)
- **H** Deleted modifier. For 2000 and later years, either the technical component (TC) or professional component (PC) shown for the code has been deleted and the deleted component is shown in the data base with the H status. (Code subject to a 90-day grace period.)
- I Not valid for Medicare purposes. Medicare uses another code for reporting of, and payment for, these services. (Code *not* subject to a 90-day grace period.)
- L Local codes. Carriers will apply this status to all local codes in effect on January 1, 1998 or subsequently approved by central office for use. Carriers will complete the RVUs and payment amounts for these codes.
- N Non-covered service. These codes are carried on HCPCS as non-covered services.
- **P** Bundled/excluded codes. There are no RVUs and no payment amounts for these services. No separate payment is made for them under the fee schedule.

If the item or service is covered as incident to a physician service and is provided on the same day as a physician service, payment for it is bundled into the payment for the physician service to which it is incident (an example is an elastic bandage furnished by a physician incident to a physician service).

If the item or service is covered as other than incident to a physician service, it is excluded from the fee schedule (for example, colostomy supplies) and is paid under the other payment provision of the Social Security Act.

# COVERAGE/REIMBURSEMENT

- **R** Restricted coverage. Special coverage instructions apply.
- T There are RVUs and payment amounts for these services, but they are only paid if there are no other services payable under the physician fee schedule billed on the same date by the same provider. If any other services payable under the physician fee schedule are billed on the same date by the same provider, these services are bundled into the physician services for which payment is made.
- X Statutory exclusion. These codes represent an item or service that is not in the statutory definition of "physician services" for fee schedule payment purposes. No RVUs or payment amounts are shown for these codes and no payment may be made under the physician fee schedule. (Examples are ambulance services and clinical diagnostic laboratory services.)

### **Global Surgery (global)**

Provides the postoperative time frames that apply to payment for each surgical procedure or another indicator that describes the applicability of the global concept to the service.

- **000** Endoscopic or minor procedure with related preoperative and postoperative relative values on the day of the procedure only included in the fee schedule payment amount; evaluation and management services on the day of the procedure generally not payable.
- **010** Minor procedure with preoperative relative values on the day of the procedure and postoperative relative values during a 10-day postoperative period included in the fee schedule amount; evaluation and management services on the day of the procedure and during this 10-day postoperative period generally not payable.
- **090** Major surgery with a 1-day preoperative period and 90-day postoperative period included in the fee schedule payment amount.
- **MMM** Maternity codes; usual global period does not apply.
- XXX Global concept does not apply
- **YYY** Carrier determines whether global concept applies and establishes postoperative period, if appropriate, at time of pricing.
- Code related to another service and is always included in the global period of the other service.(Note: Physician work is associated with intra-service time and in some instances the post service time.)

# Preoperative, Intraoperative, and Postoperative Percentages

- Preoperative percentage (**pre op**) modifier 56 Provides the percentage for the preoperative portion of the global package.
- Intraoperative percentage (**intra op**) modifier 54 Provides the percentage for the intraoperative portion of the global package including postoperative work in the hospital.
- Postoperative percentage (**post op**) modifier 55 Provides the percentage for the postoperative portion of the global package that is provided in the office after discharge from the hospital.

The total of preoperative, intraoperative, and postoperative percentages will usually equal one. Any variance is slight and results from rounding.

### Professional Component/Technical Component Indicator (PC/TC)

- **0 Physician service codes:** This indicator identifies codes that describe physician services. Examples include visits, consultations, and surgical procedures. The concept of PC/TC does not apply since physician services cannot be split into professional and technical components. Modifiers 26 and TC cannot be used with these codes. The total RVUs include values for physician work, practice expense and malpractice expense. There are some codes with no work RVUs.
- **1 Diagnostic tests or radiology services**: This indicator identifies codes that describe diagnostic tests (e.g., pulmonary function tests), or therapeutic radiology procedures (e.g., radiation therapy). These codes generally have both a professional and technical component. Modifiers 26 and TC can be used with these codes.

The total RVUs for codes reported with a 26 modifier include values for physician work, practice expense, and malpractice expense.

The total RVUs for codes reported with a TC modifier include values for practice expense and malpractice expense only. The total RVUs for codes reported without a modifier equals the sum of RVUs for both the professional and technical component.

**2 Professional component only codes**: This indicator identifies stand alone codes that describe the physician work portion of selected diagnostic tests for which there is an associated code that describes the technical component of the diagnostic test only and another associated code that describes the global test.

An example of a professional component only code is 93010, *Electrocardiogram; interpretation and report*. Modifiers 26 and TC cannot be used with these codes. The total RVUs for professional component only codes include values for physician work, practice expense, and malpractice expense.

**3** Technical component only codes: This indicator identifies stand alone codes that describe the technical component (i.e., staff and equipment costs) of selected diagnostic tests for which there is an associated code that describes the professional component of the diagnostic tests only.

An example of a technical component code is 93005, *Electrocardiogram, tracing only, without interpretation and report.* It also identifies codes that are covered only as diagnostic tests and therefore do not have a related professional code. Modifiers 26 and TC cannot be used with these codes.

The total RVUs for technical component only codes include values for practice expense and malpractice expense only.

# COVERAGE/REIMBURSEMENT

- **4 Global test only codes**: This indicator identifies stand alone codes for which there are associated codes that describe: a) the professional component of the test only and b) the technical component of the test only. Modifiers 26 and TC cannot be used with these codes. The total RVUs for global procedure only codes include values for physician work, practice expense, and malpractice expense. The total RVUs for global procedure only codes equals the sum of the total RVUs for the professional and technical components only codes combined.
- **5 Incident to codes**: This indicator identifies codes that describe services covered incident to a physicians service when they are provided by auxiliary personnel employed by the physician and working under his or her direct supervision.

Payment may not be made by carriers for these services when they are provided to hospital inpatients or patients in a hospital outpatient department. Modifiers 26 and TC cannot be used with these codes.

- **6 Laboratory physician interpretation codes**: This indicator identifies clinical laboratory codes for which separate payment for interpretations by laboratory physicians may be made. Actual performance of the tests is paid for under the lab fee schedule. Modifier TC cannot be used with these codes. The total RVUs for laboratory physician interpretation codes include values for physician work, practice expense and malpractice expense.
- **7 Physical therapy service**: Payment may not be made if the service is provided to either a hospital outpatient or inpatient by an independently practicing physical or occupational therapist.
- 8 Physician interpretation codes: This indicator identifies the professional component of clinical laboratory codes for which separate payment may be made only if the physician interprets an abnormal smear for hospital inpatient. This applies only to code *85060*. No TC billing is recognized because payment for the underlying clinical laboratory test is made to the hospital, generally through the PPS rate.

No payment is recognized for code *85060* furnished to hospital outpatients or non-hospital patients. The physician interpretation is paid through the clinical laboratory fee schedule payment for the clinical laboratory test.

**9** Concept of a professional/technical component does not apply.

### Multiple Procedure (m/s) - Modifier 51

Indicates which payment adjustment rule for multiple procedures applies to the service.

**0** No payment adjustment rules for multiple procedures apply. If procedure is reported on the same day as another procedure, base payment on the lower of: (a) the actual charge or (b) the fee schedule amount for the procedure.

- **1** Standard payment adjustment rules in effect before January 1, 1996 or multiple procedures apply. In the 1996 MPFSDB, this indicator only applies to codes with procedure status of "D." If a procedure is reported on the same day as another procedure with an indicator of 1,2, or 3, rank the procedures by fee schedule amount and apply the appropriate reduction to this code (100 percent, 50 percent, 25 percent, 25 percent, 25 percent, and by report). Base payment on the lower of: (a) the actual charge or (b) the fee schedule amount reduced by the appropriate percentage.
- 2 Standard payment adjustment rules for multiple procedures apply. If procedure is reported on the same day as another procedure with an indicator of 1, 2, or 3, rank the procedures by fee schedule amount and apply the appropriate reduction to this code (100 percent, 50 percent, 50 percent, 50 percent, and by report). Base payment on the lower of: (a) the actual charge or (b) the fee schedule amount reduced by the appropriate percentage.
- **3** Special rules for multiple endoscopic procedures apply if procedure is billed with another endoscopy in the same family (i.e., another endoscopy that has the same base procedure). The base procedure for each code with this indicator is identified on page 15.

Multiple endoscopy rules are applied to a family before ranking the family with other procedures performed on the same day (for example, if multiple endoscopies in the same family are reported on the same day as endoscopies in another family or on the same day as a non-endoscopic procedure).

If an endoscopic procedure is reported with only its base procedure, carriers do not pay separately for the base procedure. Payment for the base procedure is included in the payment for the other endoscopy.

**9** Concept does not apply.

### Bilateral Surgery (b/s) - Modifier 50

Provides an indicator for services subject to a payment adjustment.

**0** 150 percent payment adjustment for bilateral procedures does not apply. If procedure is reported with modifier -50 or with modifiers RT and LT, base payment for the two sides on the lower of: (a) the total actual charge for both sides or (b) 100 percent of the fee schedule amount for a single code.

Example: The fee schedule amount for code XXXXX is \$125. The physician reports code XXXXX-LT with an actual charge of \$100 and XXXXX-RT with an actual charge of \$100. Payment would be based on the fee schedule amount (\$125) since it is lower than the total actual charges for the left and right sides (\$200).

The bilateral adjustment is inappropriate for codes in this category because of (a) physiology or anatomy or (b) because the code descriptor specifically states that it is a unilateral procedure and there is an existing code for the bilateral procedure.

1 150 percent payment adjustment for bilateral procedures applies. If code is billed with the bilateral modifier or is reported twice on the same day by any other means (e.g., with RT and LT modifiers or with a 2 in the units field), base payment for these codes when reported as bilateral procedures on the lower of: (a) the total actual charge for both sides or (b) 150 percent of the fee schedule amount for a single code

If code is reported as a bilateral procedure and is reported with other procedure codes on the same day, apply the bilateral adjustment before applying any applicable multiple procedure rules.

**2** 150 percent payment adjustment for bilateral procedure does not apply. RVUs are already based on the procedure being performed as a bilateral procedure. If procedure is reported with modifier -50 or is reported twice on the same day by any other means (e.g., with RT and LT modifiers with a 2 in the units field), base payment for both sides on the lower of (a) the total actual charges by the physician for both sides or (b) 100 percent of the fee schedule amount for a single code.

Example: The fee schedule amount for code YYYYY is \$125. The physician reports code YYYYY-LT with an actual charge of \$100 and YYYYY-RT with an actual charge of \$100. Payment would be based on the fee schedule amount (\$125) since it is lower than the total actual charges for the left and right sides (\$200).

The RVUs are based on a bilateral procedure because: (a) the code descriptor specifically states that the procedure is bilateral; (b) the code descriptor states that the procedure may be performed either unilaterally or bilaterally; or (c) the procedure is usually performed as a bilateral procedure.

**3** The usual payment adjustment for bilateral procedures does not apply. If procedure is reported with modifier -50 or is reported for both sides on the same day by any other means (e.g., with RT and LT modifiers or with a 2 in the units field), base payment for each side or organ or site of a paired organ on the lower of: (a) the actual charge for each side or (b) 100% of the fee schedule amount for each side. If procedure is reported as a bilateral procedure and with other procedure codes on the same day, determine the fee schedule amount for a bilateral procedure before applying any applicable multiple procedure rules.

Services in this category are generally radiology procedures or other diagnostic tests which are not subject to the special payment rules for other bilateral procedures.

9 Concept does not apply.

### Assistant at Surgery (a/s)

Provides an indicator for services where an assistant at surgery is never paid for per the Medicare Carriers Manual.

0 Payment restriction for assistants at surgery applies to

### COVERAGE/REIMBURSEMENT

this procedure unless supporting documentation is submitted to establish medical necessity.

- **1** Statutory payment restriction for assistants at surgery applies to this procedure. Assistant at surgery may not be paid.
- **2** Payment restriction for assistants at surgery does not apply to this procedure. Assistant at surgery may be paid.
- 9 Concept does not apply.

### Co-Surgeons (co) - Modifier 62

Provides an indicator for services for which two surgeons, each in a different specialty, may be paid.

- 0 Co-surgeons not permitted for this procedure.
- **1** Co-surgeons could be paid; supporting documentation required to establish medical necessity of two surgeons for the procedure.
- 2 Co-surgeons permitted; no documentation required if two specialty requirements are met.
- 9 Concept does not apply.

### Team Surgeons (team) - Modifier 66

Provides an indicator for services for which team surgeons may be paid.

- 0 Team surgeons not permitted for this procedure.
- 1 Team surgeons could be paid; supporting documentation required to establish medical necessity of a team; pay by report.
- 2 Team surgeons permitted; pay by report.
- 9 Concept does not apply.

### Physician Supervision of Diagnostic Procedures (supv dx)

Provides levels of physician supervision required for diagnostic tests payable under the physician fee schedule.

*General supervision* means the procedure is furnished under the physician's overall direction and control, but the physician's presence is not required during the performance of the procedure. Under general supervision, the training of the nonphysician personnel who actually performs the diagnostic procedure and the maintenance of the necessary equipment and supplies are the continuing responsibility of the physician.

**Direct supervision** in the office setting means the physician must be present in the office suite and immediately available to furnish assistance and direction throughout the performance of the procedure. It does not mean that the physician must be present in the room when the procedure is performed.

*Personal supervision* means a physician must be in attendance in the room during the performance of the procedure.

- **01**Procedure must be performed under the general supervision of a physician.
- **02**Procedure must be performed under the direct supervision of a physician.

### COVERAGE/REIMBURSEMENT

- **03**Procedure must be performed under the personal supervision of a physician.
- **04** Physician supervision policy does not apply when procedure is furnished by a qualified, independent psychologist or a clinical psychologist; otherwise must be performed under the general supervision of a physician.
- **05** Physician supervision policy does not apply when procedure is furnished by a qualified audiologist; otherwise must be performed under the general supervision of a physician.
- **06**Procedure must be performed by a physician or a physical therapist (PT) who is certified by the American Board of Physical Therapy Specialties (ABPTS) as a qualified electrophysiologic clinical specialist and is permitted to provide the procedure under state law.
- **21**Procedure may be performed by a technician with certification under general supervision of a physician; otherwise must be performed under direct supervision of a physician.
- 22 May be performed by a technician with on-line realtime contact with physician.
- **66** May be performed by a physician or by a physical therapist with ABPTS certification and certification in this specific procedure.

### 2003 Multiple Endoscopy Procedures (see page 12)

- **6A** Supervision standards for level 66 apply; in addition, the PT with ABPTS certification may supervise another PT, but only the PT with ABPTS certification may bill.
- 77 Procedure must be performed by a PT with ABPTS certification or by a PT without certification under direct supervision of a physician, or by a technician with certification under general supervision of a physician.
- **7A** Supervision standards for level 77 apply; in addition, the PT with ABPTS certification may supervise another PT, but only the PT with ABPTS certification may bill.

09 Concept does not apply.

### **Facility Pricing**

Codes that have reduced fees when performed in a facility setting are not identified in the tables that follow. However, these codes are annotated with an asterisk (\*) in the 2003 Medicare Physician and Non-Physician Practitioner Fee Schedule book. Facility fees are calculated at a national level with a reduced practice expense, because of reduced physician overhead associated with services provided in a facility.

Place of service (POS) codes to be used to identify facilities may be found in the Fourth Quarter 2003 *Medicare B Update!* (pages 57-61).

BASE	RELATED
29805	29806, 29807, 29819, 29820, 29821, 29822, 29823, 29824, 29825, 29826
29830	29834, 29835, 29836, 29837, 29838
29840	29843, 29844, 29845, 29846, 29847
29860	29861, 29862, 29863
29870	29871, 29874, 29875, 29876, 29877, 29879, 29880, 29881, 29882, 29883, 29884, 29885, 29886, 29887
31505	31510, 31511, 31512, 31513
31525	31527, 31528, 31529, 31530, 31535, 31540, 31560, 31570
31526	31531, 31536, 31541, 31561, 31571
31575	31576, 31577, 31578, 31579
31622	31623, 31624, 31625, 31628, 31629, 31630, 31631, 31635, 31640, 31641, 31645
43200	43201, 43202, 43204, 43205, 43215, 43216, 43217, 43219, 43220, 43226, 43227, 43228
43235	43231, 43232, 43236, 43239, 43241, 43242, 43243, 43244, 43245, 43246, 43247, 43248, 43249, 43250, 43251, 43255, 43256, 43258, 43259
43260	43240, 43261, 43262, 43263, 43264, 43265, 43267, 43268, 43269, 43271, 43272
44360	44361, 44363, 44364, 44365, 44366, 44369, 44370, 44372, 44373
44376	44377, 44378, 44379
44388	44389, 44390, 44391, 44392, 44393, 44394, 44397
45300	45303, 45305, 45307, 45308, 45309, 45315, 45317, 45320, 45321, 45327

COVERAGE/REIMBURSEMENT

45330	45331, 45332, 45333, 45334, 45335, 45337, 45338, 45339, 45340, 45345
45378	45379, 45380, 45381, 45382, 45383, 45384, 45385, 45386, 45387
46600	46604, 46606, 46608, 46610, 46611, 46612, 46614, 46615
47552	47553, 47554, 47555, 47556
49320	38570, 49321, 49322, 49323, 58550, 58551, 58660, 58661, 58662, 58670, 58671, 58672, 58673
50551	50555, 50557, 50559, 50561
50570	50572, 50574, 50575, 50576, 50578, 50580
50951	50953, 50955, 50957, 50959, 50961
50970	50974, 50976
52000	52007, 52010, 52204, 52214, 52224, 52250, 52260, 52265, 52270, 52275, 52276, 52277, 52281, 52282, 52283, 52285, 52290, 52300, 52301, 52305, 52310, 52315, 52317, 52318
52005	52320, 52325, 52327, 52330, 52332, 52334, 52341, 52342, 52343, 52344
52010	52347
52351	52345, 52346, 52352, 52353, 52354, 52355
57452	57454, 57455, 57456, 57460, 57461
58555	58558, 58559, 58560, 58561, 58562, 58563

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology*. *CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## FLORIDA ONLY

# 2003 Carrier-Priced Codes for Florida—Correction

We provided allowances for certain carrier-priced codes (MPFSDB status=C) in the Fourth Quarter 2003 *Medicare B Update!* (pages 15-18). The fees for Florida were labeled incorrectly; the correct fees and labels are provided below.

This does not affect fees listed for Connecticut. We apologize for any inconvenience this has caused.

This does not affect rees fisted for connected it. We appropriate for any meon venteries this data									
Par				Nonpar			Limiting Charge		
Code/Mod L		Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04
G0030	138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0030 TC	82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0031	185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0031 TC	111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0032	138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0032 TC	82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0033	185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0033 TC	111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0034	138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0034 TC	82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0035	185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0035 TC	111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0036	138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0036 TC	82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0037	185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0037 TC	111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0038	138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0038 TC	82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0039	185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0039 TC	111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
							1		

# COVERAGE/REIMBURSEMENT

	Par			Nonpar		Lim	niting Charg	Δ
Code/Mod Loc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04
G0040 138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0040 TC 82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0041 185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0041 TC 111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0042 138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0042 TC 82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0043 185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0043 TC 111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0044 138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0044 TC 82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0045 185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0045 TC 111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0046 138.05	145.14	150.70	131.15	137.88	143.16	150.82	158.57	164.64
G0046 TC 82.83	87.09	90.42	78.69	82.74	85.90	90.49	95.15	98.78
G0047 185.46	194.79	202.07	176.19	185.05	191.97	202.62	212.81	220.76
G0047 TC 111.27	116.87	121.24	105.71	111.03	115.18	121.56	127.68	132.45
G0125 2,099.10	2,397.25	2,412.98	1,994.14	2,277.39	2,292.33	2,293.27	2,619.00	2,636.18
G0125 TC 2,024.88	2,215.98	2,332.20	1,923.64	2,105.18	2,215.59	2,212.18	2,420.96	2,547.93
G0186 593.27	627.80	651.72	563.61	596.41	619.13	648.15	685.87	712.00
G0187 840.56	888.50	922.33	798.53	844.07	876.21	918.31	970.69	1,007.65
G0210 2,101.42	2,296.18	2,415.14	1,996.35	2,181.37	2,294.38	2,295.80	2,508.58	2,638.54
G0210 TC 2,024.88	2,215.99	2,332.20	1,923.64	2,105.19	2,215.59	2,212.18	2,420.97	2,547.93
	2,296.18	2,415.14		2,181.37	2,294.38	2,295.80	2,508.58	2,638.54
G0211 TC 2,024.88		2,332.20	1,923.64	2,105.19		2,212.18		2,547.93
		2,415.14		2,181.37		2,295.80		2,638.54
G0212 TC 2,024.88	2,215.99	2,332.20		2,105.19	2,215.59	2,212.18		2,547.93
G0213 2,101.42		2,415.14		2,181.37		2,295.80		2,638.54
G0213 TC 2,024.88	2,215.99	2,332.20		2,105.19		2,212.18		2,547.93
G0214 2,101.42		2,415.14	1,996.35			2,295.80		2,638.54
G0214 TC 2,024.88	2,215.99	2,332.20		2,105.19		2,212.18		2,547.93
G0215 2,101.42	2,296.18	2,415.14	1,996.35	2,181.37	2,294.38	2,295.80	2,508.58	2,638.54
G0215 TC 2,024.88	2,215.99	2,332.20	1,923.64	2,105.19	2,215.59	2,212.18	2,420.97	2,547.93
•	2,296.18	2,415.14		2,181.37	2,294.38	2,295.80	2,508.58	2,638.54
G0216 TC 2,024.88	2,215.99 2,296.18	2,332.20		2,105.19	2,215.59	2,212.18	2,420.97	2,547.93
G0217 2,101.42 G0217 TC 2,024.88	2,296.18	2,415.14	1,996.35 1,923.64	2,181.37	2,294.38 2,215.59	2,295.80 2,212.18	2,508.58 2,420.97	2,638.54 2,547.93
	2,215.99	2,332.20		2,105.19 2,181.37			2,420.97	
G0218 TC 2,024.88					2,294.38		2,308.38	
		2,332.20			2,215.59		2,420.97	
G0220 TC 2,024.88					2,234.30		2,300.30	
	2,296.18				2,294.38		2,508.58	
G0221 TC 2,024.88					2,215.59		2,420.97	
	2,296.18				2,294.38		2,508.58	
G0222 TC 2,024.88				2,105.19			2,420.97	
	2,296.18			2,181.37			2,508.58	
G0223 TC 2,024.88					2,215.59		2,420.97	
	2,296.18				2,294.38		2,508.58	
G0224 TC 2,024.88					2,215.59		2,420.97	
		2,415.14			2,294.38	-	2,508.58	
G0225 TC 2,024.88					2,215.59		2,420.97	
	2,296.18				2,294.38		2,508.58	
G0226 TC 2,024.88					2,215.59		2,420.97	
	2,296.18				2,294.38		2,508.58	
G0227 TC 2,024.88					2,215.59		2,420.97	
		2,415.14			2,294.38		2,508.58	
G0228 TC 2,024.88					2,215.59		2,420.97	
			1,996.35					
G0229 TC 2,024.88								

# COVERAGE/REIMBURSEMENT

	Par		Nonpar		Lim	niting Charg	Ie.
Code/Mod Loc 01/02	Loc 03 Loc (	4 Loc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04
G0230 2,101.42	2,296.18 2,415.2		2,181.37	2,294.38	2,295.80	2,508.58	2,638.54
G0230 TC 2,024.88	2,215.99 2,332.2			2,215.59	2,212.18	2,420.97	2,547.93
G0231 2,101.42	2,296.18 2,415.2				2,295.80	2,508.58	2,638.54
G0231 TC 2,024.88					2,212.18	•	2,547.93
•	2,296.18 2,415.2		2,181.37		2,295.80		2,638.54
G0232 TC 2,024.42			2,101.37		2,235.00		2,030.34 2,547.93
G0233 2,101.42			2,181.37		2,295.80		2,638.54
G0233 TC 2,024.88			2,101.37		2,295.80		2,038.34 2,547.93
G0234 2,101.42			2,103.19		2,212.18		
G0234 TC 2,024.88	, ,		•		2,295.80		2,638.54
			2,105.19				2,547.93
,	2,296.18 2,415.				2,295.80		2,638.54
G0253 TC 2,024.88	2,215.99 2,332.2			2,215.59	2,212.18		2,547.93
G0254 2,101.42					2,295.80	2,508.58	2,638.54
G0254 TC 2,024.88					2,212.18	2,420.97	2,547.93
R0070 97.02	97.02 97.0			92.17	105.99	105.99	105.99
R0075 97.02	97.02 97.0			92.17	105.99	105.99	105.99
21088 6,173.48	6,173.48 6,173.4		5,864.81	5,864.81	6,744.53	6,744.53	6,744.53
62367 58.72	62.24 65.3		59.13	62.05	64.15	68.00	71.36
62367 TC 35.23	37.35 39.4			37.23	38.49	40.80	42.82
62368 90.47	96.06 100.9		91.26	95.94	98.84	104.95	110.33
62368 TC 54.29	57.64 60.6		54.76	57.57	59.31	62.97	66.21
74300 45.91	48.60 50.8		46.17	48.30	50.16	53.10	55.54
74300 TC 27.55	29.16 30.5			28.98	30.10	31.86	33.33
74301 26.10	27.52 28.7		26.14	27.27	28.51	30.07	31.37
74301 TC 15.66	16.51 17.2		15.68	16.36	17.11	18.04	18.81
75952 639.19	698.08 752.2		663.18	714.66	698.32	762.65	821.85
75952 TC 38.51	415.85 451.3		395.06	428.80	42.07	454.32	493.12
75953 248.03	292.51 337.2		277.88	320.42	270.97	319.57	368.48
75953 TC 148.82	175.51 202.3		166.73	192.25	162.59	191.74	221.09
76012 189.45	208.37 226.0		197.95	214.75	206.97	227.64	246.96
76012 TC 113.67	125.02 135.6		118.77	128.85	124.18	136.58	148.18
76013 227.43	260.76 293.6		247.72	278.93	248.47	284.88	320.77
76013 TC 136.46	156.45 176.2		148.63	167.36	149.08	170.92	192.47
76350 14.50	15.98 16.9		15.18	16.10	15.84	17.46	18.52
78172 67.25	70.73 73.4		67.19	69.80	73.47	77.27	80.27
78172 TC 40.35	42.44 44.0		40.32	41.88	44.08	46.37	48.16
78282 47.71	50.43 52.6			50.06	52.12		57.56
78282 TC 28.63	30.26 31.6			30.03	31.28	33.06	34.53
78414 56.60	59.65 62.7				61.84		67.89
78414 TC 33.96	35.79 37.2			35.42	37.10	39.10	40.73
	2,296.18 2,415.7		2,181.37			2,508.58	
78459 TC 2,024.88				2,215.59		2,420.97	
79300 210.76	222.29 231.4			219.85	230.26	242.85	252.83
79300 TC 126.46	133.38 138.8			131.91	138.16	145.72	151.69
79420 189.35	199.23 207.2			196.79	206.86	217.66	226.31
79420 TC 113.61	119.54 124.2			118.08	124.12	130.60	135.79
86485 15.78	17.40 19.3			18.42	17.24	19.01	21.18
91132 65.26	69.16 72.3			68.74	71.30	75.56	79.05
91132 TC 39.15	41.50 43.4	9 37.19		41.32	42.77	45.34	47.51
91133 81.39	85.86 89.4	5 77.32	81.57	84.98	88.92	93.80	97.72
91133 TC 48.83	51.52 53.6	7 46.39		50.99	53.35	56.29	58.63
93318 280.81	294.27 304.4	5 266.77	279.56	289.23	306.78	321.49	332.61
93318 TC 168.49	176.56 182.6	7 160.07	167.73	173.54	184.08	192.89	199.57
93621 282.30	300.62 316.0	4 268.19	285.59	300.24	308.41	328.43	345.27
93621 TC 169.38	180.38 189.6	2 160.91	171.36	180.14	185.05	197.07	207.16
93622 469.01	521.31 570.9	0 445.56	495.24	542.35	512.39	569.53	623.71
93622 TC 281.41	312.79 342.5	4 267.34	297.15	325.41	307.44	341.72	374.22

### COVERAGE/REIMBURSEMENT

		Par			Nonpar		Lim	iting Charg	е
Code/Mod L	_oc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04	Loc 01/02	Loc 03	Loc 04
93623	376.23	398.35	416.03	357.42	378.43	395.23	411.03	435.20	454.51
93623 TC	225.92	239.01	249.62	214.62	227.06	237.14	246.82	261.12	272.71
93662	396.20	432.09	465.04	376.39	410.49	441.79	432.85	472.06	508.06
93662 TC	237.72	259.25	279.03	225.83	246.29	265.08	259.71	283.23	304.84
94642	26.69	29.09	30.50	25.36	27.64	28.97	29.16	31.78	33.32
95824	88.92	99.71	104.70	84.47	94.72	99.47	97.15	108.93	114.38
95824 TC	53.35	59.82	62.82	50.68	56.83	59.68	58.28	65.35	68.63
95965	1,018.11	1,065.94	1,101.87	967.20	1,012.64	1,046.78	1,112.29	1,164.54	1,203.79
95965 TC	610.87	639.57	661.12	580.33	607.59	628.06	667.38	698.73	722.27
95966	518.80	547.25	570.02	492.86	519.89	541.52	566.79	597.87	622.75
95966 TC	311.28	328.35	342.00	295.72	311.93	324.90	340.07	358.72	373.63
95967	455.41	481.00	501.68	432.64	456.95	476.60	497.54	525.49	548.09
95967 TC	273.25	288.60	301.01	259.59	274.17	285.96	298.53	315.30	328.85
99082	1.93	1.93	1.93	1.83	1.83	1.83	2.11	2.11	2.11

AMBULANCE

# Adjustment to the Rural Mileage Payment Rate for Ground Ambulance Services

The Ambulance Fee Schedule payment includes a rural adjustment to take into consideration the regional and operational variances in the cost of providing services in different areas of the country.

Effective January 1, 2004, the mileage rate for ground ambulance services originating in rural areas remains 150 percent of the urban mileage rate for the first 17 miles; the payment rate for ground ambulance miles 18 to 50, inclusive, will be equivalent to the urban mileage rate with no rural adjustment. The new payment rate for ground ambulance miles applies to all ground ambulance service claims with dates of service on or after January 1, 2004.

Source: CMS Transmittal AB-03-110, CR 2767

# Payment Policy When More Than One Patient Is Onboard an Ambulance

The final regulation to establish an ambulance fee schedule contains a provision that clarifies payment policy for pricing a single ambulance vehicle transport of a Medicare beneficiary where more than one patient is onboard the ambulance. This policy applies to both ground and air transports (for purposes of this article, the term "ground transport" includes transport by water ambulance). This policy is effective for services provided on or after April 1, 2002, processed on or after October 30, 2002.

- When more than one patient is transported in an ambulance, the Medicare allowed charge for each beneficiary is a percentage of the allowed charge for a single beneficiary transport (the "allowed charge" for a single beneficiary transport is the lower of the submitted charge and the fee schedule amount for the service—which, during the fee schedule transition period, is a blended amount). The applicable percentage is based on the total number of patients transported, including both Medicare beneficiaries and non-Medicare patients.
- If two patients are transported at the same time in one ambulance to the same destination, the adjusted payment allowance for each Medicare beneficiary would equal 75% of the single-patient allowed amount

applicable to the level of service furnished a beneficiary, plus 50% of the total mileage payment allowance for the entire trip. If three or more patients are transported at the same time in one ambulance to the same destination, the adjusted payment for each Medicare beneficiary would equal 60% of the singlepatient allowed amount applicable to the level of service furnished that beneficiary plus a proportional mileage allowed amount, (i.e., the total mileage allowed amount divided by the number of all the patients onboard). See "Processing Multiple Patient Transports," below.

- The fact that the level of medically necessary service among the patients may be different is not relevant to this payment policy. The percentage is applied to the allowed amount applicable to the level of service that is medically necessary for each beneficiary.
- If a multi-patient transport includes multiple destinations, then the Medicare allowed amount for mileage depends upon whether it is for an emergency versus non-emergency ground transport.

For an emergency ground transport, which includes basic life support - emergency (BLS-E), advanced life support 1 - emergency (ALS1-E), advanced life

support 2 (ALS2), and specialty care transport (SCT), the mileage payment is based on the number of miles to the nearest appropriate facility for each patient, divided by the number of patients on board when the vehicle arrives at the facility. This formula applies cumulatively for beneficiaries who are the second or third patient to be delivered. Absent evidence to the contrary, the carrier assumes the sequence of deliveries was predicated on the medical needs of each patient.

For a non-emergency ground transport, which includes BLS and ALS1, the mileage payment shall be based on the number of miles from the point of pick-up to the nearest appropriate facility for each beneficiary, divided by the number of beneficiaries on board at the point of pick-up. This formula applies cumulatively for beneficiaries for multiple points of pick-up. Mileage other than the mileage that would be incurred by transporting the beneficiary directly from the point of pick-up to the nearest appropriate facility is not covered. Thus, for non-emergency transports, the extra mileage that may be incurred by having multi-destinations shall not be taken into account.

For air transports the policy is the same as for emergency ground transports.

• If a Medicare beneficiary is furnished medically necessary supplies, and the supplier bills supplies separately, then the allowed amount of the supplies is not subject to an apportionment for multiple patients. The allowed amount for supplies should be determined in the same manner as if the beneficiary was the only patient onboard the vehicle.

### **Claim Submission Requirements**

Suppliers must identify claims for multiple transports with modifier **GM** (multiple patients on one ambulance trip). Documentation to specify particulars of a multiple transport must be submitted that includes at a minimum the total number of patients transported in the vehicle at the same time, and the health insurance claim number for each Medicare beneficiary. Submit the charge applicable to the appropriate service rendered to each beneficiary, and the total mileage for the trip. Suppliers should make every effort to submit all associated Medicare claims for that multiple transport at the same time. Associated Medicare claims for multiple transport must be submitted within a reasonable number of days of submitting the first claim.

Failure to comply with the documentation requirements and timely filing of associated claims may result in a delay of payment determination, additional development requests, and possible denials.

### **Processing Multiple Patient Transports**

Carriers will process claims for covered multiple patient transports as follows:

When two patients are transported, for each beneficiary the carrier will allow 75% of the allowed amount for a single-person transport (excluding separately billable mileage). For mileage to a single destination, half of the total mileage will be allowed. For mileage for both emergency ground transports and all air transports to multiple destinations, the allowed amount for the first leg is the amount for the mileage divided by two. The allowed amount for the second leg is the full mileage. Thus, payment on behalf of a beneficiary whose transport is to the first nearest appropriate facility is based on half the mileage amount to that facility. Payment on behalf of the second beneficiary, whose transport was to the next nearest appropriate facility, is based on half of the mileage to the first facility plus all of the mileage from the first facility to the second facility. For mileage for non-emergency ground transports, only the mileage from the point of pickup to the nearest appropriate facility may be allowed. That amount is divided by the number of beneficiaries loaded on board at the point of pick-up. Mileage other than what would be incurred by transporting the beneficiary directly from the point of pick-up to the nearest appropriate facility is not covered.

When three or more patients are transported, for each beneficiary the carrier will allow 60% of the allowed amount for a single-person transport (excluding separately billable mileage). For mileage to a single destination, a pro rata share of the total mileage will be allowed. For mileage for emergency ground transports and all air transports to multiple destinations, the allowed amount for each leg of the transport is a pro rata share of the total mileage based on the number of patients on board upon arrival at each destination. For mileage for non-emergency ground transports, the allowed amount for each beneficiary is based on the mileage to the nearest appropriate facility divided by the number of beneficiaries loaded on board at the point of pick-up (including any intermediate points of pickup). Mileage other than what would be incurred by transporting each beneficiary directly from the point of pick-up to the nearest appropriate facility may not be taken into account.

Source: CMS Transmittal B-02-060, CR 1945

# **D**RUGS AND **B**IOLOGICALS

### Medicare Covered Drugs—Quarterly Pricing Update

The quarterly revisions to the single drug pricer (SDP) for most drugs and biologicals are provided below. These changes are effective for services rendered on or after January 1, 2003, processed on or after October 1, 2003.

*Note:* this is not a complete replacement file; only revisions are included. Please refer to previous publications for drugs not listed here.

	11 % CM	A 11		TT '4 CM	A 11		11 ' CM	A 11
	Unit of Measure	Allowance		Unit of Measure	Allowance		Unit of Measure	Allowance
	30 mg	15.94	J1742		251.35		10 mg	9.69
	Up to 125 mg	2.66		Per 15 mg	3.56		15 units	182.40
	500 mg	25.55		Up to 20 mg	0.98		Per 10 mg	15.96
	Up to 20 mg	17.06		3.75 mg	517.32		50 mg	79.80
	0.1 mg	1.03	J2000		3.99		Per 1 mg	51.30
	Up to 1000 mg	44.10		Up to 300 mg	3.18		100 mg	5.73
	Per 10 ml	6.42		200 mg	36.80		200 mg	10.89
	50 mg	3.71		25% in 50 ml	3.27		500 mg	22.86
	10 ml	2.15	J2210	Up to 0.2 mg	4.10	J9091	1 g	45.73
	500 mg	2.25		Per 1 mg	1.28	J9092	2 g	91.45
	Per 1,000 USP units	3.09	J2270	Up to 10 mg	0.77		100 mg	5.59
	Per 30 mg	0.50	J2324	0.5 mg	151.62		200 mg	11.17
J0780	Up to 10 mg	4.18		Up to 1 ml	1.28	J9100	100 mg	3.19
J0850	Per vial	712.07		Up to 60 mg	3.56	J9110	500 mg	8.55
J1020	20 mg	2.68	J2510	Up to 600,000 units	9.60	J9140	200 mg	22.06
J1030	40 mg	4.13	J2515	Per 50 mg	1.32	J9150	10 mg	74.23
J1040	80 mg	8.27	J2545	Per 300 mg	50.77	J9160	300 mcg	1330.95
J1051	50 mg	5.04	J2590	Up to 10 units	1.72	J9180	50 mg	690.99
J1056	5 mg/25 mg	24.61		Up to 1 ml	0.31	J9181	10 mg	1.71
	Up to 100 mg	4.95	J2680	Up to 25 mg	9.42		100 mg	17.10
	1 cc, 200 mg	9.43		Up to 1 g	1.43	J9185	50 mg	356.07
	Up to 500 mg	20.52		Up to 5 mg	31.92		500 mg	2.07
	Up to 4 mg	1.55	J2765	Up to 10 mg	1.99		500 mg	136.80
J1190	Per 250 mg	233.97		500 mg	114.58		20 mg	145.74
	Per 10 mg	5.70		50 mcg	34.77		1 million units	14.88
	Per 25 mg	61.51		50 mg	17.31	J9216	3 million units	209.22
J1460		12.17		Up to 40 mg	1.95	J9218		70.28
J1470	2 cc	24.35		Up to 125 mg	3.24		Per single dose vial	1543.75
J1480	3 cc	36.56	J2941		45.92	J9280		63.84
J1490	4 cc	48.69		18.1 mg	1364.44		20 mg	207.48
J1500		60.87	J2997		36.70		40 mg	285.00
J1510		72.88		50 mg	2690.88		100 mg	501.13
J1520		85.12		Up to 100 mg	8.98	J9320		141.47
J1530		97.38		Up to 200 mg	17.96		10 mg	58.13
J1540		109.66		10  mg/ml	1.56		10 mg	89.36
	10 cc	121.72		Per 10 mg	1.60	P9041	5%, 50 ml	14.54
	Up to 80 mg	1.90		3.75 mg	398.62	P9048	5%, 250 ml	29.10
	Up to 5 mg	6.83		Up to 2 g	28.27		Per 1.2 mg	1681.50
	Per 50 mg	9.12		Up to 5 mg	0.86		40 mg	0.62
	Per 1000 units	0.40		15 mg	1603.13	Q4077		37.05
	Per 2500 IU	15.69		Per 500 mg	0.27	-	Per dose	34.77
I1650	10 mg	6.47		Up to 5 cc	0.27		Per dose	25.38
	1000 IU	3.83		20 to 25 mg	138.71		Per dose	19.43
	Up to 250 units	119.70		2010/25/ling 250 mg	278.70		Per dose	19.43
		2.49			357.58		Per dose	13.03
J1/20	Up to 100 mg	2.49	J/311	25 mg	557.58	90752		18.02

### Source: October 2003 SDP files

Single Drug Pricer (SDP) Coverage: The presence or absence of a particular drug on the SDP file does not represent a determination that the Medicare Program either covers or does not cover that drug. The amounts shown on the SDP file indicate the maximum Medicare payment allowance, if the Medicare contractor determines that the drug meets the program's requirements for coverage. Similarly, the absence of a particular drug from the SDP file means that if the Medicare contractor determines that the drug is covered by Medicare, the local contractor must then determine the program's payment allowance by applying the program's standard drug payment policy rules. Medicare contractors separately determine whether a particular drug meets the program's general requirements for coverage and, if so, whether payment may be made for the drug in the particular circumstance under which it was furnished. Examples of this latter determination include, but are not limited to, determinations as to whether a particular drug and route of administration are reasonable and necessary to treat the beneficiary's condition, whether a drug may be excluded from payment because it is usually self-administered, and whether a least costly alternative to the drug exists.

# DURABLE MEDICAL EQUIPMENT

# New Requirements - Physician's Order and Certificates of Medical Necessity (CMNs)

Effective January 1, 2004, section 2100.4 of the Medicare Carriers Manual (MCM), "Repairs, Maintenance, Replacement, and Delivery," has been revised to reflect the current policy for Durable Medical Equipment (DME) replacements.

Under the circumstance specified below, payment may be made for repair, maintenance, and replacement of medically required DME, including equipment that had been in use before the user enrolled in Part B of the program. However, payment may not be made for repair, maintenance, or replacement of equipment in the frequent and substantial servicing or oxygen equipment payment categories. In addition, payments for repair and maintenance may not include payment for parts and labor covered under a manufacturer's or supplier's warranty.

### Repairs

To repair means to fix or mend and to put the equipment back in good condition after damage or wear. Repairs to equipment that a beneficiary owns are covered when necessary to make the equipment serviceable. However, payment may not be made for repair of previously denied equipment or equipment in the frequent and substantial servicing or oxygen equipment payment categories. If the expense for repairs exceeds the estimated expense of purchasing or renting another item of equipment for the remaining period of medical need, no payment can be made for the excess.

Since renters of equipment recover from the rental charge the expenses they incur in maintaining in working order the equipment they rent out, separately itemized charges for repair of rented equipment are not covered. This includes items in the frequent and substantial servicing, oxygen equipment, capped rental, and inexpensive or routinely purchased payment categories which are being rented.

A new CMN and/or physician's order is not needed for repairs.

### Maintenance

Routine periodic maintenance, such as testing, cleaning, regulating, and checking of the beneficiary's equipment is not covered. Such routine maintenance is generally expected to be done by the owner rather than by a retailer or some other person who charges the beneficiary. Normally, purchasers of DME are given operating manuals that describe the type of servicing an owner may perform to properly maintain the equipment. It is reasonable to expect that beneficiaries will perform this maintenance. Thus, hiring a third party to do such work is for the convenience of the beneficiary and is not covered.

However, more extensive maintenance performed by authorized technicians (based on the manufacturers' recommendations) is covered as repairs for medically necessary equipment a beneficiary owns. This might include, for example, breaking down sealed components and performing tests that require specialized testing equipment not available to the beneficiary. Payment may not be made for maintenance of purchased items that require frequent and substantial servicing or oxygen equipment (MCM section 5102.2.G).

Since renters of equipment recover from the rental charge the expenses they incur in maintaining in working order the equipment they rent out, separately itemized charges for maintenance of rented equipment are generally not covered. Payment may not be made for maintenance of rented equipment other than the maintenance and servicing fee established for capped rental items in MCM section 5102.1.E.4.

A new CMN and/or physician's order is not needed for covered maintenance.

### Replacement

Replacement refers to the provision of an identical or nearly identical item. Situations involving the provision of a different item because of a change in medical condition are not addressed in this section.

Equipment the beneficiary owns (or is a capped rental item) may be replaced in cases of loss or irreparable damage. Irreparable damage refers to a specific accident or to a natural disaster (e.g., fire, flood, etc.). A physician's order and/or new CMN, when required, is needed to reaffirm the medical necessity of the item.

Irreparable wear refers to deterioration sustained from day-to-day usage over time and a specific event cannot be identified. Replacement of equipment due to irreparable wear takes into consideration the reasonable useful lifetime of the equipment. If the item of equipment has been in continuous use by the patient on either a rental or purchase basis for the equipment's useful lifetime, the beneficiary may elect to obtain a new piece of equipment. Replacement may be reimbursed when a new physician order and/or new CMN, when required, is needed to reaffirm the medical necessity of the item.

The reasonable useful lifetime of DME is determined through program instructions. In the absence of program instructions, carriers may determine the reasonable useful lifetime of equipment, but in no case can it be less than five years. Computation of the useful lifetime is based on when the equipment is delivered to the beneficiary, not the age of the equipment. Replacement due to wear is not covered during the reasonable useful lifetime of the equipment. During the reasonable useful lifetime, Medicare does cover repair up to the cost of replacement (but not actual replacement) for medically necessary equipment owned by the beneficiary.

Charges for the replacement of oxygen equipment, items that require frequent and substantial servicing or inexpensive or routinely purchased items that are being rented are not covered.

### Delivery

Payment for delivery of DME whether rented or purchased is generally included in the fee schedule allowance for the item.

Source: CMS Transmittal 1815, CR 2751

# END-STAGE RENAL DISEASE (ESRD)

# MCM Updates Pertaining to Dialysis Services—Correction to Effective Date

We published information pertaining to revisions to sections 15062.1 and 15350 of the Medicare Carriers Manual (MCM) in the Fourth Quarter 2003 *Medicare B Update!* (page 30). Since release of that publication, an additional revision to MCM section 15062.1, "Payment for Physician Services Furnished to Dialysis Inpatients," was issued. The effective date of the change to this section was published as January 1, 2003; however, the correct date is *October* 1, 2003.

We apologize for any inconvenience this may have caused

Source: CMS Transmittal 1810, CR 2622; MCM sections 15062.1 & 15350

**I**MMUNIZATIONS

# 2003 Allowances for Administration of Influenza Virus, Pneumococcal Pneumonia, and Hepatitis B Vaccines

The 2003 allowances for administration of immunizations effective for services rendered on or after March 1, 2003, are not included in the Medicare Physician Fee Schedule (MPFS). HCPCS codes are:

G0008Administration of influenza virus vaccineG0009Administration of pneumococcal vaccine

G0010 Administration of hepatitis B vaccine

The allowance for these services is based on an MPFS code, 90471 (*immunization administration [includes percutaneous, intradermal, subcutaneous, intramuscular and jet injections]; one vaccine (single or combination vaccine/toxoid).* The 2003 allowances for participating providers for this service are:

Connecticut	Florida		
\$8.86	Loc 01/02	Loc 03	Loc 04
	\$7.43	\$8.18	\$8.67

Therefore, these are the allowances for codes G0008, G0009, and G0010.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# New Diagnosis Code for Influenza Virus Vaccine Claims

A new diagnosis code has been issued for billing influenza virus vaccine claims.

All Medicare institutional providers, Part B physicians, nonphysician practitioners, and suppliers who administer the influenza virus vaccine must use the new diagnosis code ICD-9-CM, V04.81 for claims with dates of service **on and after October 1, 2003.** 

CMS has extended a 90-day grace period to accept claims billed by Part B physicians, nonphysician practitioners, and suppliers submitted with the old influenza virus vaccine diagnosis code ICD-9-CM, V04.8. Effective January 1, 2004, **only** claims submitted with the new diagnosis code ICD-9-CM V04.81 will be accepted by Medicare.

Source: Medicare Learning Network @ CMS (http://cms.hhs.gov/medlearn/)

# Payment Amount for the Influenza Virus Vaccine

The payment allowance for influenza virus vaccine codes (*CPT 90658* and *CPT 90659*) has been revised, to **\$9.95**. Part B deductible and coinsurance amounts do not apply. All physicians, non-physician practitioners and suppliers who administer the influenza virus vaccination must take assignment on the claim for the vaccine.

The whole virus vaccine (*CPT 90659*) has not been produced for the 2003 flu season; therefore, providers should not bill *90659* for the influenza virus vaccine, regardless of the inclusion of a payment rate in Change Request 2918. If claims are inadvertently submitted with *90659*, however, they shall be paid the same as *CPT 90658*.

This change is effective for services provided on or after September 1, 2003, for claims processed on or after October 1, 2003.

Source: CMS Pub. 100-20 Transmittal: 3 Date: September 12, 2003 Change Request 2918

(

# Pneumococcal Pneumonia Vaccine (PPV) Payment Increase Effective October 1, 2003

Effective October 1, 2003, the Medicare Part B payment for PPV will be increased to the lower of the charge billed to Medicare or \$18.62. Annual Part B deductible and coinsurance amounts do not apply. All physicians, non-physician practitioners, and suppliers who administer PPV must take assignment on the claim for the vaccine.

For additional information about immunizations, refer to the Immunizations Quick Reference Guide at www.cms.hhs.gov/medlearn/refimmu.asp.

Source: CMS Notification Dated August 20, 2003

# LABORATORY/PATHOLOGY

## **Guidelines for Medicare Part B Laboratory Testing**

This article explains the Centers for Medicare & Medicaid Services' (CMS) coverage policies for diagnostic and screening prostate specific antigen (PSA) laboratory tests under Medicare Part B. It also explains the importance of including the date of service on orders for laboratory testing.

### **Diagnostic PSA Laboratory Testing**

- Under section 4554(b)(1) of the Balanced Budget Act (BBA), Public Law 105-33 mandated the use of negotiated rulemaking with interested parties in the laboratory community to promote uniformity, administrative simplicity, and program integrity regarding coverage and administrative policies for clinical diagnostic laboratory services payable under Medicare Part B. As a result of this negotiated rulemaking, a National Coverage Decision (NCD) was developed for the diagnostic PSA test, which is a tumor marker for adenocarcinoma of the prostate and may be useful in the differential diagnosis of men presenting with as yet undiagnosed disseminated metastatic disease. When used in conjunction with other prostate cancer tests, such as digital rectal examination, the PSA test may assist in the decisionmaking process for diagnosing prostate cancer. PSA also serves as a marker in following the progress of most prostate tumors once a diagnosis has been established, as an aid in the management of prostate cancer patients, and in detecting metastatic or persistent disease in patients following treatment. The test is of proven value in differentiating benign from malignant disease men with lower urinary tract signs and symptoms (i.e., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia, and incontinence) as well as patients with palpably abnormal prostate glands on physical exam, and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate disorder.
- The NCD for diagnostic PSA tests does not apply to screening PSA tests.
- Use *CPT*/HCPCS code *84153* for diagnostic PSA testing.

### Screening PSA Laboratory Testing

 Screening PSA testing measures the level of prostate specific antigen in the patient's blood for the early detection of the marker for adenocarcinoma of the prostate subject to coverage, frequency, and payment limitations as follows:

-Covered at a frequency of once every 12 months for men who have attained age 50 if at least 11 months have passed following the month in which the last Medicare-covered screening PSA test was performed; and

- -Must be ordered by the patient's physician, physician assistant, nurse practitioner, clinical nurse specialist, or certified nurse midwife who is authorized under state law to perform the examination, fully knowledgeable about patient's medical condition, and who would be responsible for using the results of any examination (test) performed in the overall management of the patient's specific medical problem which includes explaining the results of the test to the patient.
- Use HCPCS code G0103 for the screening PSA test.

### Date of Service for Laboratory Testing

During the clinical diagnostic laboratory services negotiated rulemaking, CMS learned that there was considerable variability regarding the date of service on laboratory claims. In order to promote uniformity, the committee recommended a national policy related to the date of service on laboratory claims. CMS published a proposed rule for public comment on March 10, 2000 (65 FR 13082) and published the rule final on November 23, 2001 (66 FR 58788). The final rule states that:

- The date of service for laboratory tests that is reported on the claim is to be the date the tested specimen was collected; and
- The person obtaining the specimen must furnish the date of collection of the specimen to the entity billing Medicare.

Physicians or their staff who draw specimens for testing must report the date of collection of the specimen on orders for laboratory tests. Laboratories may refuse to perform tests on orders for laboratory tests that do not include the information they need in order to seek payment for services performed, i.e., the date of collection of the specimen.

Source: CMS Transmittal AB-03-132, CR 2841

# Changes to the Laboratory National Coverage Determination Edit Software for January 1, 2004

National coverage determinations (NCDs) for clinical diagnostic laboratory services were developed by the laboratory negotiated rulemaking committee and published as a final rule on November 23, 2001. Nationally uniform software has been developed by Computer Science Corporation and incorporated in the shared systems so laboratory claims subject to one of 23 NCDs are processed uniformly throughout the nation effective January 1, 2003. Listed below are changes included in the January 2004 release of the edit module for clinical diagnostic laboratory services.

- 1. In accordance with the decision memorandum published on the coverage Internet site on September 17, 2003 (see *http://cms.hhs.gov/mcd/viewdecisionmemo.asp?id=97*), the following diagnosis codes are being added to the list of ICD-9-CM Codes Covered by Medicare for the prothrombin time (PT) and fecal occult blood test (FOBT) NCDs:
  - 863.91, pancreas head with open wound into cavity;
  - 863.92, pancreas body with open wound into cavity;
  - 863.93, pancreas tail with open wound into cavity;
  - 863.94, pancreas multiple and unspecified sites with open wound into cavity;
  - 863.95, appendix with open wound into cavity; and,
  - 863.99, other gastrointestinal sites with open wound into cavity.
- 2. In accordance with the decision memorandum published on the coverage Internet site on September 23, 2003 (see *http://cms.hhs.gov/mcd/viewdecisionmem.asp?id=93*), the following diagnosis codes are being deleted from the list of ICD-9-CM Codes Covered by Medicare for prothrombin time (PT) and partial thromboplastin time (PTT) NCDs:
  - V72.81, pre-operative cardiovascular examination (from PTT);
  - V72.83, other specified pre-operative examination (from PTT); and,
  - V72.84, pre-operative examination, unspecified (from PT and PTT).
- 3. In Program Memorandum AB-03-104 (CR 2814), CMS announced the addition of diagnosis code 401.1, benign essential hypertension, to the list of covered diagnoses for lipid testing. However, the corresponding change to the narrative of the lipid NCD that authorizes this code was not announced. By inclusion in this notice, CMS is announcing a change to the narrative of the lipid NCD included in the July 17, 2003, decision memorandum posted on the Internet at *http://cms.hhs.gov/mcd/viewdecisionmemo.asp?id=94*. The third bullet listed in the lipid NCD indications section is amended to read: "Any form of atherosclerotic disease, or any disease leading to the formation of atherosclerotic disease."
- 4. In Program Memorandum AB-03-104, CMS announced a number of ICD-9-CM codes deleted by the update to ICD-9-CM codes that became effective October 1, 2003. A 90-day grace period for the provider and laboratory community to adapt to these changes is provided. Thus, while CMS announced the changes in CR 2814, the software was not altered to deny claims when these codes were used. However, the grace period expires with the January update of the software and the following ICD-9-CM codes will be denied: 282.4, 331.1, 348.3, 530.2, 600.0, 600.1, 600.2, 600.9, 767.1, 790.2, V04.8, V43.2, V53.9, V54.0, V65.1.

Source: CMS Pub. 100-20 Transmittal: 10 Date: October 24, 2003 Change Request 2940

# Fecal Leukocyte Examination under a CLIA Certificate for Provider-Performed Microscopy

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) require a facility to be appropriately certified for each test performed. A facility that has a CLIA certificate for provider-performed microscopy (PPM) procedures may only perform tests that are categorized as either PPM procedures or waived tests under CLIA.

The Healthcare Common Procedure Coding System (HCPCS) code G0026 (fecal leukocyte examination) was discontinued on December 31, 2002. For calendar year (CY) 2003, *CPT* code 89055 (*Leukocyte count, fecal*) was suggested as a possible code to be used for the discontinued G0026. However, under CLIA, the fecal leukocyte examination permitted for a PPM procedure certificate does not include a fecal leukocyte count. For CY 2003, Medicare contractors were instructed to permit the use of existing HCPCS code Q0111 (Wet mounts, including preparations of vaginal, cervical or skin specimens) for fecal leukocyte examination claims submitted by facilities with a valid PPM procedure CLIA

certificate with dates of services on or after January 1, 2003, in Transmittal AB-03-127 (Change Request 2843). This instruction was posted to our provider education Web site on September 5, 2003.

The wording of the *CPT* code 89055 has been revised for CY 2004 to read "*Leukocyte assessment*, *fecal, qualitative or semiquantitative*." The revised text meets the CLIA definition of the PPM procedure for the fecal leukocyte examination.

Therefore, effective for services rendered on or after January 1, 2004, a facility that has a CLIA certificate for PPM procedures may bill *CPT* code *89055* for fecal leukocyte examination.

Source: CMS Pub. 100-04 Transmittal: 12 Date: October 24, 2003 Change Request 2924

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2003 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Payment for Fecal Leukocyte Examination Under a CLIA Certificate for Provider-Performed Microscopy (PPM) Procedures During 2003

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires a facility to be appropriately certified for each test performed. A facility that has a CLIA certificate for PPM procedures may only perform tests that are categorized as either PPM procedures or waived tests under CLIA.

HCPCS code G0026 (fecal leukocyte examination) was discontinued effective for services rendered on or after January 1, 2003. *CPT* code 89055 (fecal leukocyte count) was a possible replacement code to be used for the discontinued G0026; however, under CLIA the fecal leukocyte examination permitted for a PPM procedure certificate does not include a fecal leukocyte count. Therefore, Medicare will permit the use of HCPCS code Q0111 (Wet mounts, including preparations of vaginal, cervical or skin specimens) for fecal leukocyte examination claims submitted by facilities with a valid PPM procedure CLIA certificate with dates of services on or after January 1, 2003.

Source: CMS Transmittal AB-03-127, CR 2843

# New CLIA Waived Tests

Listed below are the latest tests approved by the Food and Drug Administration as waived tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), effective June 1, 2002. The *Current Procedural Terminology (CPT)* codes for these new tests must be billed with modifier QW to be recognized as a waived test.

CPT Code	Test Name	Manufacturer	Effective Date	Use
80101QW	ADC CLIA Waived Marijuana (THC) Test	Advance Diagnostics Corporation (ADC)	4/29/03	Screening test for the presence/ detection of cannabinoids (THC) in urine
80101QW	ADC CLIA Waived Multiple Drug Test Card	Advance Diagnostics Corporation (ADC)	4/29/03	Screening test for the presence/ detection of cannabinoids (THC), cocaine metabolites, methamphet- amine opiates and phencyclidine (PCP) in urine.
80101QW	ADC CLIA Waived Marijuana (THC) and Cocaine Test	Advance Diagnostics Corporation (ADC)	4/30/03	Screening test for the presence/ detection of cannabinoids (THC), cocaine metabolites in urine.
86308QW	Genzyme OSOM Mono Test	Wyntek Diagnostic, Inc.	3/6/03	Quantitative screening test for the presence of heterophile antibodies in human whole blood, which is used as an aid in the diagnosis of infections mononucleosis.
87077QW	GI Supply, Div. Chek-Med Systems HP One	Phamatech	3/24/03	Presumptive identification of <i>Helicobacter pylori</i> in gastric biopsy tissue, which has been shown to cause chronic active gastritis (ulcers).

Source: CMS Pub. 100-20 Transmittal 5, CR 2791, PCM #0327503

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 American Medical Association (or other such date of publication of *CPT*). All rights reserved. Applicable FARS/ DFARS apply.

# Diagnosis Code for Screening Pap Smear and Pelvic Examination Services—Effective Date

We provided information regarding additional allowable diagnosis codes for Pap smear and pelvic examinations in the Fourth Quarter 2003 *Medicare B Update!* (page 33). We published this change as being based on the date services are provided; however, the additional diagnoses are effective for services *processed* on or after October 1, 2003. We apologize for any inconvenience this may have caused.

# ICD-9-CM Codes and Definitions Low Risk

V76.2 Cervix (routine cervical Papanicolaou smear) V76.47 Special screening for malignant neoplasm, vagi

V76.47 Special screening for malignant neoplasm, vaginaV76.49 Special screening for malignant neoplasm, other sites

### High Risk

V15.89 Other

Source: CMS Transmittal AB-03-054, CR 2637

# Use of Modifier GY to Identify Clinical Diagnostic Laboratory Services Not Covered by Medicare

In November 2002, Medicare implemented 23 national coverage determinations (NCDs) for clinical diagnostic laboratory services. These NCDs are specific down to the ICD-9-CM code level and included lists of ICD-9-CM codes that are covered and those that are not covered by Medicare. The ICD-9-CM codes that are not covered by Medicare are codes that are excluded from coverage based on technical denials, such as routine screening services, rather than denial due to lack of medical necessity. Laboratories are permitted to bill beneficiaries for services that are not covered by Medicare for reasons other than medical necessity without providing for an advance beneficiary notice (ABN).

Medicare clinical diagnostic laboratory services are processed using a standardized laboratory edit module. This edit module returns a message to the local contractor indicating whether the claim passed the NCDs coverage edits, is denied for diagnoses on the noncovered list, or is denied as not medically necessary. Healthcare Common Procedure Coding System (HCPCS) coding provides for modifier GY to be used to indicate an item or service that is statutorily excluded, or does not meet the definition of any Medicare benefit. At present, the laboratory edit module response is not affected by the use of this modifier.

By January 1, 2004, the clinical diagnostic laboratory service edit module will be changed to consider the presence of modifier GY in selecting the appropriate response for claims for clinical diagnostic laboratory services. Use of modifier GY will result in a not covered response from the edit module in all cases. Laboratories should append modifier GY to the procedure codes for any service where the appropriate diagnosis for that service is on the list of diagnoses that are not covered by Medicare.

Source: CMS Pub. 100-04 Transmittal: 11 Date: October 24, 2003 Change Request 2933

# **PHYSICAL THERAPY/OCCUPATIONAL THERAPY**

# Changes to Code List for Therapy Services

CMS Program Memorandum (PM) B-03-065 supplements PM AB-03-018, CR 2183 and directs carriers to update the code list for therapy services that will not apply to the financial limitations when billed by physicians and certain nonphysician practitioners when not done under a therapy plan of care. This PM supersedes the effective date and implementation dates of PM AB-03-057 (CR 2709) only with respect to the "+" indicators on the list of HCPCS codes.

**S** ection 4541(a)(2) of the Balanced Budget Act (BBA) (P.L. 105-33) of 1997, required payment under a prospective payment system for outpatient rehabilitation services. Outpatient rehabilitation services include the following services:

- Physical therapy (which includes outpatient speech-language pathology); and
- Occupational therapy.

Section 4541(c) of the BBA required application of a financial limitation to all outpatient rehabilitation services (with the exception of outpatient departments of a hospital). These limits were in effect in 1999, but were removed in 2000-2002. Beginning September 1, 2003, the limitations on outpatient therapy services will be implemented again.

# Applicable Outpatient Rehabilitation HCPCS Codes

The following is a complete list of the 55 "+" codes. It includes 36 newly designated codes in bold and 19 codes previously designated "+". 29065+ 29075+ 29085+ 29086+ 29105+ 29125+ 29126+ 29130+ 29131+ 29200+ 29220+ 29240+ 29260+ 29280+ 29345+ 29355+ 29365+ 29405+ 29425+ 29445+ 29505+ 29515+ 29520+ 29530+ 29540+ 29550+ 29580+ 29590+ 64550+ 90901+ 90911+ 92610+ 92611+ 92612+ 92614+ 92616+ 95831+ 95832+ 95833+ 95834+ 95851+ 95852+ 96000+ 96001+ 96002+ 96003+ 96105+ 96110+ 96111+ 96115+ 97601+ G0279+ G0280+ 0020T+ 0029T+

+ These codes will *not* apply to the financial limits when they are *not* done under a therapy plan of care and they are billed by providers of services who are represented by any specialty codes except 65 and 67 (PT in Private Practice, OT in Private Practice), also 73 and 74 (which were incorrectly noted in AB-03-018 and have since been reassigned to specialties that are not therapy services). Specialty codes 73 and 74 will be removed in a future instruction. Physicians and nonphysician practitioners should only use therapy modifiers (GP, GN, GO) with the above codes when the services are provided under a therapy plan of care.

As a reminder, a plan of care must be on file, when appropriate, for all outpatient therapy services. Providers should resubmit claims returned for lack of therapy modifiers (GP, GN, GO) on the above codes newly designated with "+" (bolded) for services provided during July and August 2003. In addition, therapy modifiers should not be used with claims with HCPCS codes noted with "+" unless that service is performed under a therapy plan of care.

Source: CMS Transmittal B-03-065, CR 2821

# Radiology

## **Billing Mammography with CAD Codes**

CMS has issued revised Medicare Carriers Manual instructions effective January 1, 2004, that change the billing requirements for computer aided detection devices (CAD) in conjunction with mammography services by deleting the two existing CAD codes and replacing them with two new codes. The revisions are as follows:

- Section 4601.1, Screening Mammography Examinations. Dates in the note (example) have been revised to reflect more recent dates.
- Section 4601.2, Identifying a Screening Mammography Claim and a Diagnostic Mammography Claim, has been updated to include a language that carriers are no longer permitted to "plug" the ICD-9-CM code for a screening mammography when the screening mammography claim has no diagnosis code. Screening mammography claims with no diagnosis code must be returned as unprocessable for assigned claims and denied for unassigned claims. It also reflects changes beginning January 1, 2004.
- Section 4601.3, Adjudicating the Claim, has been updated to reflect changes beginning January 1, 2004, the Common Working File (CWF) will not edit for place of service.
- Section 4601.6, Diagnostic and Screening Mammograms Performed With New Technologies, has been updated to add two new CAD codes, 76082 and 76083, to be billed in conjunction with screening or diagnostic film or digital mammography codes effective January 1, 2004. CAD code G0236 and CAD code 76085 should not be reported for claims with dates of service on or after January 1, 2004. Section has also been revised to include a statement that screening and diagnostic mammographies (film and digital) are subject to the FDA certification. CAD equipment does not require FDA certification. Section C has been deleted as it duplicates sections 4601.2H and 4601.2I.

Source: CMS Transmittal 1814, CR 2632

# **New Modifiers for Transportation of Portable X-Ray Equipment**

Effective January 1, 2004, one of five new modifiers Will be required on Medicare claims when reporting HCPCS code R0075 (Transportation of portable X-ray equipment and personnel to home or nursing home, per trip to facility or location, more than one patient seen).

Only a single transportation payment for each trip the portable X-ray supplier makes to a particular location (e.g., nursing home) is allowed. When reporting a transportation service and more than one Medicare patient is X-rayed at the same location, payment for R0075 is prorated among all patients receiving the services.

R0075 must be billed in conjunction with the CPT radiology codes (70000 series) and only when the X-ray

equipment used was actually transported to the location where the X-ray was taken. R0075 would not apply to the X-ray equipment stored in the location where the X-ray was done (e.g., a nursing home) for use as needed.

Below are the definitions for each modifier that must be reported with R0075. Only one of these five modifiers can be reported with R0075.

- UN Two patients served
- UP Three patients served
- UQ Four patients served
- UR Five patients served
- US Six patients or more served

Source: CMS Pub. 100-04 Transmittal: 14 Date: October 24, 2003 Change Request 2856

# SURGERY

## National Coverage Determination—Implantable Automatic Defibrillators

This provider education article discusses the background of the National Coverage Determination (NCD) to expand coverage of implantable automatic defibrillators for services rendered on or after October 1, 2003, coverage guidelines, billing instructions for providers who render services to managed care patients, and billing instructions for providers who render services to fee-for-service patients.

### Background

The NCD will be effective on October 1, 2003, to expand coverage of implantable automatic defibrillators for Medicare managed care and fee-for-service patients. Providers will be reimbursed for services provided to managed care patients for implantable automatic defibrillators that fall under the expanded coverage indications effective October 1, 2003, according to the NCD on a fee-for-service basis until capitation rates are adjusted to account for this expanded coverage.

### **Coverage Guidelines**

The following service is covered when rendered on or after July 1, 1991:

 Documented episode of cardiac arrest due to ventricular fibrillation (VF), not due to a transient or reversible cause;

### COVERAGE/REIMBURSEMENT

The following services are covered when rendered on or after July 1, 1999:

- Documented sustained ventricular tachyarrhythmia (VT), either spontaneous or induced by an electrophysiology (EP) study, not associated with an acute myocardial infarction (MI) and not due to a transient or reversible cause;
- Documented familial or inherited indications with a high risk of life-threatening VT, such as long QT syndrome or hypertropic cardiomyopathy;

As stated in the NCD, the following indications will be covered when rendered on or after October 1, 2003:

- Coronary artery disease with a documented prior MI, a measured left ventricular ejection fraction = 0.35, and inducible, sustained VT or VF at EP study. (The MI must have occurred more than 4 weeks prior to defibrillator insertion. The EP test must be performed more than 4 weeks after the qualifying MI.);
- Documented prior MI and a measured left ventricular ejection fraction = 0.30 and a QRS duration of > 120 milliseconds. Patients must not have:
  - a) New York Heart Association classification IV;
  - b) Cardiogenic shock or symptomatic hypotension while in a stable baseline rhythm;
  - c) Had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within past 3 months;
  - d) Had an enzyme-positive MI within past month;
  - e) Clinical symptoms or findings that would make them a candidate for coronary revascularization; or
  - f) Any disease, other than cardiac disease (e.g., cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year.

As stated in the NCD, effective October 1, 2003, the following additional coverage guidelines apply:

- All patients considered for implantation of a defibrillator must not have irreversible brain damage, disease, or dysfunction that precludes the ability to give informed consent;
- MIs must be documented by elevated cardiac enzymes or Q-waves on an electrocardiogram.
- Ejection fractions must be measured by angiography, radionuclide scanning, or echocardiography; and
- All other indications remain noncovered except in Category B IDE clinical trials (60 CFR 48417) or as a routine cost in clinical trials defined under CIM 30-1.

*Note*: Refer to Coverage Issues Manual, Section 35-85 (revisions effective October 1, 2003).

### Billing Instructions for Providers Who Render Services to Managed Care Patients

The following instructions apply to providers who render expanded implantable automatic defibrillator services to managed care patients:

- Providers are encouraged not to submit claims for services rendered on or after October 1, 2003, because Medicare will not be able to process the claims until January 5, 2004. Providers should begin billing for these services on or after January 5, 2004.
- Physicians must use modifier KZ (new coverage not implemented by managed care) when billing for services rendered on and after October 1, 2003.
- Providers billing fiscal intermediaries on or after October 1, 2003, must use condition code 78 (payment for coverage not implemented by HMO).
- Providers who are paid under the Outpatient Prospective Payment System (OPPS) must bill all services related to this expanded coverage on one claim and for the same date of service, using condition code 78.
- Providers billing carriers and providers who are paid under the OPPS must split the bills if they overlap September 2003 and October 2003.
- Patients who receive these services must pay any applicable coinsurance amounts.
- For services rendered to managed care patients whose indications fall outside this expanded coverage, providers must not bill using condition code 78 or modifier KZ.

### Billing Instructions for Providers Who Render Services to Fee-for-Service Patients

The following instructions apply to providers who render expanded implantable automatic defibrillator services to fee-for-service patients:

• Claims for these services cannot be billed using modifier KZ, condition code 78, or for services outside of this expanded coverage.

### **Procedure Codes**

The new G codes listed at right are payable under OPPS effective October 1, 2003. These new G codes are **not** payable under the Medicare physician fee schedule and, therefore, should not be billed to Medicare carriers.

### G0297, G0298, G0299, G0300,

ICD-9-CM Procedure Code 37.94 (for 11X TOBs)

The physician should bill for the appropriate service from the range of *CPT* codes below. These services should be billed to the appropriate Medicare carrier for payment.

33240, 33241, 33243, 33244, 33245, 33246, 33249

Source: CMS Transmittal AB-03-134, CR 2880 CMS PUB. 100-20 Transmittal 4, CR 2922

## **Processing and Payment of Incomplete Screening Colonoscopies**

**Background**– Medicare covers colorectal cancer screening test/procedures for the early detection of colorectal cancer when coverage conditions are met. Among the screening procedures covered are screening colonoscopies (G0105–Colorectal cancer screening; colonoscopy on individual at high risk; and G0121– Colorectal screening; colonoscopy on individual not meeting criteria for high risk).

In some instances, a provider may begin a screening colonoscopy, but, because of extenuating circumstances, be unable to complete the procedure. At another time, the provider may attempt and complete the intended screening colonoscopy on the patient. This situation parallels those of diagnostic colonoscopies in which the provider is unable to complete the colonoscopy because of extenuating circumstances and must attempt a complete colonoscopy at a later time. If coverage conditions are met, Medicare pays for both the uncompleted colonoscopy and the completed colonoscopy whether the colonoscopy is screening in nature or diagnostic.

Because coverage of these services is subject to frequency limitations, we must be able to distinguish between those services that are subject to the frequency limitation from those that are not. It is not appropriate to count the incomplete colonoscopy toward the beneficiary's frequency limit for a screening colonoscopy because that would preclude the beneficiary's being able to obtain a covered completed colonoscopy. We are making changes to ensure that incomplete screening colonoscopies are not counted when calculating frequency limitations for this benefit.

**Policy**– When a covered colonoscopy is attempted but cannot be completed because of extenuating circumstances (refer to Medicare Carriers Manual section 15100B), Medicare will pay for the interrupted colonoscopy at a rate consistent with that of a flexible sigmoidoscopy as long as coverage conditions are met for the incomplete procedure. When a covered colonoscopy is next attempted and completed, Medicare will pay for that colonoscopy according to its payment methodology for this procedure as long as coverage conditions are met. This policy is applied to both screening and diagnostic colonoscopies. When submitting a claim for the interrupted colonoscopy, professional providers are to suffix the colonoscopy code with modifier -53 to indicate that the procedure was interrupted. When submitting a claim for the facility fee associated with this procedure, Ambulatory Surgical Centers (ASCs) are to append the colonoscopy code with modifier -73 or -74, as appropriate. Payment for covered screening colonoscopies, including that for the associated ASC facility fee when applicable, will be consistent with payment for diagnostic colonoscopies, whether the procedure is complete or incomplete.

The provider is expected to maintain adequate information in the patient's medical record in case it is needed by the contractor to document the incomplete procedure.

Source: CMS Transmittal AB-03-114, CR 2822

# **Other Services and Procedures**

# Coverage of Hyperbaric Oxygen (HBO) Therapy for the Treatment of Diabetic Wounds of the Lower Extremities— Clarification

CMS has revised the national coverage decision for hyperbaric oxygen (HBO) therapy for the treatment of diabetic wounds of the lower extremities. Changes have been made to the ICD-9-CM codes in this policy effective for services furnished on or after April 1, 2003.

The following ICD-9-CM codes have been updated to the fifth level of specificity:

- 250.7 updated to 250.70
- 250.8 updated to 250.83
- 707.1 updated to 707.10, 707.12, 707.13, 707.14, 707.15 and 707.19
- ICD-9-CM 707 has been removed since this is the title of a category, not a valid ICD-9-CM code.

All other information and instructions in the local medical review policy (LMRP) 99183: Hyperbaric Oxygen Therapy (HBO Therapy) remain in effect. The LMRP reflecting these changes will be revised in the near future.

Source: CMS Transmittal AB-03-102, CR 2769

# General Information

# FRAUD, WASTE, AND ABUSE

## Office of Inspector General Special Advisory Bulletin, April 2003— Contractual Joint Ventures

This Special Advisory Bulletin addresses certain complex contractual arrangements for the provision of items and services previously identified as suspect in our 1989 Special Fraud Alert on Joint Venture Arrangements.<sup>1</sup> While much of the discussion in the 1989 Special Fraud Alert focused on investor referrals to newly formed entities, we observed that:

> [t]he Office of Inspector General has become aware of a proliferation of arrangements between those in a position to refer business, such as physicians, and those providing items or services for which Medicare or Medicaid pays. Some examples of the items or services provided in these arrangements include clinical diagnostic laboratory services, durable medical equipment (DME), and other diagnostic services. Sometimes these deals are called "joint ventures." A joint venture may take a variety of forms: it may be a contractual arrangement between two or more parties to cooperate in providing services, or it may involve the creation of a new legal entity by the parties, such as a limited partnership or closely held corporation, to provide such services. [Emphasis added.]

Notwithstanding that caution, the Office of Inspector General (OIG) is concerned that contractual joint venture arrangements are proliferating.<sup>2</sup>

### A. Questionable Contractual Arrangements

The federal anti-kickback statute, section 1128B(b) of the Social Security Act (the Act), prohibits knowingly and willfully soliciting, receiving, offering, or paying anything of value to induce referrals of items or services payable by a federal health care program. Kickbacks are harmful because they can (1) distort medical decisionmaking, (2) cause overutilization, (3) increase costs to the federal health care programs, and (4) result in unfair competition by freezing out competitors unwilling to pay kickbacks. Both parties to an impermissible kickback transaction may be liable. Violation of the statute constitutes a felony punishable by a maximum fine of \$25,000, imprisonment up to 5 years, or both. The OIG may also initiate administrative proceedings to exclude persons from the federal health care programs or to impose civil money penalties for kickback violations under sections 1128(b)(7) and 1128A(a)(7) of the Act.

This Special Advisory Bulletin focuses on questionable contractual arrangements where a health care provider in one line of business (hereafter referred to as the "Owner") expands into a related health care business by contracting with an existing provider of a related item or service (hereafter referred to as the "Manager/ Supplier") to provide the new item or service to the Owner's existing patient population, including federal health care program patients. The Manager/Supplier not only manages the new line of business, but may also supply it with inventory, employees, space, billing, and other services. In other words, the Owner contracts out substantially the entire operation of the related line of business to the Manager/Supplier – otherwise a potential competitor – receiving in return the profits of the business as remuneration for its federal program referrals.

Some examples of potentially problematic contractual arrangements include the following:

- A hospital establishes a subsidiary to provide DME. The new subsidiary enters into a contract with an existing DME company to operate the new subsidiary and to provide the new subsidiary with DME inventory. The existing DME company already provides DME services comparable to those provided by the new hospital DME subsidiary and bills insurers and patients for them.
- A DME company sells nebulizers to federal health care beneficiaries. A mail order pharmacy suggests that the DME company form its own mail order pharmacy to provide nebulizer drugs. Through a management agreement, the mail order pharmacy runs the DME company's pharmacy, providing personnel, equipment, and space. The existing mail order pharmacy also sells all nebulizer drugs to the DME company's pharmacy for its inventory.
- A group of nephrologists establishes a wholly-owned company to provide home dialysis supplies to their dialysis patients. The new company contracts with an existing supplier of home dialysis supplies to operate the new company and provide all goods and services to the new company.

These problematic arrangements typically exhibit certain common elements. First, the Owner expands into a related line of business, which is dependent on referrals from, or other business generated by, the Owner's existing business.<sup>3</sup> The new business line may be organized as a part of the existing entity or as a separate subsidiary. Typically, the new business primarily serves the Owner's existing patient base.

Second, the Owner neither operates the new business itself nor commits substantial financial, capital, or human resources to the venture. Instead, it contracts out

### GENERAL INFORMATION

substantially all the operations of the new business. The Manager/Supplier typically agrees to provide not only management services, but also a range of other services, such as the inventory necessary to run the business, office and health care personnel, billing support, and space. While the Manager/Supplier essentially operates the business, the billing of insurers and patients is done in the name of the Owner. In many cases, the contractual arrangements result in either practical or legal exclusivity for the Manager/Supplier through inclusion of noncompetition provisions or restrictions on access. While the contract terms of these arrangements may appear to place the Owner at financial risk, the Owner's actual business risk is minimal because of the Owner's ability to influence substantial referrals to the new business.

Third, the Manager/Supplier is an established provider of the same services as the Owner's new line of business. In other words, absent the contractual arrangement, the Manager/Supplier would be a competitor of the new line of business, providing items and services in its own right, billing insurers and patients in its own name, and collecting reimbursement.

Fourth, the Owner and the Manager/Supplier share in the economic benefit of the Owner's new business. The Manager/Supplier takes its share in the form of payments under the various contracts with the Owner; the Owner receives its share in the form of the residual profit from the new business.

Fifth, aggregate payments to the Manager/Supplier typically vary with the value or volume of business generated for the new business by the Owner. While in some arrangements certain payments are fixed (for example, the management fee), other payments, such as payments for goods and services supplied by the Manager/Supplier, will vary based on the number of goods and services provided. In other words, the aggregate payment to the Manager/Supplier from the whole arrangement will vary with referrals from the Owner. Likewise, the Owner's payments, that is, the difference between the net revenues from the new business and its expenses (including payments to the Manager/Supplier), also vary based on the Owner's referrals to the new business. Through these contractual payments, the parties are able to share the profits of the new line of business.

# B. Safe Harbor Protection May Be Unavailable

Under the kickback statute, a number of statutory and regulatory "safe harbors" immunize certain arrangements that might otherwise violate the anti-kickback statute. (See 42 U.S.C. 1320a-7b(b)(3); 42 CFR 1001.952.) To qualify for safe harbor protection, an arrangement must fit squarely in one of these safe harbor provisions. Some parties attempt to carve otherwise problematic contracting arrangements into several different contracts for discrete items or services (e.g., a management contract, a vendor contract, and a staffing contract), and then qualify each separate contract for protection under a "safe harbor." Such efforts may be ineffectual and leave the parties subject to prosecution for the following reasons.

First, many of these questionable joint venture arrangements involve contracts pursuant to which the Manager/Suppliers agree to sell items and services to the Owners at a discounted price. However, where a discount is given as part of an overarching business arrangement, it cannot qualify for protection under the discount safe harbor. Simply put, the discount safe harbor does not protect – and has never protected – prices offered by a seller to a buyer in connection with a common enterprise. To be protected under the discount safe harbor, a price reduction must be based on an *arms length transaction*. (See 42 CFR 1001.952(h) under which "the term *discount* means a reduction in the amount a buyer . . . is charged for an item or service based on an arms-length transaction."). As we expressly stated in the preamble to the 1991 safe harbor regulations, the provision of items or services to a joint venture by a participant in the venture is not an "arms length" transaction:

> Another problem exists where an entity, which is both a provider and supplier of items or services and joint venture partner with referring physicians, makes discounts to the joint venture as a way to share its profits with the physician partners. Very often this entity furnishes items or services to the joint venture, and also acts as the joint venture's general partner or provides management services to the joint venture. . . . These arrangements are not arms length transactions where the joint venture shops around for the best price on a good or service. Rather it has entered into a collusive arrangement with a particular provider or supplier of items or services that seeks to share its profits with referring physician partners. [We did] . . . not intend to protect these types of transactions which are sometimes made to appear as 'discounts'.... [Emphasis added] (See 56 FR 35977; July 29, 1991).

In short, a discount is not based on arms length transaction if it is provided by a seller to a purchaser in connection with a common venture, regardless of whether the venture is memorialized in separate contracts. Second, even if the various contracts could fit in one or more safe harbors, they would only protect the remuneration flowing from the Owner to the Manager/ Supplier for actual services rendered. In the contractual arrangements that are the subject of this Bulletin, however, the illegal remuneration is often the difference between the money paid by the Owner to the Manager/ Supplier and the reimbursement received from the federal health care programs. By agreeing effectively to provide services it could otherwise provide in its own right for less than the available reimbursement, the Manager/Supplier is providing the Owner with the opportunity to generate a fee and a profit. The opportunity to generate a fee is itself remuneration that may implicate the anti-kickback statute.

# C. Indicia of a Suspect Contractual Joint Venture

To help identify the suspect contractual joint ventures that are the focus of this Special Advisory Bulletin, we describe below some characteristics, which, taken separately or together, potentially indicate a prohibited arrangement. This list is illustrative, not exhaustive.

**New Line of Business.** The Owner typically seeks to expand into a health care service that can be provided to the Owner's existing patients. As illustrated in Part A, examples include, but are not limited to, hospitals

### **GENERAL INFORMATION**

expanding into DME services, DME companies expanding into the nebulizer pharmacy business, or nephrologists expanding into the home dialysis supply business.<sup>4</sup>

**Captive Referral Base.** The newly-created business predominantly or exclusively serves the Owner's existing patient base (or patients under the control or influence of the Owner). The Owner typically does not intend to expand the business to serve new customers (i.e., customers not already served in its main business) and, therefore, makes no or few *bona fide* efforts to do so.

Little or No *Bona Fide* Business Risk. The Owner's primary contribution to the venture is referrals; it makes little or no financial or other investment in the business, delegating the entire operation to the Manager/Supplier, while retaining profits generated from its captive referral base. Residual business risks, such as nonpayment for services, are relatively ascertainable based on historical activity.

**Status of the Manager/Supplier.** The Manager/Supplier is a would-be competitor of the Owner's new line of business and would normally compete for the captive referrals. It has the capacity to provide virtually identical services in its own right and bill insurers and patients for them in its own name.

### **Scope of Services Provided by the Manager/Supplier.** The Manager/Supplier provides all, or many, of the

• day-to-day management;

following key services:

- billing services;
- equipment;
- personnel and related services;
- office space;
- training;
- health care items, supplies, and services.<sup>5</sup>

In general, the greater the scope of services provided by the Manager/Supplier, the greater the likelihood that the arrangement is a contractual joint venture.

**Remuneration.** The practical effect of the arrangement, viewed in its entirety, is to provide the Owner the opportunity to bill insurers and patients for business otherwise provided by the Manager/Supplier. The remuneration from the venture to the Owner (i.e., the profits of the venture) takes into account the value and volume of business the Owner generates.

**Exclusivity.** The parties may agree to a non-compete clause, barring the Owner from providing items or services to any patients other than those coming from Owner and/or barring the Manager/Supplier from providing services in its own right to the Owner's patients.

As noted above, these factors are illustrative, not exhaustive. The presence or absence of any one of these factors is not determinative of whether a particular arrangement is suspect. As indicated, this Special Advisory Bulletin is not intended to describe the entire universe of suspect contractual joint ventures. This Bulletin focuses on arrangements where substantially all of the operations of a new line of business are contracted out to a would-be competitor. Arrangements involving the delegation of fewer than substantially all services, or delegation to a party not otherwise in a position to bill for the identical services, may also raise concerns under the anti-kickback statute, depending on the circumstances.

<sup>1</sup>The 1989 Special Fraud Alert was reprinted in the Federal Register in 1994. See 59 FR 65372 (December 19, 1994). The Special Fraud Alert is also available on our web page at *http://oig.hhs.gov/fraud/docs/alertsandbulletins/121994.html*.

<sup>2</sup>The kinds of contractual arrangements addressed in this Special Advisory Bulletin are sometimes referred to as "joint ventures" or "contractual joint ventures" or may be referenced by other terminology. For purposes of the analysis set forth in this Bulletin, a "joint venture" is any common enterprise with mutual economic benefit. The application of this Bulletin is not limited to "joint ventures" that meet technical qualifications under applicable state or common law.

<sup>3</sup>The Owner's referrals may be direct or indirect and may include not only ordering or purchasing goods or services, but also "arranging for" or "recommending" goods and services. See section 1128B(b) of the Act. For example, a hospital may generate business for a DME company, notwithstanding that orders for specific DME items must be signed by a physician who may or may not be a hospital employee.

<sup>4</sup>These examples are illustrative only. This list is not intended to suggest that other analogous ventures are not equally suspect.

<sup>5</sup>The Manager/Supplier may also provide marketing services, although in many instances no such services are required since the Owner generates substantially all of the venture's business from its existing patient base.

The Office of Inspector General (OIG) was established at the Department of Health and Human Services by Congress in 1976 to identify and eliminate fraud, abuse, and waste in the department's programs and to promote efficiency and economy in departmental operations. The OIG carries out this mission through a nationwide program of audits, investigations, and inspections.

The Fraud and Abuse Control Program, established by the Health Insurance Portability and Accountability Act of 1996 (HIPAA), authorized the OIG to provide guidance to the health care industry to prevent fraud and abuse and to promote the highest level of ethical and lawful conduct. To further these goals, the OIG issues Special Advisory Bulletins about industry practices or arrangements that potentially implicate the fraud and abuse authorities subject to enforcement by the OIG.

Source: OIG Special Advisory Bulletin April 2003

### CONNECTICUT ONLY

## New England Benefit Integrity Support Center Selected as New Program Safequards Contractor for Connecticut

On August 1, 2003, CMS expanded the New England Benefit Integrity Support Center (NE-BISC) to include Medicare benefits integrity functions formerly performed by TriCenturion, LLC. Benefit integrity workload for Part B in Connecticut is now included in the scope of work for EDS' NE-BISC. This project is part of the CMS Medicare Integrity Program to engage new program safeguards contractors to address Medicare fraud, waste, and abuse. EDS will begin this work effective October 1, 2003.

The NE-BISC does not replace the Medicare program administration work that is performed by First Coast Service Options, Inc. (FCSO). FCSO will continue their current responsibilities including processing and paying claims, performing customer service, reviewing medical necessity, and auditing facilities for Medicare expenses and reimbursement.

The NE-BISC will incorporate this work into the EDS team focused on detecting and deterring fraud in the Medicare Part A and Part B programs in Connecticut. The NE-BISC will perform extensive and unique Medicare regional data analysis to identify aberrant Medicare activities in this region. The NE-BISC will develop cases for referral to law enforcement and provide ongoing support of those cases as needed. The NE-BISC will also process complaints alleging fraud. Additional responsibilities shall include coordination of benefit integrity activities in the region, and dissemination of relevant benefits integrity information to the related affiliated contractors (e.g., FCSO), providers, and beneficiaries.

Expected outcomes include:

• Identification of situations of potential fraud, waste, and abuse in the Medicare Program for case development and referral to law enforcement.

- Timely and accurate resolution of complaints alleging fraud.
- Identification of Medicare program weaknesses and vulnerabilities, and communication of recommendations for corrective actions including overpayment recovery and provider education.

Questions may be directed to Eileen M. Guinney, UMBI (Utilization Management Benefit Integrity), at:

Eileen M. Guinney NE-BISC UMBI 75 Sgt. Wm. Terry Dr. Hingham, MA 02043 Ph: 1-781-741-3207 Fax: 1-781-741-3283 email: eileen.guinney@eds.com

### **Teams and Locations**

### **NE-BISC Program Administration** EDS

Mail Stop: A1-2F-70 5400 Legacy Dr. Plano, TX 75024

### Complaints, Investigations & Data Analysis

NE-BISC 75 Sgt. Wm. Terry Dr. Hingham, MA 02043

### **Investigations & Data Analysis**

NE-BISC 43 Landry St Biddeford, ME 04005 NE-BISC 800 Connecticut Blvd E. Hartford, CT 06108

# FINANCIAL SERVICES

## **Overpayment Interest Rate**

Medicare assesses interest on overpaid amounts that are not refunded timely. Interest will be assessed if the overpaid amount is not refunded within 30 days from the date of the overpayment demand letter. The interest rate on overpayments is based on the higher of the private consumer rate (PCR) or the current value of funds rate.

**Effective August 11, 2003,** the interest rate applied to Medicare overpayments is **12.125 percent**, based on the revised PCR. The following table lists previous interest rates.

April 28, 2003 – August 10, 2003	11.625%
February 11, 2003 – April 27, 2003	10.75%
November 19, 2002 – February 10, 2003	11.25%
August 8, 2002 – November 18, 2002	12.625%
May 8, 2002 – August 7, 2002	11.75%
February 1, 2002 – May 7, 2002	12.625%
October 31, 2001 – January 31, 2002	13.25%
August 7, 2001 – October 30, 2001	13.25%
· · · · · · · · · · · · · · · · · · ·	

Source: Transmittal AB-03-122; CR 2432

# HOME HEALTH CONSOLIDATED BILLING

# **Correction to Quarterly Update of HCPCS Codes Used for Home Health Consolidated Billing Enforcement**

**D**rogram Memorandum AB-03-096, the third quarterly home health (HH) consolidated billing (CB) update for calendar year 2003, was published on July 3, 2003. Among other changes, it removed code A4421 (Ostomy Supply misc) from the list of supply codes subject to HH CB. Removing code A4421 was an error. This instruction is to notify providers that code A4421 will not be deleted from HH CB enforcement:

Providers and suppliers interested in an updated complete list of codes subject to HH CB should refer to the HH CB master code list available at http:// cms.hhs.gov/providers/hhapps/.

Source: CMS Transmittal AB-03-136 Date: August 29, 2003 Change Request 2892

# Annual Update of HCPCS Codes Used for Home Health Consolidated Billing Enforcement

MS periodically updates the lists of Healthcare Common Procedure Coding System (HCPCS) codes that are subject to the consolidated billing provision of the home health prospective payment system (HH PPS). With the exception of therapies performed by physicians, supplies incidental to physician services, and supplies used in institutional settings, services appearing on this list submitted to Medicare contractors will not be paid separately on dates when a beneficiary for whom such service is being billed is in a home health episode (i.e., under a home health plan of care administered by a home health agency). Medicare will only directly reimburse the primary home health agencies that have opened such episodes during the episode periods. Therapies performed by physicians, supplies incidental to physician services and supplies used in institutional settings are not subject to HH consolidated billing. Medicare contractors include fiscal intermediaries (FIs), carriers, and durable medical equipment regional carriers (DMERCs).

The HH consolidated billing code lists are updated annually, to reflect the annual changes to the HCPCS code set itself. Additional updates may occur as frequently as quarterly in order to reflect the creation of temporary HCPCS codes (e.g., 'K' codes) throughout the calendar year. The new coding identified in each update describes the same services that were used to determine the applicable HH PPS payment rates. No additional services will be added by these updates; that is, new updates are required by changes to the coding system, not because the services subject to HH consolidated billing are being redefined.

This notification provides the annual HH consolidated billing update for calendar year 2004. Quarterly updates may follow in the course of calendar year 2004 if necessary. The specific changes are described in the attached code list.

The HH consolidated billing master code list is available at http://www.cms.hhs.gov/providers/hhapps/ #billing.

### New & Deleted Codes for HH CB

New a Deleted Codes for HH CD		
Code	Action	<b>Replacement Code or Code</b>
		Being Replaced
Non-Routine Supplies		
K0581	Delete	Replacement Code: A4416
K0582	Delete	Replacement Code: A4417
K0583	Delete	Replacement Code: A4418
K0584	Delete	Replacement Code: A4419
K0585	Delete	Replacement Code: A4420
K0586	Delete	Replacement Code: A4423
K0587	Delete	Replacement Code: A4424
K0588	Delete	Replacement Code: A4425
K0589	Delete	Replacement Code: A4426
K0590	Delete	Replacement Code: A4427
K0591	Delete	Replacement Code: A4428
K0592	Delete	Replacement Code: A4429
K0593	Delete	Replacement Code: A4430
K0594	Delete	Replacement Code: A4431
K0595	Delete	Replacement Code: A4432
K0596	Delete	Replacement Code: A4433
K0597	Delete	Replacement Code: A4434
A4416	Add	Replaces Code: K0581
A4417	Add	Replaces Code: K0582
A4418	Add	Replaces Code: K0583
A4419	Add	Replaces Code: K0584
A4420	Add	Replaces Code: K0585
A4423	Add	Replaces Code: K0586
A4424	Add	Replaces Code: K0587
A4425	Add	Replaces Code: K0588
A4426	Add	Replaces Code: K0589
A4427	Add	Replaces Code: K0590
A4428	Add	Replaces Code: K0591
A4429	Add	Replaces Code: K0592
A4430	Add	Replaces Code: K0593
A4431	Add	Replaces Code: K0594
A4432	Add	Replaces Code: K0595
A4433	Add	Replaces Code: K0596
A4434	Add	Replaces Code: K0597
A4319	Delete	Replacement codes: A4216 & A4217
A4323	Delete	Replacement codes: A4216 & A4217
A4216	Add	Replaces A4319 & A4323
A4217	Add	Replaces A4319 & A4323
A4712	Delete	-
A4622	Delete	Replacement codes: A7520, A7521,
		& A7522

#### CONNECTICUT AND FLORIDA Code Action **Replacement Code or Code** Code Action **Being Replaced Non-Routine Supplies Non-Routine Supplies** A7520 Add Replaces code: A4622 A6444 Add A7521 Add Replaces code: A4622 A6445 Add A7522 Add Replaces code: A4622 A6446 Add Add A7523 Add Tracheostomy A6447 A7524 Add From or related to discontinued code, A6448 Add A4622 and/or A4623: Tracheostomy A6449 Add A4623 Add A6450 Add A7525 Add Replaces code: A4623 A6451 Add A7526 Add Replaces code: A4623 A6452 Add K0621 Delete Replacement code: A6407 A6453 Add A6407 Add Replaces: K0621 A6454 Add A4248 Add A6455 Add A4366 Add A6456 Add A6025 Add A6441 Add Therapies 97755 Add A6442 Add A6443 Add Source: CMS Pub. 100-04 Transmittal: 8 Date: October 17, 2003 Change Request 2931

## GENERAL INFORMATION

**Replacement Code or Code Being Replaced** 

# MANAGED CARE (MEDICARE+CHOICE)

# Billing Instructions for Claims for Ventricular Assist Devices for Beneficiaries in a Medicare+Choice Plan

MS recently expanded coverage for ventricular assist devices (VADs). Until Medicare capitation rates to Medicare+Choice (M+C) organizations are adjusted to account for this expanded VADs coverage, Medicare will pay providers on a fee-for-service basis for VADs that fall under the new indication for destination therapy (see National Coverage Determination [NCD] manual section 20.9). This notification provides billing instructions for claims for VADs for beneficiaries in a M+C Plan.

The fee-for-service claim processing system automatically excludes claims for services provided for risk M+C beneficiaries except in certain circumstances for which editing has been created (e.g. NETT claims, clinical trial claims).

Physicians/practitioners are instructed to use modifier KZ (new coverage not implemented by managed care) and hospitals to use condition code 78 (new coverage not implemented by HMO) when billing for services for VADs for beneficiaries in an M+C plan when conditions fall under the new indications for destination therapy, which are effective October 1, 2003.

Claims for M+C organizations' beneficiaries with existing covered indications (NCD manual section 20.9) should *not* be billed with the condition code or modifier; such indications are currently included in the M+C plan's capitated rates.

Source: CMS Pub. 100-04 Transmittal: 10 Date: October 17, 2003 Change Request 2958

# MEDICARE SECONDARY PAYER (MSP)

# Clarification of Policy for the Medicare Secondary Payer Working Aged Provision

Section 10.2 of the Medicare Secondary Payer (MSP) manual (Publication 100-05) has been revised to clarify what individuals are not subject to the limitation on payment. The last bullet (below) has been added as a result of this revision.

The Medicare secondary provision for working aged does not apply to:

- Individuals enrolled in Part B only.
- Individuals enrolled in Part A on the basis of a monthly premium. Anyone who is under age 65. (Medicare is secondary to large group health plans [GHP] that cover at least one employer of 100 or more employees for certain disabled individuals under age 65.).
- Individuals covered by a health plan other than a GHP as defined above, e.g., one that is purchased by the individual privately, and not as a member of a group, and for which payment is not made through an employer.
- Employees of employers of fewer than 20 employees who are covered by a single employer plan, or members of multi-employer plans that have been approved by CMS for the "multi-employer exemption," whom the plan identified as employees of employers with fewer than 20 employees.
- Retired beneficiaries who are covered by GHPs as a result of past employment and who do not have GHP coverage as the result of their own or a spouse's current employment status.
- Individuals enrolled in single employer GHPs of employers of fewer than 20 employees; or members of multi-employer plans whom the plan identified as employees of employers with fewer than 20 employees, provided the plan formally elected (see section 10.4) to exempt the plan from making primary payment for employees and spouses of employees of specifically identified employers with fewer than 20 employees.
- Domestic partners who are given "spousal" coverage by the group health plan. Federal law defines spouse as a person of the opposite sex who is a husband or a wife. Thus, a domestic partner cannot be recognized as a spouse.

Source: CMS Pub. 100-05 Transmittal: 2 Date: October 17, 2003 Change Request 2252

# **P**ROVIDER **E**NROLLMENT

## What's New from Enrollment

To ensure that only qualified providers and suppliers L enroll in the Medicare Program, validation of information obtained from providers is now directly linked to the Social Security Administration (SSA) and the Internal Revenue Service (IRS). Prior to processing an initial enrollment or making changes to existing enrollees, Medicare Enrollment must validate specific information obtained from applicants with these two agencies. We will be using existing information contained in a provider's file to accomplish this. If we do not have the required information on file, or the information we have on file does not concur with the information from the referenced agencies, CMS has instructed that we obtain the information via the applicable Form CMS-855, pursuant to section 1124(a)(1) and 1124A(a)(3) of the Social Security Act.

### [42 U.S.C. section 1320a-3a]

**1124A(a) DISCLOSURE REQUIRED TO RECEIVE PAYMENT** No payment may be made under part B of title XVIII for items or services furnished by any disclosing Part B provider unless such provider has provided the Secretary with full and complete information—

**1124A(a)(1)** on the identity of each person with an ownership or control interest in the provider or in any subcontractor (as defined by the Secretary in regulations) in which the provider directly or indirectly has a 5 percent or more ownership interest;

**1124A(a)(3)** including the employer identification number (assigned pursuant to section 6109 of the Internal Revenue Code of 1986) and social security account number (assigned under section 205(c)(2)(B)) of the disclosing part B provider and any person, managing employee, or other entity identified or described under paragraph (1) or (2).

Please ensure that you promptly supply Medicare Enrollment with any requested information on initial enrollments or changes regarding your practice in order to prevent possible disruption of claims payment.

## SKILLED NURSING FACILITY (SNF) CONSOLIDATED BILLING (CB)

## Guidelines for Skilled Nursing Facility (SNF) Consolidated Billing

This provider education article discusses the background of the SNF consolidated billing regulation; services, supplies, and facilities included and excluded from SNF consolidated billing; professional and technical components of diagnostic tests; and ambulance services. In addition, the article includes information resources for SNF consolidated billing.

#### Background

SNF consolidated billing, which was effective for cost reporting periods beginning on or after July 1, 1998, states that SNFs must submit Medicare claims to the fiscal intermediary (FI) for all Part A and Part B services that its residents receive during the course of a covered Part A stay, except for a limited number of specifically excluded services. These services must be furnished either directly or under arrangement with outside providers. Section 4432(b) of the Balanced Budget Act of 1997 (BBA, PL 105-33), mandated the exclusion of entire categories of services from SNF consolidated billing. These services are separately billable to the Part B Medicare carrier and include the services of physicians and certain other types of medical practitioners.

Section 103 of the Balanced Budget Refinement Act of 1999 (BBRA, PL 106-113, Appendix F), effective on April 1, 2000, enacted a second more targeted set of exclusions for high cost, low probability services within a number of broader service categories (e.g., chemotherapy services) that otherwise remained subject to consolidated billing.

Effective January 1, 2002, Section 313 of the Benefits Improvement and Protection Act restricted SNF consolidated billing to the majority of services provided to patients in a Medicare Part A covered stay and only to physical, occupational, and speech-language therapy services provided to patients in a noncovered stay.

For claims with dates of service on or after April 1, 2001, for those services and supplies that are not specifically excluded by law and furnished to a SNF resident covered under the Part A benefit, physicians must forward the technical portions of any services to the SNF to be billed by the SNF to the FI. The SNF cannot receive additional payment for these technical services and is to pay the physician for the technical portion of the service. Physical, occupational, and speech-language therapy services provided to patients in a non-covered stay must also be forwarded to the SNF to be billed by the SNF to the FI for payment. It is the responsibility of the rendering physician or nonphysician practitioner to develop a business relationship with the SNF in order to receive payment from the SNF for services they render that are included in consolidated billing.

#### Services and Supplies Included in SNF Consolidated Billing

The SNF consolidated billing requirement confers on SNFs the billing responsibility for the entire package of services that residents receive including:

- All services and supplies received during the course of a Part A covered stay (including physical, occupational, and speech-language therapy services), with the exception of statutory exclusions; and
- For SNF residents in noncovered stays (e.g., Part A benefits exhausted or no prior qualifying hospital stay), physical, occupational, and speech-language therapy services.

#### Services and Supplies Excluded from SNF Consolidated Billing

- A. The following are excluded from SNF consolidated billing and must be billed separately to the Medicare carrier:
  - The professional component of physician services (see Section 1861(r) of the Social Security Act for the definition of a physician for Medicare purposes) except physical, occupational, and speech-language therapy services;
  - Physician assistant services, when a physician assistant is working under a physician's supervision;
  - Nurse practitioner services, when a nurse practitioner is working in collaboration with a physician;
  - Clinical nurse specialists, when a clinical nurse specialist is working in collaboration with a physician;
  - Certified mid-wife services;
  - Qualified psychologist services; and
  - Certified registered nurse anesthetist services.

**Note**: Physical, occupational, and speech-language therapy services included in SNF consolidated billing are subject to SNF consolidated billing regardless of who provides them, even if the services that type of practitioner normally provides are excluded from SNF consolidated billing.

- A. The following are excluded from SNF consolidated billing and the institutional or technical component must be billed separately to the Medicare FI:
  - The following services furnished on an outpatient basis by a hospital or critical access hospital (CAH):
    - Cardiac catheterization services;
    - Computerized axial tomography scans;
    - Magnetic resonance imaging;
    - Ambulatory surgery involving the use of an
    - operating room;
    - Radiation therapy;
    - Emergency services;
    - Angiography;

### **GENERAL INFORMATION**

Lymphatic and venous procedures; and
 Ambulance services furnished in connection with any of the above outpatient hospital services.

- Maintenance dialysis received in a renal dialysis facility by an end stage renal disease patient;
- Certain dialysis-related services including covered ambulance transportation to obtain dialysis services;
- Erythropoietin for certain dialysis patients when given along with dialysis; and
- Hospice care related to a patient's terminal condition;

C. The following are excluded from SNF consolidated billing and must be billed separately to the Medicare carrier or FI, as appropriate:

- Ambulance trips that transport a patient to the SNF for initial admission or from the SNF following a final discharge (see below for additional ambulance services information);
- Services to risk based HMO enrollees; and
- The following services for residents in a Part A covered stay (only certain services in these categories are excluded):
  - Certain chemotherapy drugs;
  - Certain chemotherapy administrative services;
  - Certain radioisotope services; and
  - Certain customized prosthetic devices.

#### Facilities Included in SNF Consolidated Billing

 Medicare participating SNFs, including Medicare-certified distinct part SNFs and swing beds in all hospitals except CAHs.

## Facilities Excluded from SNF Consolidated Billing

- Nursing homes that have no Medicare certification (e.g., do not participate at all in either the Medicare or Medicaid program);
- Nursing homes that exclusively participate only in the Medicaid program as a nursing facility;
- The nonparticipating portion of a nursing home that also contains a Medicare-certified distinct part SNF; and
- Swing beds in CAHs.

#### Professional and Technical Components of Diagnostic Tests

The professional component, or the physician's interpretation of a diagnostic test, is considered a physician service and is separately billable to the Medicare carrier. The technical component, or the diagnostic test itself, is considered a diagnostic test and is subject to consolidated billing. As an example, for diagnostic radiology services, the exclusion of physician services from consolidated billing applies only to the professional component of the diagnostic radiology service. The technical component of the diagnostic radiology service is considered a diagnostic test that must be billed to the Medicare FI by the SNF and is included in the SNF consolidated billing payment for covered Part A stays. Because the technical component is already included within Part A's comprehensive per diem payment to the SNF for the covered stay, an outside entity that actually furnishes the technical component would look to the SNF, rather than Part B, for payment.

#### Ambulance Services

Except for specific exclusions, SNF consolidated billing includes those medically necessary ambulance trips that are furnished during the course of a Part A stay. In most cases, ambulance trips are excluded from SNF consolidated billing when the covered Part A stay has ended, at which time the ambulance company must bill the Medicare carrier or FI directly for payment. The specific circumstances under which a patient may receive ambulance services that are covered by Medicare but excluded from SNF consolidated billing are:

- A medically necessary ambulance trip to a Medicare participating hospital or CAH for the specific purpose of receiving emergency or other excluded outpatient hospital services;
- A medically necessary ambulance trip after a formal discharge or other departure from the SNF, unless the patient is readmitted or returns to that or another SNF before midnight of the same day;
- An ambulance trip to receive dialysis or dialysis-related services;
- An ambulance trip for an inpatient admission to a Medicare participating hospital or CAH; and
- After discharge from a SNF, a medically necessary ambulance trip to the patient's home where he/she will receive services from a Medicare participating home health agency under a plan of care.

**Note**: A patient's transfer from one SNF to another before midnight of the same day is not excluded from SNF consolidated billing. The first SNF is responsible for the ambulance services.

## SNF Consolidated Billing Information Resources

- Consolidated Billing Web Site
  - www.cms.hhs.gov/medlearn/snfcode.asp - General SNF consolidated billing information.

- HCPCS codes that can be separately paid by the Medicare carrier (i.e., services not included in consolidated billing).

- Therapy codes that must be consolidated in a noncovered stay.

- All code lists are subject to quarterly and annual updates and should be reviewed periodically for the latest revisions.

- Program Memoranda www.cms.hhs.gov/manuals/transmittals/
  - comm\_date\_dsc.asp
    - Transmittal AB-03-094 dated 7/3/2002
    - Transmittal AB-02-175 dated 12/13/2002
    - Transmittal A-02-118 dated 11/8/2002 1) Updated codes for exclusions
      - 2) SNF Help File
        - a) HCPCS codes included in the SNF Part A payment
        - b) Codes that may be paid and on what
      - basis to a SNF by the FI under Part B
    - Transmittal AB-02-038 dated 3/27/2002
- The SNF Help File will be available on a new CMS Web site in the near future.
- Medicare Carriers Manual Part 3, Section 4210
- Source: CMS Joint Signature Memorandum dated August 29, 2003

## 2004 Annual Update for Skilled Nursing Facility Consolidated Billing

The coding files for skilled nursing facility consolidated billing will be updated effective January 1, 2004. These updates will appear on the CMS Web site at *www.cms.hhs.gov/medlearn/snfcodes.asp* on or about December 1, 2003. In order to correctly bill services, physicians, nonphysician practitioners, and suppliers should carefully review the revised codes files.

Source: CMS Transmittal B-03-068, CR 2858



## 2004 Holiday Schedule

First Coast Service Options, Inc will observe the following holiday closings in 2004:

January 1, (Thursday) January 19, (Monday) April 9, (Friday) May 31, (Monday) July 5, (Monday) September 6, (Monday) November 25, (Thursday) November 26, (Friday) December 23, (Thursday) December 24, (Friday) New Year's Day Martin Luther King Jr. Day Good Friday Memorial Day Independence Day Labor Day Thanksgiving Holiday Thanksgiving Holiday Christmas Holiday Christmas Holiday

## Interactive Voice Response Unit Operating Guide

To better serve you, First Coast Service Options' interactive voice response unit (IVR) operating guides have been developed to improve your navigation through the IVR. These operating guides will help to increase your knowledge of the technology and services we offer our beneficiaries and providers. By utilizing the IVR, you can also obtain claims status, eligibility, and the most up to date Medicare information.

#### Connecticut 1-866-419-9455

#### HELPFUL TIPS Use Power Keys

Repeat Information, press 1 Repeat Menu, Press 7 Return to Main Menu, press 8 To end call, press 9 To speak to an associate, press 0

To receive any information, you must enter your Provider number, Beneficiary name, Medicare number and date of birth.

To enter the alphabetical portion of your provider number, indicate you are entering an alphabetical character by pressing the \* key. Then, press the key containing the letter you wish to enter. To complete, press the number 1,2 or 3 depending on the position of the number on that key.

For Example: To enter A, press \*, 2, 1 To enter B, press \*, 2, 2

If the Medicare number begins with a letter, please enter the number that corresponds to the letter(s) below:

- For the letter **A**, press **1**
- For the letter MA, press 2

- For the letter **WA**, press **3**
- For the letter WCA, press 4
- For the letter **CD**, press **5**
- For all other letters, press 7

If the Medicare number ends with a letter, please enter the number that corresponds to the letter below:

- For the letter **A**, press **1**
- For the letter **B**, press **2**
- For the letter C, press 3
- For the letter **D**, press **4**
- For the letter **T**, press **5**
- For the letter **M**, press **6**
- For all other letters, press 7

To enter the Beneficiary's date of birth:

- Enter 2-digit month
- Enter 2-digit year

#### To enter date of claim:

- Enter 2-digit month
- Enter 2-digit day
- Enter 2-digit year

#### END HELPFUL TIPS

\*\*\*\*\*\*\*

#### **PRICING LEGISLATION**

- To hear 2003 legislation, press 1
- Otherwise, press 2

#### MAIN MENU

- For information about current Medicare changes and issues, press 1
- To receive claim status, correspondence Status and Medicare Remittance notices, press 2
- For eligibility, HMO, deductible and physical and occupational limitation information, press **3**
- For pending and payment floor claims or to receive month – year dollar amounts Currently on file, press
- To receive check information, press 5

#### CHECK HISTORY BY CHECK NUMBER

• From the main menu, press 5, then press 3

#### CHECK HISTORY BY ISSUE DATE

• From the main menu, press 5, then press 2

#### CLAIM STATUS

- From the main menu, press 2, then press 1
- If the beneficiary's number begins with a letter, press 1
- If the beneficiary's Medicare number is nine digits and is followed by a number, press 2
- If the beneficiary's Medicare number is followed by two or more letters, press 0

#### CORRESPONDENCE STATUS

- From the main menu, press 2, then press 2
- Receive info on another claim, press 2
- To receive info on a different control number, press 3
- To receive info on a different provider number, press **6**

#### Florida 1-877-847-4992

## HELPFUL TIPS

Use Power Keys

Repeat Information, press 1 Repeat Menu, Press 7 Return to Main Menu, press 8 To end call, press 9 To speak to an associate, press 0

To receive any of the information, you must enter your Provider number, Medicare number and date of birth.

To enter the alphabetical portion of your provider number, you must indicate you are entering an alphabetical character, by pressing the \* key. Second, press the key containing the letter you wish to enter. Third, press the number 1,2 or 3 depending on the position of the number on that key.

For Example: To enter A, press \*, 2, 1 To enter B, press \*, 2, 2

If the Medicare number begins with a letter, please enter the number that corresponds to the letter(s) below:

- For the letter **A**, press **1**
- For the letter MA, press 2
- For the letter **WA**, press **3**

## GENERAL INFORMATION

## ELIGIBILITY, HMO, DEDUCTIBLE, AND PHYSICAL AND OCCUPATIONAL LIMITATION INFORMATION

- From the main menu, press 3
- For Eligibility, HMO and deductibles, press 1
- For Physical and Occupational limitations, press 2
- For information on a different Medicare number, press 2

#### LAST THREE CHECKS

- From the main menu, press 5, then press 1
- For check history by issue date, press 2
- For check history by check number, press **3**

#### MEDICARE CHANGES AND ISSUES

- From the main menu, press 1
- For current pricing information, press 1
- For PSC hours of operation, press 2
- For Connecticut Medicare Part B Web site, press 3
- For information you need when calling Medicare, press **4**
- To learn about the IVR features, press 5

#### MEDICARE REMITTANCE

• From the main menu, press 2, then press 3

#### MONTH OR YEAR TO DATE

#### DOLLAR AMOUNT

- From the main menu, press **4**, then press **2**
- To receive information on a different provider number, press 1

#### PENDING CLAIMS

- From the main menu, press 4, then press 1
- To receive information on different provider number, press 1
- For the letter WCA, press 4
- For the letter **CD**, press **5**
- For all other letters, press 7

If the Medicare number ends with a letter, please enter the number that corresponds to the letter below:

- For the letter **A**, press **1**
- For the letter **B**, press 2
- For the letter C, press 3
- For the letter **D**, press **4**
- For the letter T, press 5
  For the letter M, press 6
- For the letter **M**, press **6**
- For all other letters, press 7

To enter the Beneficiary's date of birth:

- Enter 2-digit month
- Enter 2-digit year

To enter date of claim:

- Enter 2-digit month
- Enter 2-digit day
- Enter 2-digit year

#### (END HELPFUL TIPS)

\*\*\*\*\*

#### **PRICING LEGISLATION**

- To hear current legislation, press 1
- Otherwise, press 2

#### MAIN MENU

- For information about legislation and other provider issues, press 1
- To receive claim status, correspondence status and Medicare Remittance notices, press 2
- For eligibility, HMO, deductible, and physical and occupational limitation information, press **3**
- For pending and payment floor claims or to receive month year dollar amounts currently on file, press 4
- To receive check information, press **5**
- For pricing information on reason codes, press 6

#### CHECK HISTORY BY CHECK NUMBER

• From the main menu, press 5, then press 3

#### CHECK HISTORY BY ISSUE DATE

• From the main menu, press 5, then press 2

#### **CLAIM STATUS**

- From the main menu, press 2, then press 1
- If the beneficiary's number begins with a letter, press 2
- For all other Medicare numbers, press 1

#### CORRESPONDENCE STATUS

- From the main menu, press 2, then press 2
- Receive info on another claim, press 2
- To receive info on a different control number, press 3
- To receive info on a different provider number, press 6

## ELIGIBILITY, HMO, DEDUCTIBLE, AND PHYSICAL AND OCCUPATIONAL LIMITATION INFORMATION

- From the main menu, press **3**
- For Eligibility, HMO and deductibles, press 1
- For Physical and Occupational limitations, press 2
- For information on a different Medicare number, press 2

### GENERAL INFORMATION

#### LAST THREE CHECKS

- From the main menu, press 5, then press 1
- For check history by issue date, press 2
- For check history by check number, press **3**

#### MEDICARE REMITTANCE

- From the main menu, press 2
- For status of claim, press **1**
- For status of correspondence, press 2

### MONTH OR YEAR TO DATE

#### DOLLAR AMOUNT

- From the main menu, press 4, then press 2
- To receive information on a different provider number, press 1

#### NEW LEGISLATION AND PROVIDER ISSUES

- From the main menu, press 1
- For what provider customer service is about, press 1
- For PSC hours of operation, press 2
- For Florida Medicare Part B Web site, press 3
- For information you need when calling Medicare, press 4
- To learn about the IVR features, press **5**

#### PENDING CLAIMS

- From the main menu, press 4, then press 1
- To receive information on different provider number, press 1

#### PRICING

•

- From the main menu, press 6
- Ambulance providers, press 1
- All others, press 2

Our Customer Service hours of operation are Monday through Friday 8:00am - 4:30pm. The hours of operation to receive patient eligibility and claim status information through the Interactive Voice Response Unit are Monday through Friday 6:00am – 6:00pm. The hours of operation to receive general Medicare Information and current issues are available 24 hours a day.

## The New Online CMS Manual System Announcement

Beginning October 1, 2003, CMS will transition from a paper-based manual system to a Web-based system. The process includes the streamlining, updating, and consolidating of CMS' various program instructions into an electronic Web-based manual system for all users. The new system is called the online CMS Manual System and is located at *http://www.cms.hhs.gov/manuals*.

The new online CMS Manual System will be organized by functional area, (e.g., eligibility, entitlement, claims processing, benefit policy, program integrity). The functional orientation of the new manual will eliminate significant redundancy within the manuals and will streamline the updating process, thus making CMS program instructions available in a more timely and accessible fashion.

Specifically, the CMS Manual System will include the following functional areas:

- Pub. 100-01-Medicare General Information, Eligibility, and Entitlement
- Pub. 100-02-Medicare Benefit Policy
- Pub. 100-03—Medicare National Coverage Determinations
- Pub. 100-04-Medicare Claims Processing
- Pub. 100-05-Medicare Secondary Payer
- Pub. 100-06-Medicare Financial Management
- Pub. 100-07-Medicare State Operations
- Pub. 100-08—Medicare Program Integrity
- Pub. 100-09-Medicare Contractor Beneficiary and Provider Communications
- Pub. 100-10-Medicare Quality Improvement Organization
- Pub. 100-11-Reserved
- Pub. 100-12-State Medicaid
- Pub. 100-13—Medicaid State Children's Health Insurance Program
- Pub. 100-14-Medicare End Stage Renal Disease Network Organization
- Pub. 100-15—Medicare State Buy-In
- Pub. 100-16-Medicare Managed Care
- Pub. 100-17-Medicare Business Partners Systems Security
- Pub. 100-18-Medicare Business Partners Security Oversight
- Pub. 100-19-Demonstrations
- Pub. 100-20—One-Time Notification

### **GENERAL INFORMATION**

The table below identifies what current paper-based manuals were used to construct the new Internet-only manuals. It is just a cursory overview. A detailed crosswalk is being developed to guide you from a specific section of the old manual to where the information now appears in the new manuals. In addition, the Internet-only manual will have a crosswalk to show how the information in each section was derived.

Paper-Based Manuals         Pub. 06—Medicare Coverage Issues         Pub. 09—Medicare Outpatient Physical Therapy         Pub. 10—Medicare Hospital         Pub. 11—Medicare Home Health Agency         Pub. 12—Medicare Skilled Nursing Facility         Pub. 13—Medicare Intermediary Manual, Parts 1, 2, 3, and 4         Pub. 14—Medicare Carriers Manual, Parts 1, 2, 3, and 4 Pub.         21—Medicare Hospice         Pub. 27—Medicare Rural Health Clinic and Federally Qualified         Health Center         Pub. 60A—Intermediaries         Pub. 60B—Carriers Pub.         60AB—Intermediaries/Carriers         Note: Information derived from Pub. 06 to Pub. 60AB was used	Internet-Only Manuals Pub. 100-01— Medicare General Information, Eligibility, and Entitlement Pub. 100-02— Medicare Benefit Policy Pub. 100-03— Medicare National Coverage Determinations Pub. 100-04— Medicare Claims Processing Pub. 100-05— Medicare Secondary Payer Pub. 100-06— Medicare Financial Management Pub. 100-08— Medicare Program Integrity Pub. 100-09— Medicare Contractor Beneficiary and Provider Communications
60AB—Intermediaries/Carriers	

Paper-Based Manuals	Internet-Only Manuals
Pub. 19—Medicare Peer Review Organization	Pub. 100-10— Medicare Quality Improvement Organization
Pub. 07—Medicare State Operations	Pub. 100-07— Medicare State Operations
Pub. 45—State Medicaid	Pub. 100-12— State Medicaid Pub. 100-13— Medicaid State Children's Health Insurance Program
Pub. 81—Medicare End Stage Renal Disease Network Organizations	Pub. 100-14— Medicare End Stage Renal Disease Network Organizations
Pub. 24—Medicare State Buy-In	Pub. 100-15— Medicare State Buy-In
Pub. 75—Health Maintenance Organization/ CompetitiveMedical PlanPub. 76—Health Maintenance Organization/ CompetitiveMedical Plan (PM)Pub. 77—Manual for Federally Qualified Health MaintenanceOrganizations	Pub. 100-16— Medicare Managed Care
Pub. 13—Medicare Intermediaries Manual, Part 2 Pub. 14—Medicare Carriers Manual, Part 2	Pub. 100-17— Business Partners Systems Security
Pub. 13—Medicare Intermediaries Manual, Part 2 Pub. 14—Medicare Carriers Manual, Part 2	Pub. 100-18— Business Partners Security Oversight
Demonstrations (PMs)	Pub 100-19— Demonstrations
Program instructions that impact multiple manuals or have no manual impact.	Pub 100-20— One-Time Notification

Source: CMS Pub. 100-20, Transmittal: 2, September 12, 2003, Change Request 2886

## HIPAA - THE HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT

This material provides a basic overview of the consumer privacy protection rules adopted by the United States Department of Health and Human Services in conformance with the Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996. This material does not interpret these rules or attempt to apply the rules to your particular circumstances. The information provided is (1) for your information only, (2) subject to change without notice, and (3) provided "as is" without warranty of any kind, expressed or implied. FIRST COAST SERVICE OPTIONS, INC. DISCLAIMS RESPONSIBILITY FOR ANY CONSEQUENCES OR LIABILITY ATTRIBUTABLE TO OR RELATED TO ANY USE, NON-USE, OR INTERPRETATION OF INFORMATION CONTAINED OR NOT CONTAINED IN THIS MATERIAL. FIRST COAST SERVICE OPTIONS, INC. DISCLAIMS ANY LIABILITY FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL LOSSES OR DAMAGES RELATED TO THE ACCURACY OR COMPLETENESS OF THIS MATERIAL. The information provided is no substitute for your own review and analysis of the relevant law.

This material is the property of First Coast Service Options, Inc. and may not be duplicated, reproduced, disseminated, or otherwise used for purposes other than a basic overview of specified consumer privacy protection rules.

## Contingency Plan for Health Insurance Portability and Accountability Act Transaction and Code Sets

The following article has been provided by the Centers for Medicare & Medicaid Services (CMS) to announce the implementation of a contingency plan for HIPAA transaction and code sets as of October 16, 2003.

A fter a careful analysis of Medicare provider, submitter, and other trading partner HIPAA readiness, Medicare will continue to accept and send standard and non-standard versions and/or formats for any electronic transaction for a limited time period beyond October 16, 2003.

This is a temporary measure to maintain provider cash flow and minimize operational disruption while trading partners who are not compliant on October 16, 2003, work with Medicare to achieve full compliance.

This contingency plan is only for a limited time. Providers who must continue to bill and receive non-compliant formats, should test and move into production on the HIPAA required formats as soon as possible, or risk possible cash flow problems.

Source: CMS Notification Dated September 23, 2003

## Medicare Electronic Data Interchange (EDI) Enrollments

As a condition for beginning to transmit claims electronically to Medicare, a new EDI enrollment form is required from each interested provider. Once on file, and a new form is not required for that provider as he/she participates in the Medicare program.

#### Specifically, a new EDI enrollment form is not required in any of the following situations:

- (1) submission of transaction in a HIPAA format,
- (2) as a condition of continued use of EDI,
- (3) changing from one format (National Standard Format) to another (ANSI), or
- (4) changing billing services/clearinghouses.

If you are a provider who does not currently submit claims electronically and who would like to begin, enrollment forms are available and can be downloaded from our provider education Web sites at *www.connecticutmedicare.com* for Connecticut Part B providers of service, or *www.floridamedicare.com* for Florida Part A or B providers. If you have questions related to the forms, or to getting started submitting claims electronically, please call Medicare EDI Market-ing/Operations 1-203-639-3160, option 4 (Connecticut providers), or at 1-904-791-8767, option 1 (Florida providers).

Source: CMS Joint Signature Memorandum dated July 29, 2003

### **HIPAA Privacy Medical Records**

#### Protecting the Privacy of Patients' Health Information

**Notice of Privacy Practices**: Covered health plans, doctors and other health care providers must provide a notice to their patients how they may use personal medical information and rights under the new privacy regulations. Doctors, hospitals and other direct-care providers generally will provide the notice on the patient's first visit following the April 14, 2003, compliance date and upon request. Patients generally will be asked to sign, initial or otherwise acknowledge they received this notice.

**Limits on use of Personal Medical Information**: To promote the best quality care for patients, the rule does not restrict the ability of doctors, nurses and other providers to share information needed to treat their patients. Personal health information may not be used for purposes not related to health care, and covered entities may use or share only the minimum amount of protected information needed for a particular purpose.

**Stronger State Laws**: The new federal privacy standards do not affect state laws that provide additional privacy protections for patients.

**Guidance and technical assistance materials**: HHS has provided an extensive, searchable collection of frequency asked questions that address major aspects of the rule. These materials are available at: *http://www.hhs.gov/ocr/hipaa/assist.html* 

(HHS 4/14/2003 Fact Sheet)

#### Uses and Disclosures for Treatment, Payment, and Health Care Operations

(45 CFR 164.506)

"Treatment" generally means the provision, coordination, or management of health care and related services among health care providers or by a health care provider with a third party, consultation between health care providers regarding a patient, or the referral of a patient from one health care provider to another.

"Payment" encompasses the various activities of health care providers to obtain payment or be reimbursed for their services and of a health plan to obtain premiums, to fulfill their coverage responsibilities and provide benefits under the plan, and to obtain or provide reimbursement for the provision of health care.

Common payment examples under the Privacy Rule include, but are not limited to:

- Determining eligibility or coverage under a plan and adjudicating claims;
- Risk adjustments
- Billing and collection activities
- Reviewing health care services for medical necessity, coverage, justification of charges, and the like;
- Utilization review activities; and
- Disclosures to consumer reporting agencies (limited to specified identifying information about the individual, his or her payment history, and identifying information about the covered entity).

"Health care operations" are certain administrative, financial, legal, and quality improvement activities of a covered entity that are necessary to run its business and to support the core functions of treatment and payment. These activities, which are limited to the activities listed in the definition of "health care operations" at 45 CFR 164.501, include:

- Conducting quality assessment and improvement activities, population-based activities relating to improving health or reducing health care costs, and case management and care coordination;
- Reviewing the competence or qualifications of health care professionals, evaluating provider and health plan performance, training health care and non-health care professionals; accreditation, certification, licensing, or credentialing activities;
- Underwriting and other activities relating to the creation, renewal, or replacement of a contract of health insurance or health benefits, and coding, securing, or placing a contract for reinsurance of risk relating to health care claims;
- Conducting or arranging for medical review, legal, and auditing services, including fraud and abuse detection and compliance programs;
- Business planning and development, such as conducting cost-management and planning analyses related to managing and operating the entity; and
- Business management and general administrative activities, including those related to implementing and complying with the Privacy Rule and other Administrative Simplification Rules, customer service, resolution of internal grievances, sale or transfer of assets, creating de-identified health information or a limited data set, and fundraising for the benefit of the covered entity.

#### Examples:

- A health care provider may disclose protected health information about an individual as part of a claim for payment to a health plan.
- A primary care provider may send a copy of an individual's medical record to a specialist who needs the information to treat the individual
- A hospital may send a patient's health care instructions to a nursing home to which the patient is transferred.

Uses and Disclosures of Psychotherapy Notes: Except when psychotherapy notes are used by the originator to carry out treatment, or by the covered entity for certain other limited health care operations, uses and disclosures of psychotherapy notes for treatment, payment, and health care operations require the individual's authorization. See 45 CFR 164.508(a)(2).

Minimum Necessary: A covered entity must develop policies and procedures that reasonably limit its disclosures of, and requests for, protected health information for payment and health care operations to the minimum necessary. A covered entity also is required to develop role-based access policies and procedures that limit which members of its workforce may have access to protected health information for treatment, payment, and health care operations, based on those who need access to the information to do their jobs. However, covered entities are not required to apply the minimum necessary standard to disclosures to or requests by a health care provider for treatment purposes. See the fact sheet and frequently asked questions on this web site about the minimum necessary standard for more information.

Consent: A covered entity may voluntarily choose, but is not required, to obtain the individual's consent for it to use and disclose information about him or her for treatment, payment, and health care operations.

Notice: Any use or disclosure of protected health information for treatment, payment, or health care operations must be consistent with the covered entity's notice of privacy practices.

#### **Questions and Answers (HHS 2003)**

*May a health care provider disclose parts of a medical record that were created by another provider?* Yes, the Privacy Rule permits a provider who is a covered entity to disclose a complete medical record including portions that were created by another provider, assuming that the disclosure is for a purpose permitted by the Privacy Rule, such as treatment.

#### Does the HIPAA Privacy Rule strictly prohibit the use, disclosure, or request of an entire medical record?

No. The Privacy Rule does not prohibit the sue, disclosure, or request of an entire medical record, and a covered entity may use, disclose, or request an entire medical record without a case-by-case justification, if the covered entity has documented in its policies and procedures that the entire medical record is the amount reasonably necessary for certain identified purposes.

#### Does the HIPAA Privacy Rule require my doctor to send my medical records to the government?

No. The Rule does not require a physician or any other covered entity to send medical information to the government for a government data base or similar operation. This Rule does not require or allow any new government access to medical information, with one exception: the Rule does give the Department of Health and Human Services Office for Civil Rights (OCR) the authority to investigate complaints that Privacy Rule protections or rights have been violated, and otherwise to ensure that covered entities comply with the Rule.

#### If patients require copies of their medical records, are they required to pay for the copies?

The Privacy Rule permits the covered entity to impose reasonable, cost-based fees. The fee may include only the cost of copying (including supplies and labor) and postage, if the patient requests that the copy be mailed. If the patient has agreed to receive a summary or explanation of his or her protected health information, the covered entity may also charge a fee for preparation of the summary or explanation. The fee may not include costs associated with searching for and retrieving the requested information. See 45 CFR 164.524.

#### Can a physician's office FAX patient medical information to another physician's office?

The HIPAA Privacy Rule permits physicians to disclose protected health information to another health care provider for treatment purposes. Covered entities must have in place reasonable and appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information that is disclosed using a fax machine. Examples of measures that could be reasonable and appropriate in such a situation include the sender confirming that the fax number to be used is in fact the correct one for the other physician's office, and placing the fax machine in a secure location to prevent unauthorized access to the information.

#### **References**:

United States Department of Health & Human Services. Office for Civil Rights – HIPAA. Medical Privacy – National Standards to Protect the Privacy of Personal Health Information. OCR Summary of the HIPAA Privacy Rule. April 11, 2003. Available at: *http://www.hhs.gov/ocr/hipaa/privacy.html* 

United States Department of Health & Human Services. Protecting the Privacy of Patients' Health Information. Monday, April 14, 2003. Fact Sheet. Available at: *http://www.hhs.gov/news/facts/privacy.htm* 

## Connecticut Medical Review

This section of the *Medicare B Update!* features summaries of new and revised medical policies developed as a result of either local medical review or comprehensive data analysis initiatives. These initiatives are designed to ensure the appropriateness of medical care and that the carrier's medical policies and review guidelines are consistent with accepted standards of medical practice.

In accordance with publication requirements specified by the Centers for Medicare & Medicaid Services (CMS), carriers no longer include fulltext local medical review policies (LMRPs) to providers in the *Update!* Summaries of revised and new LMRPs are provided instead. Providers may obtain full-text LMRPs on our provider education Web site,

www.connecticutmedicare.com. Final LMRPs, draft LMRPs available for comment, LMRP statuses, and LMRP comment/response summaries may be printed from the Part B Medical Policy section.

#### **Effective and Notice Dates**

Effective dates are provided in each policy, and are based on the date claims are *processed*, not the date of service (unless otherwise noted in the policy). Medicare contractors are required to offer a 45-day notice period for LMRPs; the date the LMRP is posted to the Web site is considered the notice date.

#### **Electronic Notification**

To receive quick, automatic notification when new and revised LMRPs are posted to the Web site, subscribe to the FCSO *eNews* mailing list. It's very easy to do; simply sign on to the provider education Web site, *wwwconnecticutmedicare.com;* click on the yellow "Join our electronic mailing list" bar and follow the prompts.

#### **More Information**

For more information, or, if you do not have Internet access, to obtain a hardcopy of a specific LMRP, contact Medical Policy at:

> Attention: Medical Policy First Coast Service Options, Inc. P.O. Box 9000 Meriden, CT 06450-9000

Phone: 1-866-419-9455

#### **Medical Review - Table of Contents**

Comprehensive Data Analysis	
Nidespread Probe Review Results—Codes 36245, 75724, and 93508	47
Nidespread Probe Review Results—Codes 92225 and 92226	
Videspread Probe Review Results—Code 92235	48
Videspread Probe Review Results—Code 92250	
	10
_ocal Medical Review Policy (New)	
ERASV: Endoluminal Radiofrequency Ablation of the Saphenous Vein	49
NCSVCS: The List of Medicare Noncovered Services	49
D0120: Dental Services	
G0179: Physician Certification and Re-certification of Home Health Service	es 50
J2792: Rho (D) Immune Globulin Intravenous	
I2820: Sargramostim (GM-CSF, Leukine®)	
31525: Laryngoscopy	
64561: Sacral Neuromodulation	51
74150: Computed Tomography of the Abdomen	52
33880: B-Type Natriuretic Peptide (BNP)	52
34154: Free Prostate Specific Antigen	52
38180: Flow Cytometry and Morphometric Analysis	53
38271: Urinary Fluorescent In Situ Hybridization (FISH) Test for Recurrer	nt
Bladder Cancer	53
00257: Ocular Corneal Pachymetry	54
Local Medical Review Policy (Revised)	
2004 ICD-9-CM Coding Changes	54
Policy Revision Initiative	55
EPO: Epoetin Alfa (formerly 99-4 V1.1 Final: Labeled and Off-Labeled uses	
of Erythropoietin)	56
G0030: Positron Emission Tomography (PET) Scan	56
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD)	56 57
30030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs	56 57 57
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA)	56 57 57 57
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging	56 57 57 57 58
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging 38141: Pap Smears Laboratory Testing	56 57 57 57 58 58
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging 38141: Pap Smears Laboratory Testing	56 57 57 57 58 58 58
G0030: Positron Emission Tomography (PET) Scan I2430: Pamidronate (Aredia®, APD) I9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging 38141: Pap Smears Laboratory Testing 09001: Biofeedback 22136: Optical Coherence Biometry	56 57 57 57 58 58 58
G0030: Positron Emission Tomography (PET) Scan J2430: Pamidronate (Aredia®, APD) J9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging 38141: Pap Smears Laboratory Testing 90901: Biofeedback 32136: Optical Coherence Biometry 38940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal	56 57 57 57 58 58 58 58
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>I2430: Pamidronate (Aredia®, APD)</li> <li>I9999: Antineoplastic Drugs</li> <li>70544: Magnetic Resonance Angiography (MRA)</li> <li>78460: Myocardial Perfusion Imaging</li> <li>38141: Pap Smears Laboratory Testing</li> <li>90901: Biofeedback</li> <li>92136: Optical Coherence Biometry</li> <li>98940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> </ul>	56 57 57 57 58 58 58 58 58 58 58 58 58
G0030: Positron Emission Tomography (PET) Scan J2430: Pamidronate (Aredia®, APD) J9999: Antineoplastic Drugs 70544: Magnetic Resonance Angiography (MRA) 78460: Myocardial Perfusion Imaging 38141: Pap Smears Laboratory Testing 90901: Biofeedback 32136: Optical Coherence Biometry 38940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal	56 57 57 57 58 58 58 58 58 58 58 58 58
G0030: Positron Emission Tomography (PET) Scan	56 57 57 57 58 58 58 58 58 58 58 58 58
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>J2430: Pamidronate (Aredia®, APD)</li> <li>J9999: Antineoplastic Drugs</li> <li><i>70544</i>: Magnetic Resonance Angiography (MRA)</li> <li><i>78460</i>: Myocardial Perfusion Imaging</li> <li><i>78460</i>: Myocardial Perfusion Imaging</li> <li><i>78141</i>: Pap Smears Laboratory Testing</li> <li><i>790901</i>: Biofeedback</li> <li><i>792136</i>: Optical Coherence Biometry</li> <li><i>78940</i>: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> <li><i>79183</i>: Hyperbaric Oxygen Therapy (HBO Therapy)</li> <li>Local Medical Review Policy (Retired)</li> </ul>	
G0030: Positron Emission Tomography (PET) Scan	
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>I2430: Pamidronate (Aredia®, APD)</li> <li>I9999: Antineoplastic Drugs</li> <li>70544: Magnetic Resonance Angiography (MRA)</li> <li>78460: Myocardial Perfusion Imaging</li> <li>88141: Pap Smears Laboratory Testing</li> <li>20901: Biofeedback</li> <li>22136: Optical Coherence Biometry</li> <li>28940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> <li>29183: Hyperbaric Oxygen Therapy (HBO Therapy)</li> <li>Local Medical Review Policy (Retired)</li> <li>26 LMRP010-V1.0-97010: Physical Medicine for Chronic Pain</li> </ul>	
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>I2430: Pamidronate (Aredia®, APD)</li> <li>I9999: Antineoplastic Drugs</li> <li>70544: Magnetic Resonance Angiography (MRA)</li> <li>78460: Myocardial Perfusion Imaging</li> <li>38141: Pap Smears Laboratory Testing</li> <li>20901: Biofeedback</li> <li>22136: Optical Coherence Biometry</li> <li>28940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> <li>29183: Hyperbaric Oxygen Therapy (HBO Therapy)</li> <li>Local Medical Review Policy (Retired)</li> <li>35 LMRP010-V1.0-97010: Physical Medicine for Chronic Pain</li> </ul>	56 57 57 57 58 58 58 58 58 58
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>I2430: Pamidronate (Aredia®, APD)</li> <li>I9999: Antineoplastic Drugs</li> <li>70544: Magnetic Resonance Angiography (MRA)</li> <li>78460: Myocardial Perfusion Imaging</li> <li>38141: Pap Smears Laboratory Testing</li> <li>90901: Biofeedback</li> <li>22136: Optical Coherence Biometry</li> <li>98940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> <li>99183: Hyperbaric Oxygen Therapy (HBO Therapy)</li> <li>Local Medical Review Policy (Retired)</li> <li>95 LMRP010-V1.0-97010: Physical Medicine for Chronic Pain</li> <li>Corrections</li> <li>Comprehensive Data Analysis for Eye Exams—Correction</li> </ul>	
<ul> <li>G0030: Positron Emission Tomography (PET) Scan</li> <li>I2430: Pamidronate (Aredia®, APD)</li> <li>I9999: Antineoplastic Drugs</li> <li>70544: Magnetic Resonance Angiography (MRA)</li> <li>78460: Myocardial Perfusion Imaging</li> <li>38141: Pap Smears Laboratory Testing</li> <li>20901: Biofeedback</li> <li>22136: Optical Coherence Biometry</li> <li>28940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)</li> <li>29183: Hyperbaric Oxygen Therapy (HBO Therapy)</li> <li>Local Medical Review Policy (Retired)</li> <li>25 LMRP010-V1.0-97010: Physical Medicine for Chronic Pain</li> </ul>	

## **Advance Notice Statement**

Advance Beneficiary Notice (ABN) is required in the event the service may be denied or reduced for reasons of medical necessity. See page 5 for details concerning ABNs.

## CONNECTICUT ONLY

## COMPREHENSIVE DATA ANALYSIS

## Widespread Probe Review Results—Codes 36245, 75724, and 93508

**D**rocedure codes *36245*, *75724*, and *93508* were chosen for comprehensive data analysis for fiscal year 2003, based on a study performed by the New York PRO in conjunction with the CMS PRO Staff, to examine the medical necessity of diagnostic procedures performed at the same time as primary cardiac catheterizations. The study focused on a review of Medicare beneficiaries who undergo renal arteriogram during inpatient admission for cardiac catheterization. The findings of the New York study indicated providers were inappropriately performing and or billing medically unnecessary services. This review was performed following a recommendation from the Office of the Carrier Medical Director to ensure that the services performed in Connecticut were performed and or billed appropriately for medically necessary services.

#### Summary of the Findings

*CPT* code 36245 (Selective catheter placement, arterial system; each first order abdominal, pelvic, or lower extremity artery branch, within a vascular family)

- 73 services (out of a total of 103) were billed with covered indications and allowed as billed.
- 29 services were denied due to the lack of documented signs or symptoms or clinical indications or diagnostic studies to substantiate that the service was medically necessary.
- 1 service was denied due to the lack documentation submitted for review.
- The review of procedure code *36245* consisted of 13 providers; including 12 cardiologists, 10 diagnostic radiologists, 1 interventional radiologist; and 61 beneficiaries.
- 10 of the services were performed by cardiologists, 6 of the services were performed by interventional radiologists, and 87 of the services were performed by diagnostic radiologists.

# *CPT* code 75724 (Angiography, renal, bilateral, selective [including flush], radiological supervision and interpretation)

- 14 services (out of a 15) were billed with covered indications and allowed as billed.
- 1 service was denied due to the lack of documented signs or symptoms or clinical indications or diagnostic studies to substantiate that the service was medically necessary.
- The review of procedure code 75724 included 4 providers, 3 cardiologists, 1 diagnostic radiologist; and 13 beneficiaries.

- 3 of the services were performed by a diagnostic radiologist and 11 of the services were performed by cardiologists.
- The documentation for 2 of the beneficiaries representing 3 services stated that renal arteriograms and cardiac catheterizations were performed on the same day, by cardiologists.
- The documentation for 4 beneficiaries representing 6 services clearly demonstrated the medical necessity of the renal studies. 3 of these services were performed by cardiologists, and 3 services were performed by a diagnostic radiologist.

CPT code 93508 (Catheter placement in coronary artery[s], arterial coronary conduit[s], and/or venous coronary bypass graft[s] for coronary angiography without concomitant left heart catheterization)

- 59 services (out of a total of 60) were billed with covered indications and allowed as billed.
- 1 service was denied because it was a duplicate bill.
- The review of procedure code *93508* included 13 providers and 60 beneficiaries. Cardiologists performed all of the services.
- None of the documentation submitted stated that renal arteriograms and cardiac catheterization procedures were performed on the same day.

Based on the wide spread probe findings, a local medical review policy will be developed to include cardiac catheterization services, renal angiography, and selective catheter placement services. Educational letters will be written to the providers that failed to sufficiently document the medical necessity and reasonability of the services, failed to submit documentation of the billed services, and billed for one service twice on the same day. Overpayments will be collected from providers included in the wide spread probe in which the medical records failed to demonstrate that the services were a covered service or the documentation did not sufficiently support the services being performed (e.g., insufficient or no documentation submitted), and for the service that was billed twice.

## Widespread Probe Review Results—Codes 92225 and 92226

Procedure codes 92225 (Ophthalmoscopy, extended, with retinal drawing [e.g. for retinal detachment, melanoma], with interpretation and report; initial) and 92226 (Ophthalmoscopy, extended, with retinal drawing [e.g. for retinal detachment, melanoma], with interpretation and report, subsequent) were chosen for comprehensive data analysis for fiscal year 2003, based on data from May through October 2002. The data revealed a carrier-to-nation ratio of allowed dollars of 2.08 with a maximum potential savings of \$357.014 for procedure code 92225, and a carrier-to-nation ratio of allowed dollars of 2.31 with a maximum potential savings of \$875,982 for procedure code 92226. Based on the conclusions of the findings, the performance of these services were considered a widespread problem; therefore, recommendation to perform a widespread probe and subsequent enhancement/revision of the current local medical review policy (LMRP) for CPT codes 92225 and 92226. A widespread probe of 100 claims from 20 providers from May 1, 2002 to October 31, 2002 was conducted. The purpose of the review was to determine if the services billed to Medicare were documented as having been performed, and to determine the medical conditions for which the services were being performed. The American Medical Association's Physicians' Current Procedural Terminology (CPT 2001) was used in reviewing the services.

## Summary of the Findings

- Of the 100 claims reviewed, 100% of the services billed were for either procedure code 92225 or 92226.
- Indications documented for procedure code 92225 • included: vitreous degeneration, non-exudative macular degeneration, exudative macular degeneration, diabetic retinopathy, and vitreous membranes. Indications documented for procedure code 92226 included: non-exudative macular degeneration, exudative macular degeneration, diabetic retinopathy, vitreous degeneration, and proliferative diabetic retinopathy.
- All 100 services reviewed were allowed as billed.

An article will be published in a future issue of the Medicare B Update! upon completion of a revision of the current LMRP for 92225 and 92226. Changes will include: revision of the LMRP description, expansion of indications and limitations, clarification of documentation requirements, and addition of ICD-9-CM codes that support medical necessity for this service.

Italicized and/or quoted material is excerpted from the American Medical Association Current Procedural Terminology. CPT codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of CPT) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

#### Widespread Probe Review Results-Code 92235

Procedure code 92235 (Fluorescein angiography lincludes multification [includes multiframe imaging] with interpretation and report) was chosen for comprehensive data analysis for fiscal year 2003, based on data from May through October 2002. The data revealed a carrier-to-nation ratio of allowed dollars of 1.71, with a maximum potential savings of \$579,019. Based on the conclusions of the findings, performance of these services was considered a widespread problem; therefore, recommendation was made to perform a widespread probe and subsequent enhancement/revision of the current local medical review policy (LMRP) for CPT code 92235. A widespread probe of 100 claims from 20 providers from May 1, 2002 to October 31, 2002 was conducted. The purpose of the review was to determine if the services billed to Medicare were documented as having been performed, and to determine the medical conditions for which the services were being performed. The American Medical Association's Physicians' Current Procedural Terminology (CPT 2001) was used in reviewing the services.

#### Summary of the Findings

- Of the 100 claims reviewed, 100% of the services billed were for code 92235.
- Indications documented for 92235 included: exuda-• tive macular degeneration, non-exudative macular degeneration, retinal edema, diabetic retinopathy, and cystoid macular degeneration.
- 99 services were allowed as billed.
- 1 service was denied, as the documentation submitted indicated that this service was not rendered as billed.

An article will be published in a future issue of the Medicare B Update! upon completion of a revision of the current LMRP. Revisions will include clarification/ expansion of the LMRP description, and addition of ICD-9-CM codes that support medical necessity for this service.

## Widespread Probe Review Results—Code 92250

Procedure code 92250 (Fundus photography with interpretation and report) was chosen for comprehensive data analysis for fiscal year 2003, based on data from May through October 2002. The data revealed a carrier-to-nation ratio of allowed dollars of 2.20 with a maximum potential savings of \$550,473. Based on the conclusions of the findings, performance of these services were considered a widespread problem; therefore, a recommendation to perform a widespread probe and a possible revision to the local medical review policy (LMRP) was made. A widespread probe of 100 claims from 20 providers from May 1, 2002 to October 31, 2002 was conducted. The purpose of the review was to determine if the services billed to Medicare were documented as having been performed, and to determine the medical conditions for which the services were being performed. The American Medical Association's Physicians' Current Procedural Terminology (CPT 2001) was used in reviewing the services.

#### Summary of the Findings

- Of the 100 claims reviewed, 100% of the services billed were for 92250.
- Indications noted for 92250 included: exudative macular degeneration, primary open-angle glaucoma, open-angle glaucoma with borderline findings, non-exudative macular degeneration, and diabetic retinopathy.
- 96 services were allowed as billed.
- 4 services were denied, as the procedure billed was not sufficiently documented (no interpretation and report).

An article will be published in a future issue of the Medicare B Update! upon completion of an LMRP, which will identify a procedure to diagnosis relationship, and clarify coding guidelines and documentation requirements.

Italicized and/or quoted material is excerpted from the American Medical Association Current Procedural Terminology. CPT codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of CPT) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## LOCAL MEDICAL REVIEW POLICY (NEW)

## ERASV: Endoluminal Radiofrequency Ablation of the Saphenous Vein

local medical review policy (LMRP) has been Adeveloped for endoluminal radiofrequency ablation of the saphenous vein to define the indications and limitations for this service.

This procedure is a minimally invasive alternative to vein ligation and stripping. It has received FDA approval for treatment of varicose veins. The technique involves delivery of radiofrequency energy through a catheter inserted into the affected vein. The energy from the radiofrequency damages the intimal wall of the vessel resulting in fibrosis and obliteration of a long segment of the vein thus eliminating reflux. The procedure is performed by inserting a specially designed catheter through a small incision in the distal medial thigh to

within 1-2 cm of the sapheno-femoral junction. High radiofrequency energy is delivered to the vein wall, causing it to heat. As the vein warms, it collapses and seals shut. The procedure is generally done in an outpatient setting under local anesthesia. When billing this service, the unlisted CPT code 37799 should be used, and a comment should be placed in item 19 of Form CMS-1500 (or in the appropriate comment field for electronic submitters), indicating that this code corresponds to radiofrequency ablation of the saphenous vein.

This LMRP is available on our provider education Web site, www.connecticutmedicare.com, and is effective for claims processed on or after January 5, 2004.

## NCSVCS: The List of Medicare Noncovered Services

The purpose of this new local medical review policy  $\mathbf{L}$  (LMRP) is to create a working list of medical services and procedures that are never covered by Medicare.

A service or procedure on the national noncoverage list may be noncovered for a variety of reasons. It may be noncovered based on a specific exclusion contained in the Medicare law; it may be viewed as not proven safe and effective and, therefore, not medically reasonable and necessary; or it may be a procedure that is always considered cosmetic in nature. The precise basis for a national decision to noncover a procedure may be found in references cited in the LMRP.

A service or procedure on the local noncoverage list is always denied on the basis that we do not believe it is medically reasonable and necessary. The list of LMRP exclusions contains procedures that are experimental, not yet proven safe and effective, or not yet approved by the FDA, but are not included on the national noncoverage list.

It is our policy that new services, procedures, drugs, or technology must be evaluated and approved nationally or by our LMRP process before they may be considered Medicare-covered services.

The full-text LMRP is effective for claims processed on or after January 5, 2004, and may be found on our provider education Web site, www.connecticutmedicare.com.

## **D0120: Dental Services**

Dental care includes items and services in connection with the care, treatment, filling, removal, or replacement of teeth or structures directly supporting the teeth. "Structures directly supporting the teeth" means the periodontium, which includes the gingivae, dentogingival junction, periodontal membrane, cementum of the teeth, and alveolar process. Although payment may be made for certain services by a dentist, items and services in connection with the care, treatment, filling, removal, or replacement of teeth, or structures directly supporting the teeth are not covered (Medicare Carriers Manual, Part 3, CMS-Pub. 14-3). As a result of data analysis, a widespread probe for the period October 1, 2001, through March 31, 2002, was completed for medical services performed by specialty 19 (Dentist/Oral Surgery). Based on the review findings, a local medical review policy (LMRP) has been developed to define the indications and limitations of coverage, coding and documentation requirements; as well as, restricted coverage and special coverage instructions for dental services (D0120-D9999).

This LMRP is effective for claims processed on or after January 5, 2004. The full-text LMRP is available on our provider education Web site at *www.connecticutmedicare.com*.

# G0179: Physician Certification and Re-certification of Home Health Services

Physician's services involved in physician certification (and re-certification) of Medicare-covered home health services may be separately coded and reimbursed. These services include creation and review of a plan of care, and verification that the home health agency initially complies with the physician's plan of care. The physician's work in reviewing data collected in the home health agency's patient assessment would be included in these services.

Using statistical medical data obtained for dates of service from July 1 2002, to December 31, 2002, the use of codes G0179 and G0180 was found to have an aberrancy ratio of 5.93 and 2.17, respectively, per 1000 enrollees. Analysis of the data revealed that the majority of services were performed by internal medicine and family practice physicians in the office and home settings.

Due to these findings, local medical review policy (LMRP) is being developed to define the indications and limitations of coverage and clarify the appropriate use of physician certification and recertification of home health services (codes G0179 and G0180).

## J2792: Rho (D) Immune Globulin Intravenous

Statistical medical data obtained for code J2792 (Injection, Rho [D] immune globulin, intravenous, human, solvent detergent, 100 iu) was found to have an aberrancy ratio of 2.83 per 1,000 enrollees. Local medical review policy (LMRP) has been developed to define the indications and limitations for this service.

Rho (D) immune globulin intravenous (Rho (D) IGIV) is a gamma globulin (IgG) which contains antibodies to Rho (D). Rho (D) IGIV currently has two medical applications. Connecticut Medicare will consider Rho (D) Immune Globulin Intravenous medically necessary for the suppression of Rh isoimmunization. Coverage is additionally provided for the treatment of immune thrombocytopenic purpura (ITP) for non-splenectomized Rho (D) positive individuals in clinical situations requiring an increase in platelet count to prevent excessive hemorrhaging.

The full-text of this new LMRP is effective for claims processed on or after January 5, 2004, and is available on our provider education Web site at *www.connecticutmedicare.com*.

The following CPT/HCPCS codes are included in the LMRP:

- G0179 Physician re-certification for Medicarecovered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per re-certification period
- G0180 Physician certification for Medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per certification period

This new LMRP is effective for claims processed on or after January 5, 2004, and is available on our provider education Web site at *www.connecticutmedicare.com*.

## J2820: Sargramostim (GM-CSF, Leukine®)

Granulocyte macrophage colony stimulating factor (GM-CSF) is an antineutropenic growth factor, which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cell. GM-CSF is also capable of activating mature granulocytes and macrophages. This drug is not a cancer chemotherapy agent. GM-CSF is considered reasonable and necessary for the treatment of FDA-approved indications when it is not self/caregiver administered.

Statistical medical data identified HCPCS code J2820 (Injection, sargramostim (GM-CSF), 50 mcg) with an aberrancy ratio of 1.66. Therefore, local medical review policy (LMRP) has been developed to define the indications and limitations for this service.

This new LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

### CONNECTICUT ONLY

### 31525: Laryngoscopy

A new local medical review policy (LMRP) has been developed to define the indications and limitations for diagnostic laryngoscopy services. This procedure provides direct visualization of the larynx and secondary structures. The fiberoptic technique utilizes specialized endoscopic techniques.

The *CPT* codes included in this policy are:

31525 Laryngoscopy, direct, with or without tracheoscopy; diagnostic, except newborn 31575 Laryngoscopy, flexible fiberoptic; diagnostic

The full-text of this new LMRP available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 64561: Sacral Neuromodulation

**S** acral neuromodulation is a new treatment modality used in the management of patients who suffer from refractory urinary urge incontinence, significant urgency/ frequency, and urinary retention in patients without mechanical obstruction. The aim of therapy is to modulate the micturation reflex by electrically stimulating the sacral nerves that influence the bladder and pelvic floor muscles.

This therapy involves the surgical implantation of a system for long-term use. The system consists of a lead, a neurostimulator, and an extension that connects the two. Under general anesthesia, the lead is placed through an open incision over the selected foramen. The proximal end of the lead is tunneled around to the neurostimulator implanted into the lower abdomen or upper buttock. An extension connects the neurostimulator to the lead. Noninvasive programming of the neurostimulator parameters and modes occurs post-operatively.

Based on CMS Transmittal AB-01-143, Change Request 1881, effective January 1, 2002, sacral nerve stimulation is covered for the treatment of urinary urge incontinence, urgency-frequency syndrome, and urinary retention. Local medical review policy (LMRP) has been developed to further define the indications and limitations of coverage and/or medical necessity, to allow access to care, and to outline proper utilization of this procedure. The following *CPT*/HCPCS codes are included in the LMRP:

64561 Percutaneous implantation of neurostimulator electrodes; sacral nerve (transforaminal placement) 64581 Incision for implantation of neurostimulator electrodes; sacral nerve (transforaminal placement) 64585 Revision or removal of peripheral neurostimulator electrodes 64590 Incision and subcutaneous placement of peripheral neurostimulator pulse generator or receiver, direct or inductive coupling 64595 Revision or removal of peripheral neurostimulator pulse generator or receiver 95970 Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configu-

ratie, puise amplitude and duration, conjuguration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, autonomic nerve, neuromuscular) neurostimulator pulse generator/ transmitter, without reprogramming

- 95971 simple brain, spinal cord, or peripheral (ie, peripheral nerve, autonomic nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming
- 95972 complex brain, spinal cord, or peripheral (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, first hour
- 95973 complex brain, spinal cord, or peripheral (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure) (Use 95973 in conjunction with code 95972)
- A4290 Sacral nerve stimulation test lead, each
- E0745 Neuromuscular stimulator, electronic shock unit
- E0752 Implantable neurostimulator electrode, each E0754 Patient programmer (external) for use with implantable programmable neurostimulator pulse generator
- E0756 Implantable neurostimulator pulse generator
- E1399 Durable medical equipment, miscellaneous

The following ICD-9-CM codes are included in the "ICD-9 Codes that Support Medical Necessity:"

595.1	Chronic interstitial cystitis
788.20-788.29	Retention of urine
788.31	Urge incontinence
788.41	Urinary frequency

The full-text of this new LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

# 74150: Computed Tomography of the Abdomen

computed tomography (CT) image is a display of A the anatomy of a thin slice of the body developed from multiple X-ray absorption measurements made around the periphery of the body. Unlike conventional tomography, where the image of a thin section is created by blurring out the information from unwanted regions, the CT image is constructed mathematically using data arising only from the section of interest. Generating such an image is confined to cross-sections of the anatomy that are oriented essentially perpendicular to the axial dimensions of the body. Reconstruction of the final image can be accomplished in any plane. A CT of the abdomen extends from the dome of the diaphragm to the pelvic brim or pubic symphysis depending upon whether one groups the pelvis with the abdomen or treats it separately.

Statistical medical data obtained for dates of service from July 2002 through December 2002 found *CPT* code 74150 to have an aberrancy ratio of 1.91 per 1000 enrollees. Based on these findings, local medical review policy (LMRP) has been developed to provide indications and limitations for this service. The *CPT* codes included in this policy are:

74150 Computed tomography, abdomen; without contrast material

74160 with contrast material(s)
 74170 without contrast material, followed by contrast material(s) and further sections

The full-text of this LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

## 84154: Free Prostate Specific Antigen

**P**rostate-specific antigen (PSA) is a serum glycoprotein tumor marker used in the early detection of prostate cancer. PSA exists in multiple forms in serum and is predominantly complexed to protease inhibitors; however, one form of PSA, free PSA, is not bound to these proteins. The measurement of PSA forms in serum helps discriminate between prostate cancer and benign prostatic disease. For unknown reasons, the percentage of free PSA (fPSA) is lower in serum samples from patients with prostate cancer than in serum samples from patients with a normal prostate or benign disease.

Statistical medical data obtained for dates of service from January 1, 2002, to June 30, 2002, use of *CPT* code *84154 (Prostate specific antigen; free)* was found to have an aberrancy ratio of 16.38 per 1000 enrollees. Analysis of the data revealed that the services were performed by clinical laboratories. Some of the diagnoses submitted were determined to be inappropriate for the services billed (e.g., impotence, hyperlipidemia, hypertension, urinary obstruction).

Due to these findings, local medical review policy (LMRP) has been developed to define the indications and

# 83880: B-Type Natriuretic Peptide (BNP)

Congestive heart failure (CHF) is characterized by a progressive activation of the neurohormonal systems that control vasoconstriction and sodium retention; the activation of these systems plays a role in its pathogenesis and progression. As the heart fails, B-Type Natriuretic Peptide (BNP), a cardiac neurohormone is secreted from the cardiac ventricles in response to ventricular volume expansion and pressure overload. Used in conjunction with other clinical information, rapid measurement of BNP is useful in establishing or excluding the diagnosis and assessment of severity of CHF in patients with acute dyspnea so that appropriate and timely treatment can be initiated. BNP levels are also useful for risk stratification among patients with acute coronary syndrome (myocardial infarction with or without T-wave elevation and unstable angina).

Local medical review policy (LMRP) has been developed for *CPT* code 83880 (*Natriuretic peptide*) to allow providers access to this new technology, and to provide indications and limitations for this procedure. For the purposes of this policy, the total and N terminal assays are both acceptable.

The full-text of this LMRP is available on the provider education Web site *www.connecticutmedicare.com*, and will be effective for claims processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

limitations of coverage, establish a procedure to diagnosis application, and clarify the appropriate use of fPSA (procedure code *84154*).

Connecticut Medicare will consider 84154 medically reasonable and necessary in the following circumstances:

- To evaluate the patient whose total PSA level is between 4.0-10.0 ng/mL and has a palpable benign prostate gland; and
- To eliminate the need for unnecessary biopsies.

The following ICD-9-CM code is included in the "ICD-9 Codes that Support Medical Necessity" for *CPT* code *84154*:

790.93 Elevated prostate specific antigen, (PSA)

The full-text LMRP is available on our provider education Web site, *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

## 88180: Flow Cytometry and Morphometric Analysis

Flow cytometric analysis of DNA provides a useful method of quantifying the changes in nuclear DNA that accompany neoplastic transformation. This technique may be used as an adjuvant diagnostic tool in cases where the subjective staging of a tumor is particularly difficult.

Morphometric analysis utilizes a quantitative image analysis system (light or fluorescent microscopy with quantitative morphometry and computerized data reduction) to assess a sample after the diagnosis of malignancy has already been established by histopathology. This assessment can assist in estimating prognosis and planning treatment for patients from whom tumors have been sampled or excised. Local medical review policy (LMRP) has been developed to address flow cytometry and morphometric analysis services in one policy. Therefore, existing policies 88180 Immunophenotypic Analysis of Tissues by Flow Cytometry and 88182 Cell Cycle or DNA Analysis by Flow Cytometry will be deleted. The new policy defines the indications and limitations of coverage, establishes a procedure to diagnosis application, and clarifies the appropriate use of flow cytometry and morphometric analysis of tumor.

The full-text of this LMRP is available on the provider education Web site *www.connecticutmedicare.com*, and will be effective for claims processed on or after January 5, 2004.

## 88271: Urinary Fluorescent In Situ Hybridization (FISH) Test for Recurrent Bladder Cancer

The urinary FISH test for recurrent bladder cancer is an FDA-approved multiprobe fluorescent in situ hybridization DNA technology designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via FISH in voided urine specimens from patients with transitional cell carcinoma of the bladder (urothelial carcinoma). In situ hybridization is a technique that allows visualization of specific nucleic acid sequences within a cellular preparation. Specifically, DNA FISH involves the precise annealing of a single stranded fluorescently labeled DNA probe to complementary target sequences. Hybridization of the probe with the cellular DNA site is visible by direct detection using fluorescence microscopy. Results from the urinary FISH test are intended for use as a noninvasive method for monitoring tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

Local medical review policy (LMRP) has been developed to allow providers access to this new technology, and to provide indications and limitations for this procedure.

#### CPT/HCPCS Codes

- 88271 Molecular cytogenetics; DNA probe, each (eg, FISH)
- 88274 Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells
- 88291 Cytogenetics and molecular cytogenetics, interpretation and report

ICD-9-CM codes that support medical necessity for this service include:

188.0-188.9	Malignant neoplasm of bladder
189.0-189.9	Malignant neoplasm of kidney and
	other and unspecified urinary organs
198.1	Secondary malignant neoplasm of other
	urinary organs
233.7	Carcinoma in situ of bladder
236.7	Neoplasm of uncertain behavior of
	bladder
239.4	Neoplasms of unspecified nature,
	bladder
V10.50	Personal history of malignant neo-
	plasm, urinary organ, unspecified
V10.51	Personal history of malignant neo-
	plasm, bladder
V10.52	Personal history of malignant neo-
	plasm, kidney

The full-text of this LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after January 5, 2004.

## 00257: Ocular Corneal Pachymetry

Ocular corneal pachymetry is the ultrasonic measurement of corneal thickness. Measurement of corneal thickness in individuals presenting with increased intraocular pressure assists in determining if there is a risk of glaucoma or if the individual's increased eye pressure is the result of abnormal corneal thickness.

A recent study has demonstrated the benefit of assessing corneal thickness in individuals with increased intraocular pressure. Several physicians requested evaluation of this technology for separate reimbursement consideration. Development of a local medical review policy (LMRP) for *CPT* code 0025T (Determination of corneal thickness [eg, pachymetry] with interpretation and report, bilateral) resulted from the evaluation.

*CPT 0025T* is considered medically necessary for specific diseases of the cornea. The full text of this new LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for services processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## LOCAL MEDICAL REVIEW POLICY (REVISED)

## 2004 ICD-9-CM Coding Changes

The 2004 update to the ICD-9-CM diagnosis coding structure became effective October 1, 2003. Updated diagnosis codes *must* be used for all services billed on or after January 1, 2004. A 90-day grace period is provided during which Connecticut Medicare will accept both old and new ICD-9-CM codes, for claims received October 1 through December 31, 2003. This grace period is to allow providers sufficient time to obtain and integrate the updated ICD-9-CM codes into their billing systems. All claims for services rendered on or after January 1, 2004 *must* be billed with the updated 2004 ICD-9-CM codes.

Connecticut Medicare has reviewed all local medical review policies (LMRPs) for procedure codes with specific diagnosis criteria that are affected by the 2004 ICD-9-CM update. The table on the following pages lists the LMRPs affected, the publication in which diagnosis criteria appeared, and the specific conditions revised as a result of the 2004 ICD-9-CM update:

LMRP Title	2004 Changes
53850: Prostate Treatments	Change 600.0 to 600.00-600.01 (Hypertrophy [benign] of prostate) for procedure codes 53850, 53852, and 53853
55700: Ultrasound Guided Prostate Needle Biopsy	Change 600.0-600.9 to 600.00-600.91 (Hyperplasia of prostate) for procedure code 55700
71010: Radiologic Examination of the Chest	$\begin{array}{l} \mbox{Add} 011.90-011.96, 018.90-018.96, 033.9, 084.0-084.8, 093.9, 115.93-115.95, 142.9, 143.9, \\ 144.9, 145.9, 147.9, 148.9, 150.9, 151.9, 162.9, 163.9, 164.9, 174.9, 180.9, 183.9, 185, 189.0, \\ 189.9, 191.0-191.9, 196.9, 231.9, 236.90, 236.99, 239.1, 239.3, 254.9, 396.9, 398.90, 401.0- \\ 401.9, 402.00-402.91, 403.00-403.91, 404.91, 404.93, 405.01-405.19, 410.90-410.92, 414.8, \\ 414.9, 417.9, 422.90, 423.9, 424.90, 427.69, 427.9, 428.9, 429.0, 429.9, 447.2, 480.9, 482.84, \\ 482.9, 493.02, 493.12, 493.22, 493.90-493.92, 505, 506.9, 518.6, 518.83, 518.84, 519.9, \\ 530.12, 745.8, 745.9, 746.9, 786.9, 770.9, 785.0, 785.50, 786.00-786.09, 786.50, 807.00, \\ 807.10, 810.10, 848.40, 862.29, 862.31, 862.32, 934.9, 942.00, 942.10, 942.20, 942.30, \\ \end{array}$

#### 2004 ICD-9-CM Part B LMRP Changes

	942.40, 942.50, 983.9, 993.9, 996.00, 996.60, 997.00, V10.00, V10.20, V10.40, V10.48, V10.50, V10.53, V45.00, and V58.81-V58.89 for procedure codes <i>71010</i> , <i>71015</i> , <i>71020</i> , <i>71021</i> , <i>71022</i> , <i>71023</i> , <i>71030</i> , <i>71034</i> , and <i>71035</i> to be consistent with Florida's policy. (Not related to 2004 ICD-9-CM Update) Change 959.1 to 959.11 (Other injury of chest wall) and 959.19 (Other injury of other sites of trunk) for procedure codes <i>71010</i> , <i>71015</i> , <i>71020</i> , <i>71021</i> , <i>71022</i> , <i>71023</i> , <i>71030</i> , <i>71034</i> , and <i>71035</i> Change V43.2-V43.3 to V43.21-V43.3 (Organ or tissue replaced by other means, heart and heart valve) for procedure codes <i>71010</i> , <i>71015</i> , <i>71020</i> , <i>71021</i> , <i>71022</i> , <i>71023</i> , <i>71030</i> , <i>71034</i> , and <i>71035</i>
78460: Myocardial Perfusion Imaging	Add 414.07 (Coronary atherosclerosis of bypass graft [artery] [vein] of transplanted heart) for procedure codes 78460, 78461, 78464, 78465, 78478, and 78480
<i>83735</i> : Serum Magnesium	Change 255.1 to 255.10-255.14 (Hyperaldosteronism) for procedure code <i>83735</i> Change 458.0-458.2 to 458.0 (Orthostatic hypotension), 458.1 (Chronic hypotension), and 458.21-458.29 (Iatrogenic hypotension) for procedure code <i>83735</i> Change 638.1-638.9 to 638.0-638.9 (Failed attempted abortion) for procedure code <i>83735</i> (Not related to 2004 ICD-9-CM Update) Change 643.10-643.93 to 643.00-643.93 (Excessive vomiting in pregnancy) for procedure code <i>83735</i> (Not related to 2004 ICD-9-CM Update) Change 763.8 to 763.81-763.89 (Other specified complications of labor and delivery affecting fetus or newborn) for procedure code <i>83735</i> (Not related to 2004 ICD-9-CM Update)
90801: Psychiatric Diagnostic Interview Examination	Add 780.93 (Memory loss) for procedure code 90801
92980: Interventional Cardiology in the Treatment of Ischemic Heart Disease	Add 414.06 (Coronary atherosclerosis of native coronary artery of transplanted heart) for procedure codes <i>92980</i> , <i>92981</i> , <i>92982</i> , <i>92984</i> , <i>92995</i> , and <i>92996</i> ( <b>Not related to 2004 ICD-9-CM Update</b> ) Add 414.07 (Coronary atherosclerosis of bypass graft [artery] [vein] of transplanted heart) for procedure codes <i>92980</i> , <i>92981</i> , <i>92982</i> , <i>92984</i> , <i>92995</i> , and <i>92996</i>
93000: Electrocardiography	Change 959.1 to 959.11-959.19 (Injury, trunk) for procedure codes 93000, 93005, and 93010 Change 995.0-995.89 to 995.0-995.94 (Certain adverse effects not elsewhere classified) for procedure codes 93000, 93005, and 93010 (Not related to 2004 ICD-9-CM Update)
J0150: Adenosine (Adenocard®, Adenoscan®)	Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure code J0150 Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure code J0151

## **Policy Revision Initiative**

**S** everal local medical review policies (LMRP) have been revised. In the process of updating these policies, the diagnosis to procedure code edits were reviewed and changes were identified that occurred due to the MCS conversion. The system was updated under the direction of the Connecticut Carrier Medical Director (CMD) and medical staff to reflect diagnoses that were included in the edits prior to MCS conversion. System updates were done prior to policy revisions due to provider inquiries and a high volume of post-payment reviews.

Policy #	Policy Title
65855	Laser Trabeculoplasty
71010	Radiological Examination of the Chest
99-2 V1.0 FINAL	Biofeedback Therapy for Fecal Incontinence
94004A V1.2	Coverage for Services for Trimming, Reduction of Non-dystrophic and Dystrophic Toenails, Reduction of Corns and Calluses of the Feet
76700 formerly 98043 V1.0 FINAL	Abdominal Ultrasound
92567	Tympanometry
44388	Colonoscopy

The following LMRPs have been revised by the addition of ICD 9-CM diagnosis criteria:

The full-text of these local medical review policies may be viewed on our provider education Web site at *www.connecticutmedicare.com* when they become available.

## EPO: Epoetin Alfa (formerly 99-4 V1.1 Final: Labeled and Off-Labeled uses of Erythropoietin)

Erythropoietin is a glycoprotein that stimulates red blood cell production. It is produced in the kidneys and stimulates the division and differentiation of accurate to the stimulates the division and differentiation of accurate to the stimulates the division and differentiation of accurate to the stimulates the division and differentiation of accurate to the stimulates the division and differentiation of accurate to the stimulates to the s stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. The local medical review policy (LMRP) for labeled and off-labeled uses of erythropoietin was last updated January 1, 2003.

This policy has been revised to define the indications and limitations of coverage and/or medical necessity; and to clarify the appropriate use of epoetin alfa. The following major revisions have been incorporated:

- Laboratory requirements for initiation of epoetin alfa therapy have been revised.
- The following "Indications and Limitations of Coverage and/or Medical Necessity" have been added to the policy: - Anemia associated with malignancy

- Reduction of allogeneic blood transfusions in surgery patients
- Anemia associated with the management of hepatitis C
- The "Coding Guidelines" section of the LMRP has been revised with updated dual diagnosis requirements.
- The policy number and title have been changed to EPO: Epoetin Alfa.

The following HCPCS codes are included in the LMRP:

Q0136	Injection, epoetin alpha, (for non ESRD use), per 1,000 units
Q9920	Injection of EPO, per 1000 units, at patient HCT of 20 or less
Q9921	Injection of EPO, per 1000 units, at patient HCT of 21
Q9922	Injection of EPO, per 1000 units, at patient HCT of 22
Q9923	Injection of EPO, per 1000 units, at patient HCT of 23
Q9924	Injection of EPO, per 1000 units, at patient HCT of 24
Q9925	Injection of EPO, per 1000 units, at patient HCT of 25
Q9926	Injection of EPO, per 1000 units, at patient HCT of 26
Q9927	Injection of EPO, per 1000 units, at patient HCT of 27
Q9928	Injection of EPO, per 1000 units, at patient HCT of 28
Q9929	Injection of EPO, per 1000 units, at patient HCT of 29
Q9930	Injection of EPO, per 1000 units, at patient HCT of 30
Q9931	Injection of EPO, per 1000 units, at patient HCT of 31
Q9932	Injection of EPO, per 1000 units, at patient HCT of 32
Q9933	Injection of EPO, per 1000 units, at patient HCT of 33
Q9934	Injection of EPO, per 1000 units, at patient HCT of 34
Q9935	Injection of EPO, per 1000 units, at patient HCT of 35
Q9936	Injection of EPO, per 1000 units, at patient HCT of 36
Q9937	Injection of EPO, per 1000 units, at patient HCT of 37
Q9938	Injection of EPO, per 1000 units, at patient HCT of 38
Q9939	Injection of EPO, per 1000 units, at patient HCT of 39
Q9940	Injection of EPO, per 1000 units, at patient HCT of 40 or above

The revised LMRP is effective for claims processed on or after January 5, 2004, and is available on our provider education Web site at www.connecticutmedicare.com.

## G0030: Positron Emission Tomography (PET) Scan

The local medical review policy (LMRP) for positron emission tomography (PET) scan was last updated January 1, 2003. PET is a noninvasive diagnostic imaging procedure that assesses the level of metabolic activity and perfusion in various organ systems of the human body. A positron camera (tomograph) is used to produce cross-sectional tomographic (radiopharmaceuticals) such as 2-(F-18) fluoro-D-glucose (FDG), that are administered intravenously to the patient.

CMS Transmittal AB-03-092, Change Request 2687, provides expanded coverage for noninvasive imaging of the perfusion of the heart using FDA-approved Ammonia N-13 as a tracer. Ammonia N-13 and Rubidium are the only two tracers covered for PET scans for the perfusion

of the heart. Additional instructions are provided for carriers billing Rubidium in CMS transmittal AB-03-119, Change Request 2853.

The LMRP for PET has been revised to reflect these changes. Coverage has also been expanded to include restaging of recurrent residual thyroid cancers of follicular cell origin that have been previously treated by thyroidectomy and radioiodine ablation and have a serum thyroglobulin >10ng/ml and negative I-131 whole body scan.

The full text of the revised LMRP is available on our provider education Web site at www.connecticutmedicare.com, and is effective for services rendered on or after October 1, 2003.

## J2430: Pamidronate (Aredia®, APD)

The local medical review policy (LMRP) for pamidronate was last updated on June 30, 2003. Based on comments received from providers, it was determined the changes made effective June 30, 2003, further restricted the LMRP. Therefore, the dual diagnosis requirements contained in the "ICD-9 Codes that Support Medical Necessity" and "Coding Guidelines" sections of the LMRP have been removed.

HCPCS code J2430	(Pamidronate disodium,	, per 30 mg) may be billed	d with the following ICD-9-CM codes:
------------------	------------------------	----------------------------	--------------------------------------

- 174.0-174.9 Malignant neoplasm of female breast
  175.0-175.9 Malignant neoplasm of male breast
  198.5 Secondary malignant neoplasm of bone and bone marrow
  203.00-203.01 Multiple myeloma
  275.42 Hypercalcemia (associated with malignancy)
  731.0 Osteitis deformans without mention of bone tumor (Paget's disease of bone)
- V10.3 Personal history of malignant neoplasm; breast

The revised LMRP is effective for claims processed on or after September 30, 2003, and is available on our provider education Web site at *www.connecticutmedicare.com*.

## J9999: Antineoplastic Drugs

The local medical review policy (LMRP) for

antineoplastic drugs was last updated September 29, 2003. The following revisions have since been made:

#### Indications and Limitations of Coverage and/ or Medical Necessity

The indication for off-label use of chemotherapeutic agents has been revised.

The following off-label indications have been added to the respective agent:

- Carboplatin Hormone Refractory Prostate Cancer
- Docetaxel Soft tissue sarcomas
- Gemcitabine Soft tissue sarcomas
- Topotecan Hydrochloride Cervical carcinoma

#### **ICD-9 Codes that Support Medical Necessity**

The ICD-9-CM list for HCPCS code J9015 (Aldesleukin) has been corrected to include 205.10-205.11 (Chronic myeloid leukemia), effective for claims processed on or after September 29, 2003.

The ICD-9-CM list for HCPCS code J9355 (Trastuzumab) has been corrected to include 198.89 (Secondary malignant neoplasm of other specified sites), effective for claims processed on or after September 29, 2003.

The following ICD-9-CM codes have been added to the respective agent:

- J9045 (Carboplatin) 185 (Malignant neoplasm of prostate), effective for claims processed on or after October 20, 2003.
- J9170 (Docetaxel) 171.0-171.9 (Malignant neoplasm of connective and other soft tissue [soft tissue sarcomas]), effective for claims processed on or after October 20, 2003.
- J9185 (Fludarabine) 273.3 (Macroglobulinemia [Waldenstrom's macroglobulinemia]), effective for claims processed on or after September 22, 2003.
- J9201 (Gemcitabine) 171.0-171.9 (Malignant neoplasm of connective and other soft tissue [soft tissue sarcomas]), effective for claims processed on or after October 20, 2003.
- J9350 (Topotecan Hydrochloride) 180.0-180.9 (Malignant neoplasm of cervix uteri), effective for claims processed on or after October 20, 2003.

The full-text of the revised LMRP is available on our provider education Web site at *www.connecticutmedicare.com*.

## 70544: Magnetic Resonance Angiography (MRA)

CMS Transmittal 1795, Change Request 2673, expands coverage for MRA to include MRA of the pelvis. Therefore, the local medical review policy (LMRP) for MRA has been revised to define the indications and limitations of coverage and to add the following ICD-9-CM codes to the "ICD-9 Codes that Support Medical Necessity" section of the policy for *CPT* code **72198** (*Magnetic resonance angiography*, *pelvis, with or without contrast material[s]*):

189.0-189.9	Malignant neoplasm of kidney and other and unspecified urinary organs
198.0	Secondary malignant neoplasm of kidney
223.0	Benign neoplasm of kidney, except pelvis
223.1	Benign neoplasm of renal pelvis
233.9	Carcinoma in situ of other and unspecified urinary
	organs
236.90-236.99	Neoplasm of uncertain behavior of other and
	unspecified urinary organs
403.00-403.91	Hypertensive renal disease
404.00-404.93	Hypertensive heart and renal disease
405.01	Secondary hypertension, malignant, renovascular

405.11	Secondary hypertension, benign, renovascular
405.91	Secondary hypertension, unspecified, renovascular
440.1	Atherosclerosis of renal artery
447.3	Hyperplasia of renal artery
580.0-580.9	Acute glomerulonephritis
581.0-581.9	Nephrotic syndrome
582.0-582.9	Chronic glomerulonephritis
583.0-583.9	Nephritis and nephropathy, not specified as acute or chronic
588.0-588.9	Disorders resulting from impaired renal function
593.81	Vascular disorders of kidney
593.9	Unspecified disorder of kidney and ureter

The full-text of the revised LMRP is available on our provider education Web site at *www.connecticutmedicare.com*. These changes are effective for services processed on or after January 5, 2004.

## MEDICAL REVIEW

# 78460: Myocardial Perfusion Imaging

Information concerning the local medical review policy (LMRP) for myocardial perfusion imaging was published in the Fourth Quarter 2002 *Medicare B Update!* Based on a provider request, the policy has since been revised to add ICD-9-CM codes 410.00 - 419.02, 786.05, 786.50, and 786.51 to the "ICD-9 Codes that Support Medical Necessity" section of the policy.

The full-text of this LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for claims processed on or after October 20, 2003.

# 88141: Pap Smears Laboratory Testing

CMS Transmittal AB-03-054, Change Request 2637, expands coverage for screening Pap smears. Therefore, the local medical review policy (LMRP) for Pap smears laboratory testing has been revised to define the indications and limitations of coverage, and to add ICD-9-CM codes V76.47 and V76.49 to the "ICD-9 Codes that Support Medical Necessity" section of the policy. These changes are effective for services processed on or after October 1, 2003.

In addition, after policy reconsideration, coverage was expanded for diagnostic Pap smears to add ICD-9-CM codes to the "ICD-9 Codes that Support Medical Necessity" section of the policy, effective for services processed on or after October 20, 2003.

The full-text of this LMRP may be found on the provider education Web site *www.connecticutmedicare.com*.

## 90901: Biofeedback

**C**PT Code 90911 (Biofeedback training by any modality) was found to be aberrant based on data for services from January 1, 2002, through June 30, 2002. The local medical review policy (LMRP) has been revised to define the indications and limitations of coverage, establish a procedure to diagnosis application, and clarify the appropriate use of procedure code 90911. In addition, this revised LMRP replaces the following policies:

- 99-2 V1.0 FINAL Biofeedback Therapy for Fecal Incontinence
- 90911: Biofeedback Therapy for Urinary Incontinence

The full-text of this LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for services performed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 92136: Optical Coherence Biometry

The latest revision to the local medical review policy (LMRP) for optical coherence biometry was effective March 1, 2003. CMS Program Memorandum AB-03-119, Change Request 2853, dated August 8, 2003, was issued to communicate a change in the final update to the 2003 Medicare Physician Fee Schedule Database that indicates procedure code 92136-26 as a bilateral procedure. Therefore, the "Coding Guidelines" section of the policy has been revised accordingly.

The full-text of this local medical review policy is available on our provider education Web site *www.connecticutmedicare.com*, and is effective for services rendered on or after March 1, 2003.

## 98940: Chiropractic Services (formerly 98037 V1.0 FINAL Manual Spinal Manipulation Services by Chiropractic Physicians)

The latest revision for local medical review policy (LMRP) for manual spinal manipulation services was January 1, 2003. This LMRP has been updated to reflect: revision of policy number, title and LMRP description, clarification of indications and limitations, reasons for denials, coding guidelines, documentation requirements, revision of utilization guidelines and other comments, and addition of ICD-9-CM codes that support medical necessity.

The full-text of this LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for services processed on or after October 20, 2003.

## 99183: Hyperbaric Oxygen Therapy (HBO Therapy)

The latest revision to the local medical review policy (LMRP) for HBO therapy was effective April 1, 2003. Program Memorandum (PM) AB-03-102, Change Request 2769, dated July 25, 2003, was issued to correct PM AB-02-183, Change Request 2388, as the original PM did not include some pertinent information regarding diagnosis codes. Revisions include: addition of ICD-9-CM Code 707.15 (Ulcer of other part of foot) to the "ICD-9 Codes That Support Medical Necessity" section of the policy for this therapy and deletion of ICD-9-CM code 707.0 (Decubitus ulcer) from this section of the policy.

The full-text of the revised LMRP is available on our provider education Web site at *www.connecticutmedicare.com*, and is effective for services rendered on or after April 1, 2003.

## CONNECTICUT ONLY

## LOCAL MEDICAL REVIEW POLICY (RETIRED)

## 95 LMRP010-V1.0-97010: Physical Medicine for Chronic Pain

The local medical review policy (LMRP) for physical medicine therapy for chronic pain is retired, effective for services processed on or after September 28, 2003. It has been determined that a policy for physical medicine specifically addressing chronic pain is no longer relevant. The coverage information for physical medicine can be found in the LMRP for physical medicine and rehabilitation. The full text of the LMRP for physical medicine and rehabilitation may be found on our provider education Web site at *www.connecticutmedicare.com*.

## **C**ORRECTIONS

# Comprehensive Data Analysis for Eye Exams—Correction

An article published in the Third Quarter 2003 Medicare B Update! (page 67) made reference to two local medical review policies (LMRP), one for gonioscopy and one for visual field examination. The LMRP for visual field examination has not yet been finalized; therefore, this reference is inaccurate. Connecticut Medicare apologizes for any confusion this may have caused.

## 55700: Biopsy of Prostate Using Image Guidance—Correction

We published information concerning revisions to the local medical review policy (LMRP) for biopsy of the prostate using image guidance in the Fourth Quarter 2003 Medicare B Update! (page 69). Regrettably, we included information specific to Florida in the article for the Connecticut LMRP revision. The correct information for Connecticut is as follows:

The digital rectal exam (DRE) and prostate specific antigen (PSA) blood test are two ways to detect changes in the prostate gland. However, these procedures cannot determine if the changes are due to prostate cancer or to a non-cancerous condition. A prostate biopsy must be performed to make a definitive diagnosis of prostate cancer. The LMRP for biopsy of the prostate using image guidance has been revised to expand the indications and limitations of coverage, to add ICD-9-CM codes that support medical necessity, and clarify the appropriate use of *CPT* codes 55700 and 76942.

This revision is effective for services processed on or after September 29, 2003. The full-text LMRP will be available on the provider education Web site *www.connecticutmedicare.com* on or after that date.

## 73218: Magnetic Resonance Imaging of Upper Extremity— Correction

The new local medical review policy (LMRP) pertaining to magnetic resonance imaging of upper extremity that was effective September 29, 2003, included an invalid ICD-9-CM diagnosis code. We have corrected the LMRP to reflect ICD-9-CM code V67.00 (Follow-up examinations; following surgery) instead of V67.0.

This correction is effective for services processed on or after September 29, 2003. The full-text LMRP is available on our provider education Web site at *www.connecticutmedicare.com*. CONNECTICUT ONLY

## Connecticut Educational Resources

## "Connect with Medicare" Teleconference

Presented by First Coast Service Options, Inc., your Connecticut Medicare Part B Carrier

Hot Topics on Evaluation and Management Visit Codes that impact claim processing Important information you should know!

#### Friday, November 14, 2003

1:00 p.m.

## PowerPoint Presentation

- Commonly Used TermsSelection of Appropriate Level of Care
- Office Visit Codes
- Routine Exams with Evaluation and Management (E/M) Visits
- Consultations
- Referrals vs. Consultations
- Medical Review Case Study
- MCS processing guidelines
- Hot Topics!

2:00 - 2:30 p.m. Open Forum (limit one question per caller)

#### No Pre-Registration Required—Open to First 100 callers!

Participants may begin to dial in (1-800-860-2442) 10 minutes prior to scheduled conference time. The pass code is "EM Hot Topics."

For more information, call our Education and Outreach Department at 1-203-634-5430

If you cannot attend this teleconference, see flyer on our Web site for E/M Hot Topics Seminar

Enhance your Medicare Billing Knowledge! Visit our Web site at www.connecticutmedicare.com

# Free Medicare Part B

## **Evaluation and Management Claim Filing-Hot Topics Seminar**

Presented by First Coast Service Options, Inc., your Connecticut Medicare Part B Carrier

#### Hot Topics on Evaluation and Management Visit Codes that impact claim processing

Can you answer yes to the following questions?

- 1. Do you ever receive unprocessable claims?
- 2. Do you ever receive claim denials?
- 3. Do you know the difference between a procedure and a diagnostic test?
- 4. Do you know when to use a modifier 25 or modifier 24?
- 5. Do you know how to bill a routine visit that includes a covered visit?

If you answered yes to even one question, your practice cannot afford to miss this seminar. Your reimbursement depends on it!

You can choose between morning, or afternoon session (the content is the same). Select the time most convenient for your office. All sessions are free. No registration required. Come early, seating is limited to first 75 attendees.

Date:	Location	2 sessions daily
Tuesday		
November 18, 2003	Courtyard by Marriott	9:00-11:00 a.m.
	63 Grand Street	or
	Waterbury, CT 06702	1:00- 3:00 p.m.
	203-596-1000	
Friday		
November 21, 2003	Quality Inn and Conference Center	9:00-11:00 a.m.
	51 Hartford Turnpike, Rte. 83	or
	Vernon, CT 06066	1:00-3:00 p.m.
	860-646-5700	

For more information, call our Education and Outreach Department at 1-203-634-5430

## FLORIDA MEDICAL REVIEW

This section of the *Medicare B Update!* features summaries of new and revised medical policies developed as a result of either local medical review or comprehensive data analysis initiatives. These initiatives are designed to ensure the appropriateness of medical care and that the carrier's medical policies and review guidelines are consistent with accepted standards of medical practice.

In accordance with publication requirements specified by the Centers for Medicare & Medicaid Services (CMS), carriers no longer include fulltext local medical review policies (LMRPs) to providers in the *Update!* Summaries of revised and new LMRPs are provided instead. Providers may obtain full-text LMRPs on our provider education Web site,

www.floridamedicare.com. Final LMRPs, draft LMRPs available for comment, LMRP statuses, and LMRP comment/response summaries may be printed from the Part B Medical Policy section.

#### **Effective and Notice Dates**

Effective dates are provided in each policy, and are based on the date claims are *processed*, not the date of service (unless otherwise noted in the policy). Medicare contractors are required to offer a 45-day notice period for LMRPs; the date the LMRP is posted to the Web site is considered the notice date.

#### **Electronic Notification**

To receive quick, automatic notification when new and revised LMRPs are posted to the Web site, subscribe to the FCSO *eNews* mailing list. It's very easy to do; simply sign on to the provider education Web site, *www.floridamedicare.com;* click on the yellow "Join our electronic mailing list" bar and follow the prompts.

#### **More Information**

For more information, or, if you do not have Internet access, to obtain a hardcopy of a specific LMRP, contact Medical Policy at:

> Medical Policy First Coast Service Options, Inc. P.O. Box 2078 Jacksonville, FL 32231-0048

1-904-791-8465

#### **Medical Review - Table of Contents**

Advance Notice Statement       61         Hand Carried Device for Neuromuscular Junction Testing       62
Comprehensive Data Analysis
Widespread Probe Review Results—Code 36245 Arterial, Pelvic, or Lower
Extremity Arterial Catheter Placement
Widespread Probe Review Results—Code 75724 Renal Angiography
Myocardial Perfusion Imaging
Widespread Probe Paview Results_Code 80076 Hepatic Panel Function 63
Widespread Probe Review Results—Code 80076 Hepatic Panel Function 63 Widespread Probe Review Results—Code 93508 Catheter Placement in
Coronary Artery
Widespread Probe Review Results—Pulmonary Codes 94240, 94260, 94720,
and 94725 64
Widespread Probe Review Results—Pulmonary Codes 94240, 94260, 94360,
0/370 $0/620$ $0/720$ and $0/750$ 65
Widespread Probe Review Results—Home Visit Evaluation and Management Services Codes 99341-99345
Services Codes 99341-99345
Widespread Probe Review Results—Home Visit Evaluation and Management
Services Codes 99347-99350 66
Local Medical Review Policy (New)
ERASV: Endoluminal Radiofrequency Ablation of the Saphenous Vein
OOS: Outpatient Observation Services
19318: Reduction Mammaplasty
31525: Laryngoscopy
43842: Surgical Management of Morbid Obesity
83880: B-Type Natriuretic Peptide (BNP)
88141: Pap Smears       68         88271: Urinary Fluorescent In Situ Hybridization (FISH) Test for Recurrent
88271: Urinary Fluorescent In Situ Hybridization (FISH) Test for Recurrent
Bladder Cancer
00257: Ocular Corneal Pachymetry
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920:
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920:       73         Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J9999: Antineoplastic Drugs       75
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0401: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J9999: Antineoplastic Drugs       75         J32 15: Implantation of Automatic Defibrillators       75
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0235: Oprelvekin (Neumega®)       75         J9999: Antineoplastic Drugs       75         322 15: Implantation of Automatic Defibrillators       75         43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0401: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J9999: Antineoplastic Drugs       75         J32 15: Implantation of Automatic Defibrillators       75
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920:       73         Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J9999: Antineoplastic Drugs       75         332 15: Implantation of Automatic Defibrillators       75         43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         332 15: Implantation of Automatic Defibrillators       75         33235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         70544: Magnetic Resonance Angiography (MRA)       76
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0207: Amitostine (Neumega®)       75         J3215: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         S33215: Inagnostic and Therapeutic Esophagogastroduodenoscopy       75         S8340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         90901: Biofeedback       76         92136: Optical Coherence Biometry       76
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0208: Oprelvekin (Neumega®)       75         J3215: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         S33215: Inignostic and Therapeutic Esophagogastroduodenoscopy       75         S8340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         90901: Biofeedback       76         92136: Optical Coherence Biometry       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0207: Amitostine (Neumega®)       75         J3215: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         S33215: Inagnostic and Therapeutic Esophagogastroduodenoscopy       75         S8340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         90901: Biofeedback       76         92136: Optical Coherence Biometry       76
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         90901: Biofeedback       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J3255: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         J3235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         S3236: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         S43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       76         64561: Sacral Neuromodulation       76         709001: Biofeedback       76         97001: Biofeedback       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77         Local Medical Review Policy (Retired)       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J2355: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         90901: Biofeedback       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J355: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         33235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76         709701: Biofeedback       76         92136: Optical Coherence Biometry       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77         Local Medical Review Policy (Retired)       90657: Influenza Virus Vaccine       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920:       73         Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J0235: Oprelvekin (Neumega®)       75         J33215: Implantation of Automatic Defibrillators       75         43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical       77         Medicine and Rehabilitation)       77         Local Medical Review Policy (Retired)       70         90657: Influenza Virus Vaccine       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920:       73         Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J0235: Oprelvekin (Neumega®)       75         J33215: Implantation of Automatic Defibrillators       75         3323: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76         70544: Magnetic Resonance Angiography (MRA)       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77         Local Medical Review Policy (Retired)       70         90657: Influenza Virus Vaccine       77         Corrections       77
00257: Ocular Corneal Pachymetry       69         Local Medical Review Policy (Revised)       70         2004 ICD-9-CM Coding Changes       70         EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])       73         NCSVCS: The List of Medicare Noncovered Services       73         VISCO: Viscosupplementation Therapy for Knee       73         G0030: Positron Emission Tomography (PET) Scan       74         J0207: Amifostine (Ethyol®)       74         J0640: Leucovorin (Wellcovorin®)       74         J355: Oprelvekin (Neumega®)       75         J3215: Implantation of Automatic Defibrillators       75         33235: Diagnostic and Therapeutic Esophagogastroduodenoscopy       75         58340: Infertility       76         64561: Sacral Neuromodulation       76         709201: Biofeedback       76         90901: Biofeedback       76         97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)       77         Local Medical Review Policy (Retired)       90657: Influenza Virus Vaccine       77

## **Advance Notice Statement**

Advance Beneficiary Notice (ABN) is required in the event the service may be denied or reduced for reasons of medical necessity. See page 5 for details concerning ABNs.

## Hand Carried Device for Neuromuscular Junction Testing

Medical equipment described as "hand held device" for neuromuscular junction testing does not meet Medicare requirements for *CPT* code 95937 (*Neuromuscular junction testing [repetitive stimulation, paired stimuli], each nerve, any one method*). The equipment used to perform neuromuscular junction testing must provide the full extent, quality, completeness, and documentation required for use of that code. A "hand held device" used for neuromuscular junction testing is included in any other service performed.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## COMPREHENSIVE DATA ANALYSIS

# Widespread Probe Review Results—Code 36245 Arterial, Pelvic, or Lower Extremity Arterial Catheter Placement

**P**rocedure code 36245 (Selective catheter placement, arterial, pelvic or lower extremity artery branch within a vascular family) was chosen for comprehensive data analysis for fiscal year 2003 based on July through December 2001 data revealing a carrier to nation ratio of allowed dollars of 1.68 with a maximum potential savings of \$608,336. Based on the conclusions of the findings, the performance of this service was considered a widespread problem; therefore, a recommendation to perform a widespread probe and a possible local medical review policy (LMRP) was made. A widespread probe of 50 claims from 10 providers for the period January 1, 2002, to June 30, 2002, was performed to determine if the services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

#### Summary of the Findings

- Of the 50 claims reviewed, 100% of the services billed were for selective catheter placement, arterial, pelvic or lower extremity artery branch within a vascular family.
- Indications noted for the catheter placement included: abnormal ultrasound doppler of the kidney arteries, renal artery stenosis with prior stent placement and uncontrolled hypertension.

- 23 services were allowed as billed.
- 34 services were denied because medical necessity could not be established from the submitted documentation.

Based on these widespread probe findings, LMRP will be developed to define the indications and the limitations of coverage and/or medical necessity, to identify a procedure to diagnosis relationship, to clarify guidelines, and the documentation requirements. Overpayments will be collected from providers when medical records do not sufficiently support the medical necessity for the procedure to be performed (e.g., abnormal noninvasive test), and education will be provided via the widespread probe education letter to the provider suggesting that functional tests should be performed before arteriography so angioplasty of suitable lesions may be performed at the time of the arteriography.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## Widespread Probe Review Results—Code 75724 Renal Angiography

**P**rocedure code 75724 (Angiography, renal, bilateral, selective [including flush aortogram], radiological supervision and interpretation) was chosen for comprehensive data analysis for fiscal year 2003 based on July through December 2001 data revealing a carrier to nation ratio of allowed dollars of 3.36 with a maximum potential savings of \$396,980. Based on the conclusions of the findings, the performance of this service was considered a widespread problem; therefore, a recommendation to perform a widespread probe and a possible local medical review policy (LMRP) was made. A widespread probe of 50 claims from 10 providers for the period January 1, 2002, to June 30, 2002, was performed to determine if the

services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

#### Summary of the Findings

- Of the 50 claims reviewed, 100% of the services billed were for selective catheter placement, arterial, pelvic or lower extremity artery branch within a vascular family.
- Indications noted for the catheter placement included: abnormal ultrasound Doppler of the kidney arteries, renal artery stenosis with prior stent placement and uncontrolled hypertension.
- 30 services were allowed as billed.

- 16 services were denied because medical necessity could not be established from the submitted documentation.
- 5 services were denied for no submitted documentation for the services billed.

Based on these widespread probe findings, LMRP will be developed to define the indications and the limitations of coverage and/or medical necessity, to identify a procedure to diagnosis relationship, to clarify guidelines, and the documentation requirements. Overpayments will be collected from providers when medical records do not sufficiently support the medical necessity

## Widespread Probe Review Results—Codes 78465, 78478, and 78480 Myocardial Perfusion Imaging

Procedure code 78465 was identified as aberrant as a result of ongoing follow-up from a 1998 comprehensive data analysis study. Procedure codes 78465 (Myocardial perfusion imaging; tomographic (SPECT), multiple studies, at rest and/or stress [exercise and/or pharmacologic] and redistribution and/or rest njection, with or without quantification), 78478 (Myocardial perfusion study with wall motion, qualitative or quantitative study), and 78480 (Myocardial perfusion study with ejection fraction). were identified as aberrant based on the January through June 2001 data revealing a carrier to nation ratio of allowed dollars of 2.39, 2.27, and 2.14 with a maximum potential savings of \$35,396. Based on the conclusions of the findings, the performance of this service was considered a widespread problem; therefore, a recommendation to perform a widespread probe was made. A widespread probe of 100 claims, from 20 providers consisting of 100 ICN's and 261 services for the period September 2001 through February 2002 was performed to determine if the services billed to Medicare were documented as having been performed, to determine the medical conditions for which the service was being performed, and to determine if the local medical review policy (LMRP) for myocardial perfusion imaging should require a revision.

#### Summary of the Findings

• 92 of the services were allowed as billed and 8 services were denied based on lack of documented medical necessity.

for the procedure to be performed (e.g., abnormal non-

before arteriography so angioplasty of suitable lesions may be performed at the time of the arteriography.

Italicized and/or quoted material is excerpted from the American

Medical Association Current Procedural Terminology. CPT codes,

descriptions and other data only are copyrighted 2002 (or other

such date of publication of CPT) American Medical Association.

All rights reserved. Applicable FARS/DFARS apply.

invasive test), and education will be provided via the

widespread probe education letter to the provider suggesting that functional tests should be performed

- The top diagnoses billed for allowed services were for the following ICD-9-CM codes: 414.00 (Coronary atherosclerosis of unspecified type of vessel, native or graft), 413.9 (Other and unspecified angina pectoris), and 414.00 (Coronary atherosclerosis of native artery).
- The diagnoses billed for claims denied were for the following ICD-9-CM codes: 413.9 (Other and unspecified angina pectoris), 411.1 (Intermediate coronary syndrome), and 414.9 (Chronic ischemic heart disease, unspecified).
- The documentation for the services denied indicated the services were performed for routine screening, no prior cardiac history, normal baseline EKG, or no other present cardiac symptoms.

Based on these findings, the LMRP for myocardial perfusion imaging will be revised to incorporate the latest ACC/AHA guidelines and clarify indications and limitations for coverage.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## Widespread Probe Review Results—Code 80076 Hepatic Panel Function

Procedure code 80076 (Hepatic panel function) was identified as aberrant for July through December 2001 data as defined in, and accordance with the Statistical Medical Data Analysis (SMDA) Comprehensive Data Analysis (CDA) Standard Operating Procedure No. 1.01. The aberrant data revealed a carrier to nation ratio of allowed dollars of 1.85 with a maximum potential savings of \$836,411. Based on the conclusions of the findings, the performance of this service was considered a widespread problem. Therefore, a recommendation to perform a widespread probe to determine if hepatic panels (80076) are being billed/ performed on beneficiaries with the diagnosis of hyperlipidemia/hypercholesterolemia that are not being managed with medication and to identify the appropriateness of performing a hepatic panel for other conditions. A widespread probe of 100 randomly selected claims from 20 providers, consisting of 100 services for the period July 2001 through December 2001 was performed to determine if services rendered were medically reasonable and necessary.

#### Summary of the Findings

- 82 of the services were allowed as billed and 18 services were denied.
- 17 denials were based on the failure of documentation submitted to support the medical necessity of the services performed.
- 1 denial was based on failure to submit requested documentation for review.

## MEDICAL REVIEW

- The top diagnoses billed for allowed services were for ICD-9-CM codes 272.0 (Pure hypercholesterolemia), 272.2 (Mixed hyperlipidemia), and 272.4 (Other and unspecified hyperlipidemia)
- The top diagnoses billed for claims denied were for ICD-9-CM codes 272.4 (Other and unspecified hyperlipidemia) and 780.79 (Other malaise and fatigue). The documentation for the services denied did not support that the beneficiary exhibited any signs and symptoms that warranted this service.
- 64 of the 82 paid services documented the administration of heptatoxic medications. Clinical studies prompted manufacturers of the medications to recommend hepatic panels as a standard of care when prescribing these pharmaceuticals to patients. The remaining 18 paid services documented a history of recurrent metastatic cancer, elevated liver enzymes, or other signs of hepatic dysfunction.

### MEDICAL REVIEW

Documentation reviewed did not present an identifiable pattern of frequency. 64% of the claims reviewed revealed that services were rendered at intervals of 6 months or less. 36% of the claims reviewed revealed that services were rendered at intervals of every six months or more. 1% of the total claims reviewed reflected that services were rendered at intervals of 12 months or greater.

Efforts to educate providers will be initiated via articles in the *Medicare B Update!* A local medical review policy (LMRP) will be developed and implemented in the near future.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Widespread Probe Review Results—Code 93508 Catheter Placement in Coronary Artery

Procedure code 93508 (Catheter placement in **F** coronary artery[s], arterial coronary conduit[s], and/or venous coronary bypass graft[s] for coronary angiography without concomitant left heart catheterization) was chosen for comprehensive data analysis for fiscal year 2003 based on July through December 2001 data revealing a carrier to nation ratio of allowed dollars of 1.02 with a maximum potential savings of \$5,059. Based on the conclusions of the findings, the performance of this service was considered a widespread problem; therefore, a recommendation to perform a widespread probe and a possible local medical review policy was made. A widespread probe of 50 claims from 10 providers for the period January 1, 2002, to June 30, 2002, was performed to determine if the services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

#### Summary of the Findings

- Of the 50 claims reviewed, 100% of the services billed were for catheter placement in coronary artery(s), arterial coronary conduit(s), and/or venous coronary bypass graft(s) for coronary angiography without concomitant left heart catheterization.
- Indications noted for the catheter placement included: unstable angina, chest pain, previous beneficiaries with stent placement or bypass surgery now presenting with chest pain and exertional dyspnea.

Based on the widespread probe findings, it was determined that all services were appropriately coded for procedure performed. No additional action is required.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Widespread Probe Review Results—Pulmonary Codes 94240, 94260, 94720, and 94725

Procedure codes 94240, 94260, 94720, and 94725 were chosen for comprehensive data analysis for fiscal year 2003 based on January through June 2001 data revealing a carrier to nation ratio of allowed dollars varying from 1.83 (94720) to 6.12 (94725) with a maximum potential savings of \$2,734,265. Based on the conclusions of the findings, the performance of the services was considered a widespread problem; therefore, a recommendation to perform a widespread probe and possibly develop local medical review policy (LMRP) was made. A widespread probe of 101 claims from 21 providers for the period January 1, 2001, to June 30, 2001, was performed, to determine if the services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

The following pulmonary codes were reviewed:

94240 Functional residual capacity or residual volume: helium method, nitrogen open circuit method, or other method

94260 Thoracic gas volume

94720 Carbon monoxide diffusing capacity (eg, single breath, steady state) 94725 Membrane diffusion capacity

#### Summary of the Findings

Of the 101 services reviewed, 99 were allowed as billed and 2 were denied because no documentation was received to support that the services were performed. All submitted documentation supported some type of pulmonary symptom and/or disease. Approximately 15% of the submitted documentation did not include office or progress notes and the services were reviewed by the

submitted ICD-9-CM codes, the "reason for test" and/or the PFT results.

An LMRP will be developed to define all pulmonary services, including indications and limitations, components of each test with the expected interpretive results, and the conditions that one would expect services to be repeated. In addition, the current LMRPs related to pulmonary services (94240, 94620, and 94010, which

includes *94360*) will be retired and these codes will be included in a comprehensive pulmonary policy.

MEDICAL REVIEW

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Widespread Probe Review Results—Pulmonary Codes 94240, 94260, 94360, 94370, 94620, 94720, and 94750

**D**rocedure codes 94240, 94260, 94360, 94370, 94620, 94720, and 94750 were chosen for comprehensive data analysis for fiscal year 2003 based on January through June 2001 data revealing a carrier to nation ratio of allowed dollars varying from 1.83 (94720) to 10.15 (94750) with a maximum potential savings of \$2,734,265. Based on the conclusions of the findings, the performance of the services was considered a widespread problem; therefore, a recommendation to perform a widespread probe and possibly develop local medical review policy (LMRP) was made. A widespread probe of 100 claims from 16 providers for the period January 1, 2001, to June 30, 2001, was performed, to determine if the services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

The following pulmonary codes were reviewed:

- 94240 Functional residual capacity or residual volume: helium method, nitrogen open circuit method, or other method
- 94260 Thoracic gas volume
- 94360 Determination of resistance to airflow, oscillatory or plethysmographic methods
- 94370 Determination of airway closing volume, single breath tests
- 94620 Pulmonary stress test; simple (eg, prolonged exercise test for bronchospasm with pre- and post-spiromety)

94720 Carbon monoxide diffusing capacity (eg, single breath, steady state)

94750 Pulmonary compliance study (eg, plethysmography, volume and pressure measurements)

#### Summary of the Findings

Of the 100 services reviewed, 99 were allowed as billed and 1 was denied because no documentation was received to support that the services were performed. All submitted documentation supported some type of pulmonary symptom and/or disease. Approximately 10% of the submitted documentation did not include office or progress notes and the services were reviewed by the submitted ICD-9-CM codes, the "reason for test" and/or the PFT results.

A local medical review policy will be developed to define all pulmonary services, including indications and limitations, components of each test with the expected interpretive results, and the conditions that one would expect services to be repeated. In addition, the current policies related to pulmonary services (94240, 94620, and 94010, which includes 94360) will be retired and these codes will be included in a comprehensive pulmonary policy.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# Widespread Probe Review Results—Home Visit Evaluation and Management Services Codes 99341-99345

Drocedure codes 99341-99345 (home E/M services)  $\mathbf{r}$  were chosen for comprehensive data analysis for fiscal year 2003 based on January through June 2001 data revealing a carrier to nation ratio of allowed dollars varying from 1.63 (99341) to 3.48 (99344), with a maximum potential savings of \$587,250. Based on the conclusions of the findings, performance of this service was considered a widespread problem; therefore, a recommendation was made to perform a widespread probe and possibly develop local medical review policy (LMRP). A widespread probe of 99 claims from 10 providers for the period from January 1, 2001, to June 30, 2001, was performed, to determine if the services billed to Medicare were documented as having been performed, and determine the medical conditions for which the service was being performed.

#### Summary of the Findings

- Of the 99 services reviewed, 48 were allowed as billed, 42 were recoded to reflect the level of care documented, and 9 were denied. Of the denied services, 8 were denied because there were no records submitted for review, and 1 was denied as not sufficiently documented.
- Approximately 56% of the beneficiaries were homebound.
- Approximately 22% of the beneficiaries were not documented to be homebound.
- Approximately 12% of the beneficiaries were residents of a facility. Of these beneficiaries, 7 resided in an assisted living facility (ALF) and were receiving assistance with medication administration; and, 4 resided in a skilled nursing facility (SNF).

Based on these widespread probe findings, LMRP will be developed to include home E/M services (*CPT* codes 99341-99345) to indicate the appropriate place of service, define "homebound" and develop indications and limitations of coverage. An educational article will be written to indicate that home E/M services must be provided in a private residence. Overpayments will be collected from providers included in the widespread probe in which the medical records failed to demonstrate

the level of E/M service billed, the provider failed to submit medical records, or the documentation did not sufficiently support the E/M service was performed.

MEDICAL REVIEW

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## Widespread Probe Review Results—Home Visit Evaluation and Management Services Codes 99347-99350

**P**rocedure codes *99347-99350* (home E/M services) were chosen for comprehensive data analysis for fiscal year 2003 based on the January through June 2001 data revealing a carrier to nation ratio of allowed dollars varying from 1.47 (*99347*) to 1.92 (*99349*) with a maximum potential savings of \$2,610,568. Based on the conclusions of the findings, the performance of this service was considered a widespread problem; therefore, a recommendation was made to perform a widespread probe and possibly develop local medical review policy (LMRP). A widespread probe of 100 claims from 10 providers for the period January 1, 2001, to June 30, 2001, was performed, to determine if the services billed to Medicare were documented as having been performed and determine the medical conditions for which the service was being performed.

#### Summary of the Findings

- Of the 100 services reviewed, 74 were allowed as billed, 16 were recoded to reflect the level of care documented, and 10 were denied. Of the denied services, 7 were denied because there were no records submitted for review, 2 were denied because the procedure billed was not supported by documentation, and 1 was denied because there was no separately identifiable E/M service performed.
- Approximately 61% of the beneficiaries were homebound.

- Approximately 18% of the beneficiaries were not documented to be homebound.
- Approximately 11% of the beneficiaries were residents of a facility.
- Documentation was not received for approximately 11% of the beneficiaries; therefore, place of residence is undetermined.
- It was determined the documentation submitted for approximately 8% of the allowed services (7 services) did not support medical necessity for the E/M service billed.

Based on these widespread probe findings, LMRP will be developed to include home E/M services (*CPT* codes 99347-99350) to indicate the appropriate place of service, define "homebound" and develop indications and limitations of coverage. An educational article will be written to indicate that home E/M services must be provided in a private residence. Overpayments will be collected from providers included in the widespread probe in which the medical records failed to demonstrate the level of E/M service billed, the provider failed to submit medical records, or the documentation did not sufficiently support the E/M service was performed.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## Local Medical Review Policy (New)

## **ERASV: Endoluminal Radiofrequency Ablation of the Saphenous Vein**

A local medical review policy (LMRP) has been developed for endoluminal radiofrequency ablation of the saphenous vein to define the indications and limitations for this service.

This procedure is a minimally invasive alternative to vein ligation and stripping. It has received FDA approval for treatment of varicose veins. The technique involves delivery of radiofrequency energy through a catheter inserted into the affected vein. The energy from the radiofrequency damages the intimal wall of the vessel resulting in fibrosis and obliteration of a long segment of the vein thus eliminating reflux. The procedure is performed by inserting a specially designed catheter through a small incision in the distal medial thigh to within 1-2 cm of the sapheno-femoral junction. High radiofrequency energy is delivered to the vein wall, causing it to heat. As the vein warms, it collapses and seals shut. The procedure is generally done in an outpatient setting under local anesthesia. When billing this service, the unlisted *CPT* code *37799* should be used, and a comment should be placed in item 19 of Form CMS-1500 (or in the appropriate comment field for electronic submitters), indicating that this code corresponds to radiofrequency ablation of the saphenous vein.

This LMRP is available on our provider education Web site, *www.floridamedicare.com*, and is effective for claims processed on or after January 5, 2004.

## **OOS: Outpatient Observation Services**

A new local medical review policy (LMRP) has been developed to communicate to physicians and allied staff the Medicare provisions for outpatient observation services. This policy contains information that applies to outpatient observation services and billing guidelines, which are applicable to services billed by the hospital to the Medicare Part A fiscal intermediary (FI). It serves as a resource for physicians in clarifying Medicare's definition of outpatient observation services.

Implementation of the outpatient prospective payment system (OPPS) in August 2000 brought changes to the traditional Medicare payment methodology of hospital outpatient services. CMS continues to refine OPPS with periodic clarifications and updates. Despite the change in outpatient payment methodology from a generally cost-based reimbursement to a prospective payment system, for the services billed by the hospital to the FI, the Medicare *definition* of observation services has not changed.

Outpatient observation services are defined as: the use of a bed and periodic monitoring by nursing or other ancillary staff that are reasonable and necessary to evaluate the patient's condition for possible need of inpatient admission. These services are only considered reimbursable when performed under a specific order of a physician (or under the order of another person who is authorized by state statute and the hospital's bylaws to admit patients or order outpatient testing). The order must be based on the physician's expectation of the care that the patient will require.

Outpatient observation services are not to be used as a substitute for medically necessary inpatient admissions. Outpatient observation services are not to be used for the convenience of the hospital, its physicians, patients, or patient's families, or while awaiting placement to another facility.

In general, a patient is considered an inpatient if he/ she has been formally admitted to a hospital with the physician expectation that he/she will need hospital care for 24 hours or longer, or needs services only available in an inpatient environment. Admission to the intensive care level of service does not fit the criteria for observation. This level of care and observation is not reimbursable to a hospital as outpatient observation services.

Outpatient observation services must be patient specific. Outpatient observation services, generally, do not exceed 24 hours. Some patients may require a second day of observation; only in rare and exceptional cases do observation services span more than 48 hours.

The full-text of this LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after January 5, 2004.

## 19318: Reduction Mammaplasty

Local medical review policy (LMRP) has been developed for reduction mammaplasty. This policy was developed to define indications and limitations for this service.

*CPT* code *19318* (*Reduction mammaplasty*) is the surgical removal of a substantial portion of the breast, including the skin and underlying glandular tissue. Breasts are pair organs and breast hypertrophy generally affects both sides. Although bilateral surgery is usually performed, unilateral surgery may be reasonable and necessary.

The full-text of this LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for services for claims processed on and after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 31525: Laryngoscopy

**S** tatistical medical data obtained for dates of service from November 2002 through April 2003 found *CPT* code *31575* to have an aberrancy ratio of 1.84 per 1000 enrollees. Therefore, a new local medical review policy (LMRP) has been developed to define the indications and limitations for diagnostic laryngoscopy services. This procedure provides direct visualization of the larynx and secondary structures. The fiberoptic technique utilizes specialized endoscopic techniques.

The CPT codes included in this policy are:

31525 Laryngoscopy, direct, with or without tracheoscopy; diagnostic, except newborn
31575 Laryngoscopy, flexible fiberoptic; diagnostic The full-text of this new LMRP available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims

processed on or after January 5, 2004.

## 43842: Surgical Management of Morbid Obesity

Local medical review policy (LMRP) has been developed to define the indications and limitations for surgical management of morbid obesity (*CPT* code 43842).

Gastrointestinal surgery for obesity, also called bariatric surgery, promotes weight loss by closing off parts of the stomach to make it smaller. Procedures that only reduce stomach size are considered "restrictive" surgeries because they restrict the amount of food the stomach can hold. Procedures that combine stomach restriction with a partial bypass of the small intestine are known as "malabsorptive" surgeries. Malabsorptive surgeries create a direct connection from the stomach to the lower segment of the small intestine, bypassing the portions of the digestive tract that absorb calories and nutrients.

Florida Medicare will consider surgical management for the treatment of morbid obesity reasonable and necessary when all of the following conditions are met:

- The patient meets the definition of morbid obesity which is defined as a body mass index (BMI) of 40kg/ m<sup>2</sup> or greater and comorbid conditions exist. Documentation of the level of severity of the comorbid existing condition must be included in the patient's medical record; AND
- There is documented evidence of repeated failure of multiple attempts (usually 3) to lose weight on a supervised non-surgical management weight loss program (e.g., diet, exercises, or drugs). It would be expected that a weight loss program would consist of a consecutive 6 month period; AND

- Psychological evaluation and counseling associated with the lifestyle changes associated with the surgery have been performed prior to the surgery; AND
- Treatable metabolic causes for obesity (e.g., adrenal of thyroid disorders) have been ruled out or have been clinically treated if present.

#### CPT/HCPCS codes covered by this policy:

- 43842 Gastric restrictive procedure, without gastric bypass, for morbid obesity; verticalbanded gastroplasty
- 43843 Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty
- 43846 Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (less than 100cm) Roux-en-Y gastroenterostomy
- 43847 Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
- 43848 Revision of gastric restrictive procedure for morbid obesity (separate procedure)
- 43999 Unlisted procedure, stomach

The full-text of this new LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for services processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology*. *CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 83880: B-Type Natriuretic Peptide (BNP)

ongestive heart failure (CHF) is characterized by a progressive activation of the neurohormonal systems that control vasoconstriction and sodium retention; the activation of these systems plays a role in its pathogenesis and progression. As the heart fails, B-type natriuretic peptide (BNP), a cardiac neurohormone is secreted from the cardiac ventricles in response to ventricular volume expansion and pressure overload. Used in conjunction with other clinical information, rapid measurement of BNP is useful in establishing or excluding the diagnosis and assessment of severity of CHF in patients with acute dyspnea so that appropriate and timely treatment can be initiated. BNP levels are also useful for risk stratification among patients with acute coronary syndrome (myocardial infarction with or without T-wave elevation and unstable angina).

Local medical review policy (LMRP) has been developed for *CPT* code *83880 (Natriuretic peptide)* to allow providers access to this new technology, and to provide indications and limitations for this procedure. For the purposes of this policy, the total and N terminal assays are both acceptable.

The full-text of this LMRP is available on the provider education Web site *www.floridamedicare.com*, and will be effective for services rendered on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

## 88141: Pap Smears

CMS Transmittal AB-03-054, Change Request 2637, expands coverage for screening Pap smears. Therefore, the local medical review policy (LMRP) for Pap smears laboratory testing has been revised to define the indications and limitations of coverage, and to add ICD-9-CM codes V76.47 and V76.49 to the "ICD-9 Codes that Support Medical Necessity" section of the policy.

The full-text of this LMRP may be found on the provider education Web site *wwwfloridamedicare.com*. These changes are effective for services processed on or after October 1, 2003.

# 88271: Urinary Fluorescent In Situ Hybridization (FISH) Test for Recurrent Bladder Cancer

The urinary FISH test for recurrent bladder cancer is an FDA-approved multiprobe fluorescent in situ hybridization (FISH) DNA technology designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via FISH in voided urine specimens from patients with transitional cell carcinoma of the bladder (urothelial carcinoma). In situ hybridization is a technique that allows the visualization of specific nucleic acid sequences within a cellular preparation. Specifically, DNA FISH involves the precise annealing of a single stranded fluorescently labeled DNA probe to complementary target sequences. The hybridization of the probe with the cellular DNA site is visible by direct detection using fluorescence microscopy. Results from this urinary FISH test are intended for use as a noninvasive method for monitoring tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.

Local medical review policy (LMRP) has been developed to allow providers access to this new technology, and to provide indications and limitations for this procedure.

#### **CPT/HCPCS** Codes

- 88271 Molecular cytogenetics; DNA probe, each (eg, FISH)
- 88274 Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells
- 88291 Cytogenetics and molecular cytogenetics, interpretation and report

## 0025T: Ocular Corneal Pachymetry

Ocular corneal pachymetry is the ultrasonic measurement of corneal thickness. Measurement of corneal thickness in individuals presenting with increased intraocular pressure assists in determining if there is a risk of glaucoma or if the individual's increased eye pressure is the result of abnormal corneal thickness.

A recent study has demonstrated the benefit of assessing corneal thickness in individuals with increased intraocular pressure. Several physicians requested evaluation of this technology for separate reimbursement consideration. Development of a local medical review policy (LMRP) for *CPT* code 0025T (Determination of corneal thickness [eg, pachymetry] with interpretation

## ICD-9-CM codes that support medical necessity for this service include:

this service include.		
188.0-188.9	Malignant neoplasm of bladder	
189.0-189.9	Malignant neoplasm of kidney and	
	other and unspecified urinary organs	
198.1	Secondary malignant neoplasm of other	
	urinary organs	
233.7	Carcinoma in situ of bladder	
236.7	Neoplasm of uncertain behavior of	
	bladder	
239.4	Neoplasms of unspecified nature,	
	bladder	
V10.50	Personal history of malignant neo-	
	plasm, urinary organ, unspecified	
V10.51	Personal history of malignant neo-	
	plasm, bladder	
V10.52	Personal history of malignant neo-	
	plasm, kidney	

The full-text of this LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

and report, bilateral) resulted from the evaluation.

*CPT 0025T* is considered medically necessary for specific diseases of the cornea. The full text of this new LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for services processed on or after January 5, 2004.

## LOCAL MEDICAL REVIEW POLICY (REVISED)

## 2004 ICD-9-CM Coding Changes

The 2004 update to the ICD-9-CM diagnosis coding structure became effective October 1, 2003. Updated diagnosis codes *must* be used for all services billed on or after January 1, 2004. A 90-day grace period is provided during which Florida Medicare will accept both old and new ICD-9-CM codes, for claims received October 1 through December 31, 2003. This grace period is to allow providers sufficient time to obtain and integrate the updated ICD-9-CM codes into their billing systems. All claims for services rendered on or after January 1, 2004 *must* be billed with the updated 2004 ICD-9-CM codes.

Florida Medicare has reviewed all local medical review policies (LMRPs) for procedure codes with specific diagnosis criteria that are affected by the 2004 ICD-9-CM update. The table on the following pages lists the LMRPs affected, the publication in which diagnosis criteria appeared, and the specific conditions revised as a result of the 2004 ICD-9-CM update:

LMRP Title	2004 Changes
33999: Pacemaker Lead Extraction, Unusually Difficult	Change 959.1 to 959.11 (Other injury of chest wall) for procedure code 33999
36511: Therapeutic Apheresis (Plasma and/or Cell Change)	Change 358.0 to 358.00 (Myasthenia gravis without (acute) exacerbation) for procedure codes <i>36511</i> , <i>36512</i> , <i>36513</i> , and <i>36514</i> Add 358.01 (Myasthenia gravis with (acute) exacerbation) for procedure codes <i>36511</i> , <i>36512</i> , <i>36513</i> , and <i>36514</i>
43235: Diagnostic and Therapeutic Esophagogastroduodenoscopy	Add V58.64 (Long-term (current) use of non-steroidal anti-inflammatories [NSAID]) for procedure codes 43235, 43236, 43239, 43241, 43243-43251, 43255, and 43258
52282: Urethral Stents	Change 600.0-600.9 to 600.00-600.91 (Hyperplasia of prostate) for procedure code 52282
53850: Prostate Treatments	Change 600.0 to 600.00-600.01 (Hypertrophy (benign) of prostate) for procedure codes 53850, 53852, and 53853
55700: Biopsy of Prostate Using Image Guidance	Change 600.0-600.9 to 600.00-600.91 (Hyperplasia of prostate) for procedure code 55700
70450: Computed Tomography Scans	Change 767.1 to 767.11 (Epicranial subaponeurotic hemorrhage [massive]) and 767.19 (Other injuries to scalp) for procedure codes 70450, 70460, and 70470 Add 781.94 (Facial weakness) for procedure codes 70450, 70460, and 70470
70551: Magnetic Resonance Imaging of the Brain	Change 358.0-358.1 to 358.00-358.1 (Myasthenia gravis and myasthenic syndromes in diseases classified elsewhere) for procedure codes <i>70551</i> , <i>70552</i> , and <i>70553</i> Add 781.94 (Facial weakness) for procedure codes <i>70551</i> , <i>70552</i> , and <i>70553</i>
71010: Chest X-Ray	Change 959.1 to 959.11 (Other injury of chest wall) and 959.19 (Other injury of other sites of trunk) for procedure codes 71010, 71015, 71020, 71021, 71022, 71023, 71030, 71034, and 71035 Change V43.2-V43.3 to V43.21-V43.3 (Organ or tissue replaced by other means, heart and heart valve) for procedure codes 71010, 71015, 71020, 71021, 71022, 71023, 71030, 71034, and 71035
72192: Computed Tomography of the Pelvis	Change 752.8 to 752.81 (Scrotal transposition) and 752.89 (Other specified anomalies of genital organs) for procedure codes 72192, 72193, and 72194 Change 820.00-820.99 to 820.00-820.9 (Fracture of neck of femur) for procedure codes 72192, 72193, and 72194 (Not related to 2004 ICD-9-CM Update) Change 959.1 to 959.12 (Other injury of abdomen), 959.13 (Fracture of corpus cavernosum penis), and 959.14 (Other injury of external genitals) for procedure codes 72192, 72193, and 72194 Add 995.91 (Systemic inflammatory response syndrome due to infectious process without organ dysfunction) and 995.92 (Systemic inflammatory response syndrome due to infectious process with organ dysfunction) for procedure codes 72192, 72193, and 72194

#### 2004 ICD-9-CM Part B LMRP Changes

76512: B-Scan	Change descriptor for 282.60 (Sickle-cell disease, unspecified), 282.61 (Hb-SS disease without crisis), 282.62 (Hb-SS disease with crisis), 282.63 (Sickle-cell/Hb-C disease without crisis), and 282.69 (Other sickle-cell disease with crisis) for procedure codes 76512 and 76513 Add 282.64 (Sickle-cell/Hb-C disease with crisis) and 282.68 (Other sickle-cell disease without crisis) for procedure codes 76512 and 76513
78460: Myocardial Perfusion Imaging	Add 414.07 (Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart) for procedure codes 78460, 78461, 78464, 78465, 78478, and 78480
78472: Cardiac Blood Pool Imaging	Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure codes 78472, 78473, 78481, 78483, 78494, and 78496
82108: Aluminum	Change 348.3 to 348.30-348.39 (Encephalopathy, not elsewhere classified) for procedure code <i>82108</i> Change 973 to 973.0 (Poisoning by antacids and antigastric secretion drugs) for procedure code <i>82108</i> (Not related to 2004 ICD-9-CM Update)
82310: Total Calcium	Add 728.87 (Muscle weakness) and 728.88 (Rhabdomyolysis) for procedure code 82310 Add 780.01 (Coma) for procedure code 82310 (Not related to 2004 ICD-9-CM Update)
82435: Chloride	Change 255.1 to 255.10-255.14 (Hyperaldosteronism) for procedure code 82435
82784: Gammaglobulin (Immunoglobulins) IgA, IgD, IgG, IgM, Each	Change 600.0-600.9 to 600.00-600.91 (Hyperplasia of prostate) for procedure code 82784
83735: Magnesium	Change 255.1 to 255.10-255.14 (Hyperaldosteronism) for procedure code 83735 Change 643.10-643.83 to 643.00-643.83 (Excessive vomiting in pregnancy) for procedure code 83735 ( <b>Not related to 2004 ICD-9-CM Update</b> ) Add 728.87 (Muscle weakness) and 728.88 (Rhabdomyolysis) for procedure code 83735 Change 941.00-949.5 to 940.0-949.5 (Burns) for procedure code 83735 ( <b>Not related to 2004 ICD-9-CM Update</b> )
84100: Serum Phosphorus	Change 348.3 to 348.30-348.39 (Encephalopathy, not elsewhere classified) for procedure code <i>84100</i> Add 728.87 (Muscle weakness) and 728.88 (Rhabdomyolysis) for procedure code <i>84100</i> Change E944.0-E944.5 to E944.0-E944.7 (Drugs, medicinal and biological substances causing adverse effects in therapeutic use, water, mineral, and uric acid metabolism drugs) for procedure code <i>84100</i> ( <b>Not related to 2004 ICD-9-CM Update</b> )
90801: Psychiatric Diagnostic Interview Examination	Add 780.93 (Memory loss) for procedure code 90801
<i>92015</i> : Ophthalmological Diagnostic Services	Change 250.50-250.51 to 250.50.250.53 (Diabetes with ophthalmic manifestations) for procedure code 92250 (Not related to 2004 ICD-9-CM Update) Change 282.60 to 282.60-282.69 (Sickle-cell disease) for procedure code 92250 Change 342.0-342.92 to 342.00-342.92 (Hemiplegia and hemiparesis) for procedure code 92250 (Not related to 2004 ICD-9-CM Update) Add 379.39 (Aphakia and other disorders of lens) for procedure code 92250 (Not related to 2004 ICD-9-CM Update) Change 998.5 to 998.51-998.59 (Postoperative infection) for procedure code 92285 (Not related to 2004 ICD-9-CM Update)
92081: Visual Field Examination	Change descriptor for 282.60-282.69 (Sickle-cell disease) for procedure codes 92081, 92082, and 92083 Change 743.52-743.58 to 743.51-743.59 (Congenital anomalies of posterior segment) for procedure codes 92081, 92082, and 92083 (Not related to 2004 ICD-9-CM Update)
92973: Interventional Cardiology	Change descriptor for 414.06 (Coronary atherosclerosis of native coronary artery of transplanted heart) for procedure codes 92973, 92980, 92981, 92982, 92984, 92995, and 92996 Add 414.07 (Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart) for procedure codes 92973, 92980, 92981, 92982, 92984, 92995, and 92996
93000: Electrocardiography	Change 959.1 to 959.11-959.19 (Injury, trunk) for procedure codes 93000, 93005, and 93010 Change 995.0-995.89 to 995.0-995.94 (Certain adverse effects not elsewhere classified) for procedure codes 93000, 93005, and 93010 (Not related to 2004 ICD-9-CM Update)
93224: Electrocardiographic Monitoring for 24 Hours (Holter Monitoring)	Change descriptor for 414.06 (Coronary atherosclerosis of native coronary artery of transplanted heart) for procedure codes <i>93224</i> , <i>93225</i> , <i>93226</i> , <i>93227</i> , <i>93230</i> , <i>93231</i> , <i>93232</i> , <i>93233</i> , <i>93235</i> , <i>93236</i> , and <i>93237</i> Add 414.07 (Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart) for procedure codes <i>93224</i> , <i>93226</i> , <i>93227</i> , <i>93230</i> , <i>93231</i> , <i>93232</i> , <i>93233</i> , <i>93235</i> , <i>93236</i> , and <i>93237</i>

## MEDICAL REVIEW

93303: Transthoracic and Doppler Echocardiography and Doppler Color Flow Velocity Mapping	Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure codes 93307 and 93308 Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure codes 93320, 93321, and 93325
93312: Transesophageal Echocardiogram	Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure codes <i>93312</i> , <i>93313</i> , <i>93314</i> , <i>93315</i> , <i>93316</i> , <i>93317</i> , and <i>93318</i>
93350: Stress Echocardiography	Change descriptor for 414.06 (Coronary atherosclerosis of native coronary artery of transplanted heart) for procedure code 93350 Add 414.07 (Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart) for procedure code 93350
94760: Non-invasive Ear or Pulse Oximetry for Oxygen Saturation	Add 493.81 (Exercise induced bronchospasm) and 493.82 (Cough variant asthma) for procedure codes <i>94760</i> and <i>94761</i> Add 493.81 (Exercise induced bronchospasm) and 493.82 (Cough variant asthma) for procedure code <i>94762</i>
94799: Pulmonary Rehabilitation Services	Change descriptor for 493.00 (Extrinsic asthma, unspecified), 493.10 (Intrinsic asthma, unspecified), and 493.20 (Chronic obstructive asthma, unspecified) for procedure code 94799 Add 493.81-493.82 (Other forms of asthma) for procedure code 94799
95816: Electroencephalography (EEG)	Change 331.1 to 331.11 (Pick's disease) for procedure code 95819 Add 331.19 (Other frontotemporal dementia) and 331.82 (Dementia with Lewy bodies) for procedure code 95819 Change 348.3 to 348.30 (Encephalopathy, unspecified) for procedure code 95819 Add 348.31 (Metabolic encephalopathy) and 348.39 (Other encephalopathy) for procedure code 95819 Add 781.94 (Facial weakness) for procedure code 95819 Add 331.82 (Dementia with Lewy bodies) for procedure codes 95950, 95951, 95953, and 95956 Change 348.3 to 348.30 (Encephalopathy, unspecified) for procedure codes 95950, 95951, 95953, and 95956 Add 348.31 (Metabolic encephalopathy) and 348.39 (Other encephalopathy) for procedure codes 95950, 95951, 95953, and 95956 Add 781.94 (Facial weakness) for procedure code 95950, 95951, 95953, and 95956
95857: Tensilon Test	Change 358.0 to 358.00-358.01 (Myasthenia gravis) for procedure codes 95857 and 95858
95937: Neuromuscular Junction Testing	Change 358.0 to 358.00-358.01 (Myasthenia gravis) for procedure code <i>95937</i> Add 728.87 (Muscle weakness) and 728.88 (Rhabdomyolysis) for procedure code <i>95937</i>
A4644: Low Osmolar Contrast Media (LOCM)	Change 282.4 to 282.41-282.49 (Thalassemias) for procedure codes A4644, A4645, and A4646 Change descriptor for 282.60 (Sickle-cell disease, unspecified), 282.61 (Hb-SS disease without crisis), 282.62 (Hb-SS disease with crisis), 282.63 (Sickle-cell/Hb-C disease without crisis), and 282.69 (Other sickle-cell disease with crisis) for procedure codes A4644, A4645, and A4646 Add 282.64 (Sickle-cell/Hb-C disease with crisis) and 282.68 (Other sickle-cell disease without crisis) for procedure codes A4644, A4645, and A4646 Change descriptor for 493.00 (Extrinsic asthma, unspecified), 493.02 (Extrinsic asthma, with (acute) exacerbation), 493.10 (Intrinsic asthma, unspecified), 493.12 (Intrinsic asthma, with (acute) exacerbation), 493.90 (Asthma, unspecified), and 493.92 (Asthma, with (acute) exacerbation) for procedure codes A4644, A4645, and A4646 Add 785.52 (Septic shock) for procedure codes A4644, A4645, and A4646
G0030: Positron Emission Tomography (PET) Scans	Change descriptor for 414.06 (Coronary atherosclerosis of native coronary artery of transplanted heart) for procedure codes G0030-G0047 Add 414.07 (Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart) for procedure codes G0030-G0047
J0150: Adenosine (Adenocard®, Adenoscan®)	Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure code J0150 Change 414.00-414.06 to 414.00-414.07 (Coronary atherosclerosis) for procedure code J0151

# EPO: Epoetin Alfa (formerly Q0136: Non-ESRD Epoetin [Procrit] and Q9920: Chronic Renal Failure Erythropoietin [Epogen])

The local medical review policy (LMRP) for non-ESRD (end-stage renal disease) epoetin was last updated October 1, 2000. Erythropoietin is a glycoprotein that stimulates red blood cell production. It is produced in the kidneys and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow.

This policy has been revised to define the indications and limitations of coverage and/or medical necessity; and to clarify the appropriate use of epoetin alfa. The following major revisions have been incorporated:

- Laboratory requirements for initiation of epoetin alfa therapy have been revised.
- The following "Indications and Limitations of Coverage and/or Medical Necessity" have been added to the policy: - Anemia associated with malignancy
  - Anemia associated with the management of hepatitis C
- The "Coding Guidelines" section of the LMRP has been revised with updated dual diagnosis requirements.
- The LMRPs for non-ESRD epoetin and chronic renal failure erythropoietin have been combined. The new policy number and name is EPO: Epoetin Alfa.

The following HCPCS codes are included in the LMRP:

Q0136	Injection, epoetin alpha, (for non ESRD use), per 1,000 units
Q9920	Injection of EPO, per 1000 units, at patient HCT of 20 or less
Q9921	Injection of EPO, per 1000 units, at patient HCT of 21
Q9922	Injection of EPO, per 1000 units, at patient HCT of 22
Q9923	Injection of EPO, per 1000 units, at patient HCT of 23
Q9924	Injection of EPO, per 1000 units, at patient HCT of 24
Q9925	Injection of EPO, per 1000 units, at patient HCT of 25
Q9926	Injection of EPO, per 1000 units, at patient HCT of 26
Q9927	Injection of EPO, per 1000 units, at patient HCT of 27
Q9928	Injection of EPO, per 1000 units, at patient HCT of 28
Q9929	Injection of EPO, per 1000 units, at patient HCT of 29
Q9930	Injection of EPO, per 1000 units, at patient HCT of 30
Q9931	Injection of EPO, per 1000 units, at patient HCT of 31
Q9932	Injection of EPO, per 1000 units, at patient HCT of 32
Q9933	Injection of EPO, per 1000 units, at patient HCT of 33
Q9934	Injection of EPO, per 1000 units, at patient HCT of 34
Q9935	Injection of EPO, per 1000 units, at patient HCT of 35
Q9936	Injection of EPO, per 1000 units, at patient HCT of 36
Q9937	Injection of EPO, per 1000 units, at patient HCT of 37
Q9938	Injection of EPO, per 1000 units, at patient HCT of 38
Q9939	Injection of EPO, per 1000 units, at patient HCT of 39
Q9940	Injection of EPO, per 1000 units, at patient HCT of 40 or above
	•

The revised LMRP is effective for claims processed on or after January 5, 2004, and is available on our provider education Web site at *www.floridatmedicare.com*.

# NCSVCS: The List of Medicare Noncovered Services

The local medical review policy (LMRP) for The List of Medicare Noncovered Services was last updated on September 29, 2003.

Instructions were received from the Centers for Medicare & Medicaid Services (CMS) to designate HCPCS code J1910 (injection, kutapressin, up to 2 ml) as noncovered by Medicare. Kutapressin has not been approved by the Food and Drug Administration (FDA). Therefore, J1910 was added to the "National Noncoverage Decisions" section of the LMRP, effective for claims processed on or after September 30, 2003.

The full-text LMRP is available on our provider education Web site at *www.floridamedicare.com*.

# VISCO: Viscosupplementation Therapy for Knee

The LMRP for viscosupplementation therapy for knee was last updated on January 1, 2003.

Based on comments received from the provider community, revisions have been made to the "Indications and Limitations of Coverage and/or Medical Necessity," "ICD-9 Codes that Support Medical Necessity," "Reasons for Denials" and "Documentation Requirements" sections of the LMRP.

The following indications and limitations of coverage and/or medical necessity apply to

viscosupplementation therapy for knee:

- The patient must have painful osteoarthritis of the knee, and
- The patient must have an intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs) with a condition such as peptic ulcer disease, or

# FLORIDA ONLY

- Mild analgesics such as acetaminophen have not been effective in pain reduction, and/or the patient has failed other conservative treatment, and
- Joint effusion, if any, must be removed prior to injection, and
- The patient should not be markedly obese, and
- The joint(s) injected must be the knee(s), and
- The patient has not had a previous reaction to an earlier administration of one of these medications.

The following ICD-9-CM codes have been added to the "ICD-9 Codes that Support Medical Necessity" section of the LMRP.

715.16 Osteoarthrosis, localized, primary, lower leg715.26 Osteoarthrosis, localized, secondary, lower leg

# G0030: Positron Emission Tomography (PET) Scan

The local medical review policy (LMRP) for positron emission tomography (PET) scan was last updated on October 1, 2003.

PET is a noninvasive diagnostic imaging procedure that assesses the level of metabolic activity and perfusion in various organ systems of the human body. A positron camera (tomograph) is used to produce cross-sectional tomographic (radiopharmaceuticals) such as 2-(F-18) fluoro-D-glucose (FDG), that are administered intravenously to the patient.

CMS Transmittal AB-03-092, Change Request 2687, provides expanded coverage for noninvasive imaging of the perfusion of the heart using FDA-approved ammonia N-13 as a tracer. Ammonia N-13 and rubidium are the only two tracers covered for PET scans for the perfusion of the heart. Additional instructions are provided for carriers billing rubidium in CMS transmittal AB-03-119, Change Request 2853.

The LMRP for PET has been revised to reflect these changes. Coverage has also been expanded to include restaging of recurrent residual thyroid cancers of follicular cell origin that have been previously treated by thyroidectomy and radioiodine ablation and have a serum thyroglobulin >10ng/ml and negative I-131 whole body scan.

The full text of the revised LMRP is available on our provider education Web site at

*www.floridamedicare.com*, and is effective for services rendered on or after October 1, 2003.

# 715.36 Osteoarthrosis, localized, not specified whether primary or secondary, lower leg

In addition, the LMRP has been revised to indicate ICD-9-CM codes 715.16, 715.26, 715.36 and 715.96 (Osteoarthrosis, unspecified whether generalized or localized, lower leg) are applicable to HCPCS codes J7317 and J7320. Claims will no longer be denied when the patient has severe osteoarthritis and/or large joint effusions (joint effusion must be removed prior to injection).

Finally, the documentation requirements have been revised to state the physician should indicate in the patient's medical documentation the inability to take or respond to NSAIDs.

This LMRP revision is effective for claims processed on or after September 8, 2003.

# J0207: Amifostine (Ethyol®)

The local medical review policy (LMRP) for amifostine (Ethyol®) was last updated on June 18, 2001.

A request was received from a provider to add ICD-9-CM code **238.7** (Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues [Myelodysplastic syndrome]) to the "ICD-9 Codes that Support Medical Necessity" section of the LMRP. After reviewing the information provided, it was determined this request was appropriate.

Therefore, the "ICD-9 Codes that Support Medical Necessity" section of the LMRP has been updated to include ICD-9-CM code 238.7 for HCPCS code J0207. In addition, the following indication has been added to the "Indications and Limitations of Coverage and/or Medical Necessity" section of the LMRP: Myelodysplastic syndrome (treatment) – for salvage treatment, as part of a combination regimen (e.g., erythropoietin, topotecan, etoposide, cytarabine), for the treatment of myelodysplastic syndromes (MDS).

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after October 20, 2003.

# J0640: Leucovorin (Wellcovorin®)

The local medical review policy (LMRP) for leucovorin was implemented June 30, 2003. The policy has since been revised to correct an invalid ICD-9 CM code. Code 181.0 is invalid; the correct ICD-9-CM code is 181 (Malignant neoplasm of placenta (choriocarcinoma). The "ICD-9 Codes That Support Medical Necessity" section of the policy has been changed to reflect this correction.

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after September 23, 2003.

# J2355: Oprelvekin (Neumega®)

The local medical review policy (LMRP) for oprelvekin (Neumega®) was implemented on December 20, 1999.

Since then, a request was received from a provider to add ICD-9-CM code 273.3 (Macroglobulinemia) to the "ICD-9 Codes that Support Medical Necessity" section of the LMRP. After reviewing the information provided, it was determined this request was appropriate.

Therefore, the "ICD-9 Codes that Support Medical Necessity" section of the LMRP has been updated to include ICD-9-CM code 273.3 for HCPCS code J2355. The billing of oprelvekin requires dual diagnoses. To ensure reimbursement for this service, dual diagnoses must be submitted. Providers must use ICD-9-CM codes 140.0-202.98 or 273.3 and 287.4 (thrombocytopenia due to drugs) to report the approved indication for J2355.

The full-text of the revised LMRP is available on our provider education Web site at

*www.floridamedicare.com*, and is effective for claims processed on or after August 25, 2003.

# J9999: Antineoplastic Drugs

The local medical review policy (LMRP) for antineoplastic drugs was last updated January 1, 2003. The following revisions have since been made:

#### Indications and Limitations of Coverage and/ or Medical Necessity

The indication for off-label use of chemotherapeutic agents has been revised.

The following off-label indications have been added to the respective agent:

- Carboplatin Hormone refractory prostate cancer
- Docetaxel Soft tissue sarcomas
- Gemcitabine Soft tissue sarcomas
- Topotecan Hydrochloride Cervical carcinoma

# ICD-9 Codes that Support Medical Necessity

The ICD-9-CM range for HCPCS codes J9181-J9182 (Etoposide) has been corrected from 186.0-186 to 186.0-186.9 (Malignant neoplasm of testis), effective for claims processed on or after September 29, 2003.

The following ICD-9-CM codes have been added to the respective agent:

- J9045 (Carboplatin) 185 (Malignant neoplasm of prostate), effective for claims processed on or after October 20, 2003.
- J9170 (Docetaxel) 171.0-171.9 (Malignant neoplasm of connective and other soft tissue [soft tissue sarcomas]), effective for claims processed on or after October 20, 2003.
- J9185 (Fludarabine) 273.3 (Macroglobulinemia [Waldenstrom's macroglobulinemia]), effective for claims processed on or after September 23, 2003.
- J9201 (Gemcitabine) 171.0-171.9 (Malignant neoplasm of connective and other soft tissue [soft tissue sarcomas]), effective for claims processed on or after October 20, 2003.
- J9350 (Topotecan Hydrochloride) 180.0-180.9 (Malignant neoplasm of cervix uteri), effective for claims processed on or after October 20, 2003.

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*.

# 33215: Implantation of Automatic Defibrillators

The local medical review policy (LMRP) for implantation of automatic defibrillators was last revised on January 1, 2003. Since that time, ICD-9-CM codes **996.01** (Mechanical complication of cardiac device, implant, and graft due to cardiac pacemaker [electrode]) and **V53.31** (Fitting and adjustment of other device, cardiac pacemaker) have been added to the "ICD-9 Codes that Support Medical Necessity" section of the policy.

This change is effective for services processed on or after August 11, 2003.

Additional changes have been made to this LMRP, based on CMS Transmittal 173, Change Request 2880, dated August 22, 2003. This transmittal specifies expanded coverage to include: Coronary artery disease with a documented prior myocardial infarction (MI), a measured left ventricular ejection fraction = 0.35, and inducible, sustained ventricular tachyarrhythmia or ventricular fibrillation at electrophysiology study; or documented prior MI and a measured left ventricular ejection fraction > 120 milliseconds.

In addition, the policy has been revised to include ICD-9-CM code **412** (Old myocardial infarction) to the "ICD-9 Codes that Support Medical Necessity" section. Language has also been added to the "Indications and Limitations of Coverage and/or Medical Necessity" section of the policy.

All other indications for defibrillators not otherwise specified in section 35-85 of the Medicare Coverage Issues Manual remain noncovered except when furnished in accordance with Food and Drug Administration approved protocols governing Category B Investigational Device Exemption (IDE) clinical trials (as stated in the *Federal Register* at 60 FR 48417).

This change is effective for services rendered on or after October 1, 2003.

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*.

# **43235:** Diagnostic and Therapeutic Esophagogastroduodenoscopy

The local medical review policy (LMRP) for diagnostic and therapeutic esophagogastroduodenoscopy was last updated on January 1, 2003.

Since then, a request was received from a provider to add ICD-9-CM code V12.79 (Personal history of other diseases of digestive system) to the "ICD-9 Codes that Support Medical Necessity" section of the LMRP. After reviewing the information provided, it was determined this request was appropriate.

Therefore, the LMRP has been updated to include ICD-9-CM code V12.79 for *CPT* codes 43235, 43236, 43239, 43241, 43243-43251, 43255, and 43258.

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after September 22, 2003.

# 58340: Infertility

The latest revision to the local medical review policy (LMRP) for infertility was effective January 1, 2003. Program Memorandum AB-03-119, Change Request 2853, dated August 8, 2003, was issued by CMS to communicate a change in the final update to the 2003 Medicare physician fee schedule database that indicates reinstatement of HCPCS code G0027 (Semen analysis; presence and/or motility of sperm excluding Huhner test) to this policy. Therefore, HCPCS code G0027 has been added to the "*CPT*/HCPCS Codes" section of the policy; the 'Documentation Requirements' section of the policy has been revised accordingly.

The full-text of the revised LMRP is available on the provider education Web site at *www.floridamedicare.com*, and is effective for services

rendered on or after March 1, 2003.

# 64561: Sacral Neuromodulation

The latest revision for the local medical review policy (LMRP) for sacral neuromodulation was effective January 1, 2002. It has since been determined that ICD-9-CM code **595.1** (Chronic interstitial cystitis) should be added to the policy as a covered indication for this therapy. Therefore, diagnosis code 595.1 has been added to the "ICD-9 Codes That Support Medical Necessity" section of the policy for this service.

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for claims processed on or after September 22, 2003.

# 70544: Magnetic Resonance Angiography (MRA)

CMS Transmittal 1795, Change Request 2673, expands coverage for MRA to include MRA of the pelvis. Therefore, the local medical review policy (LMRP) for MRA has been revised to define the indications and limitations of coverage and to add the following ICD-9-CM codes to the "ICD-9 Codes that Support Medical Necessity" section of the policy for *CPT* code **72198** (*Magnetic resonance angiography*, *pelvis, with or without contrast material*[*s*]):

189.0-189.9	Malignant neoplasm of kidney and
198.0	other and unspecified urinary organs Secondary malignant neoplasm of
223.0	kidney Benign neoplasm of kidney, except
223.0	pelvis
223.1	Benign neoplasm of renal pelvis
233.9	Carcinoma in situ of other and unspeci-
	fied urinary organs
236.90-236.99	Neoplasm of uncertain behavior of
	other and unspecified urinary organs
403.00-403.91	Hypertensive renal disease
404.00-404.93	Hypertensive heart and renal disease
405.01	Secondary hypertension, malignant,
	renovascular
405.11	Secondary hypertension, benign,
	renovascular

# 90901: Biofeedback

**C**PT code 90911 (Biofeedback training by any modality) was found to be aberrant based on data for services from January 1, 2002, through June 30, 2002. The local medical review policy (LMRP) has been revised to define the indications and limitations of coverage, establish a procedure to diagnosis application, and clarify the appropriate use of procedure code 90911.

The full-text of this LMRP is available on our provider education Web site at *www.floridamedicare.com*, and is effective for services processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

405.91	Secondary hypertension, unspecified,
	renovascular
440.1	Atherosclerosis of renal artery
447.3	Hyperplasia of renal artery
580.0-580.9	Acute glomerulonephritis
581.0-581.9	Nephrotic syndrome
582.0-582.9	Chronic glomerulonephritis
583.0-583.9	Nephritis and nephropathy, not speci-
	fied as acute or chronic
588.0-588.9	Disorders resulting from impaired
	renal function
593.81	Vascular disorders of kidney
593.9	Unspecified disorder of kidney and
	ureter

The full-text of the revised LMRP is available on our provider education Web site at *www.floridamedicare.com*. These changes are effective for services processed on or after January 5, 2004.

Italicized and/or quoted material is excerpted from the American Medical Association *Current Procedural Terminology. CPT* codes, descriptions and other data only are copyrighted 2002 (or other such date of publication of *CPT*) American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

# 92136: Optical Coherence Biometry

The latest revision to the local medical review policy (LMRP) for optical coherence biometry was effective March 1, 2003. CMS Program Memorandum AB-03-119, Change Request 2853, dated August 8, 2003, was issued to communicate a change in the final update to the 2003 Medicare physician fee schedule database that indicates procedure code 92136-26 as a bilateral procedure. Therefore, the 'Coding Guidelines' section of the policy has been revised accordingly.

The full-text of this local medical review policy is available on our provider education Web site *www.floridamedicare.com*, and is effective for services rendered on or after March 1, 2003.

# 97001: Physical Medicine and Rehabilitation (formerly 97010: Physical Medicine and Rehabilitation)

The local medical review policy (LMRP) for Physical Medicine and Rehabilitation was last updated on April 1, 2003. Since that time, the policy number has been changed to *97001*.

The full-text of the revised LMRP is available on our provider education Web site at www.floridamedicare.com.

# 98940: Chiropractic Services

The latest revision for local L medical review policy (LMRP) for chiropractic services was effective January 1, 2002. Upon updating this policy, it has been determined that additional ICD-9-CM codes should be added to this policy as covered indications for this service. Therefore, additional codes have been added to the "ICD-9 Codes That Support Medical Necessity" section of the policy. In addition, revisions have been made to the "Indications and Limitations of Coverage and/or Medical Necessity," "Reasons for Denials," "Coding Guidelines," and "Documentation Requirements"

sections of the policy. The full-text of this LMRP is

available on our provider education Web site at

*www.floridamedicare.com*, and is effective for services processed on or after October 20, 2003.

# 99183: Hyperbaric Oxygen Therapy (HBO Therapy)

The latest revision to the local L medical review policy (LMRP) for HBO therapy was effective April 1, 2003. Program Memorandum (PM) AB-03-102, Change Request 2769, dated July 25, 2003, was issued to correct PM AB-02-183, Change Request 2388, as the original PM did not include some pertinent information regarding diagnosis codes. Revisions include: addition of ICD-9-CM Code 707.15 (Ulcer of other part of foot) to the "ICD-9 Codes That Support Medical Necessity" section of the policy for this therapy and deletion of ICD-9-CM code 707.0 (Decubitus ulcer) from this section of the policy.

These revisions are effective for services rendered on or after April 1, 2003. The full-text of this LMRP is available on our provider education Web site at *www.floridamedicare.com*.

# LOCAL MEDICAL REVIEW POLICY (RETIRED)

# 90657: Influenza Virus Vaccine

The local medical review policy (LMRP) for influenza virus vaccine is retired, effective for services rendered on or after October 28, 2003. It has been determined that the policy is no longer relevant based on *CPT* coding and national coverage determination. The full text of the LMRP for influenza virus vaccine may be found on our provider education Web site at *www.floridamedicare.com*.

# **C**ORRECTIONS

# 90853: Group Psychotherapy

The local medical review policy (LMRP) for group psychotherapy was published in the Second Quarter 2003 *Medicare B Update!* (page 56) with an incorrect effective date. The correct effective date is for claims processed on or after **February 18**, **2003**. We apologize for any inconvenience this may have caused.

The full-text LMRP is available on the provider education Web site www.floridamedicare.com.

# 93880, 93882: Duplex Scans, Extracranial—Correction

The article pertaining to duplex scans, extracranial, published in the Fourth Quarter 2003 Medicare B Update! (page 81) included two inappropriate ICD-9-CM diagnosis codes. The corrected article is as follows:

If you are performing an extracranial duplex scan (*CPT* code 93880 or 93882) to monitor a patient following a surgical procedure or a patient on a high-risk medication, one of the following ICD-9-CM diagnoses codes should be used when billing Medicare:

V67.00 Follow-up examination following surgery, unspecifiedV67.09 Follow-up examination following other surgery

This information is outlined in local medical review policy (LMRP) 93875: Noninvasive Extracranial Arterial Studies. The full-text LMRP is available on the provider education Web site *www.floridamedicare.com*.

# Florida Educational Resources

# Medicare Education and Training Presents: MEDICARE AT THE MOVIES

Have you ever wanted to share popcorn with a Medicare Representative? Join us for a **free** one-day educational extravaganza – attend one "movie" or all!

November 13, 2003

To be viewed at Doubletree 701 NW 53<sup>rd</sup> Street Boca Raton, Florida

Shows and times are:

#### Driving Miss Daisy to the ASC

8:30 a.m. – 10:30 a.m.

**Rating: MS** (Medicare Specialty Population)

ASC Specialty Workshop: Are you an Ambulatory Surgical Center who wants to have a sound understanding of the global surgery policy? Do you want to know if ASCs can bill for prosthetics and orthotics? Are you unsure about what modifiers are valid for ASC billing? Don't miss this opportunity to participate in a workshop designed specifically for ASCs.

### A Few Good Cases

12:30 p.m. – 2:30 p.m.

Rating: MG (Medicare General Population)

Understanding the Appeals Process: Do you want to gain a better understanding of what happens when you request a review? Do you want to know what constitutes a medical necessity denial and how to avoid them? Does your documentation substantiate the services for which you billed as well as clearly convey the patient's condition? Don't miss this opportunity to learn how to avoid the top mistakes providers make when submitting reviews.

#### **Modifier Matrix**

3:00 p.m. – 5:00 p.m.

#### Rating: MN (Medicare Novice)

**Modifiers Made Easy:** Are you having problems matching modifiers to procedure codes? Do you want to know how to avoid billing invalid/inappropriate modifiers? Do you understand how modifiers affect your reimbursement? Then you don't want to miss this workshop.

#### Special Feature: HIPAA Lunch and Learn

#### Intermission: 11:00 a.m. – 12:00 noon

Chat with a FCSO HIPAA representative while you sit and eat your lunch. Learn about the CMS contingency plan, testing, and the way enforcement will work, as well as latest updates. December 5, 2003

To be viewed at First Coast Service Options, Inc. 532 Riverside Avenue Jacksonville, Florida

Shows and times are:

You've Got Mail!

8:30 a.m. – 10:30 a.m.

Rating: MS (Medicare Specialty Population)

**Navigating FCSO's Web site**: Do you frequently look for medical policies on FCSO's Web site? Do you want to learn how to find the latest HIPAA information? Then don't miss this opportunity to understand FCSO's Web site structure, content, and functions. Participants will also gain a basic understanding of Internet and browser functions.

#### A Few Good Cases

12:30 p.m. – 2:30 p.m.

**Rating: MG** (Medicare General Population)

Understanding the Appeals Process: Do you want to gain a better understanding of what happens when you request a review? Do you want to know what constitutes a medical necessity denial and how to avoid them? Does your documentation substantiate the services for which you billed as well as clearly convey the patient's condition? Don't miss this opportunity to learn how to avoid the top mistakes providers make when submitting reviews.

#### **Modifier Matrix**

3:00 p.m. – 5:00 p.m.

Rating: MN (Medicare Novice)

**Modifiers Made Easy**: Are you having problems matching modifiers to procedure codes? Do you want to know how to avoid billing invalid/inappropriate modifiers? Do you understand how modifiers affect your reimbursement? Then you don't want to miss this workshop.

### Special Feature: HIPAA Lunch and Learn

#### Intermission: 11:00 a.m. – 12:00 noon

Chat with a FCSO HIPAA representative while you sit and eat your lunch. Learn about the CMS contingency plan, testing, and the way enforcement will work, as well as latest updates.

Want to know more? Visit our Web site at www.floridamedicare.com or call us at 1-904-791-8103.

## FLORIDA ONLY

EDUCATIONAL RESOURCES

# **MEDICARE EDUCATION & TRAINING EVENT REGISTRATION FORM**

Please complete all portions of this form.

One form per person, per registration, please.

1.	Who are you? MrMrsN	lsMDDO
	Name	
	Title/Position	
	Company/Organization	
	Address	
	City	StateZIP Code
	Phone Number ( )	Fax Number ( )
	Email Address	
2.	Which event do you want to attend?	•
	Event Name	
	Event Date	
		State
3.	To register:	
	<b>Mail</b> your completed form to: First Coast Service Options, Inc.,	

First Coast Service Options, Inc. P.O. Box 45157 Jacksonville, FL 32232-5157

or

Fax your completed form to 1-904-791-6035

Important!

Seating Is Limited. Please submit your registration form as soon as possible. Seating for most events is limited.

**Bring Your Confirmation.** Be sure to bring your event confirmation notice with you to the event. It will be treated as proof of registration when you sign in at the event and receive your materials.

Substitutions. If you cannot attend an event, you may send *only one* person to substitute in your place for the duration of the event.

Questions? Call our registration hotline at 1-904-791-8103.

# CONNECTICUT AND FLORIDA

# **ORDER FORM — 2004 PART B MATERIALS**

The following materials are available for purchase. To order these items, please complete and **submit this form along** with your check/money order payable to BCBSFL – FCSO with the account number listed by each item.

Note: Payment for fee schedules cannot be combined with payment for other items; separate payments are required for purchases of items from different accounts.

QUANTITY	ITEM			ACCOUNT NUMBER	COST PER ITEM
	free of charge online a www.floridamedicare.c providers and professio claim (to either Connec- twelve months prior to tions issued after Jun register to continue to providers will be eligit reason can be shown w cannot be utilized. Non copies may purchase a issues published during	at www.connecticutmea com. Hardcopy distribu- conal association groups cticut or Florida Medi o the release of each is <b>ne 1, 2003</b> , providers w receive the <i>Update!</i> in oble to receive one hard why the electronic public provider entities or prin annual subscription. g calendar year 2004 (	edicare B Update! is available licare.com and ttion is limited to individual s who billed at least one Part B care) for processing during the ssue. <b>Beginning with publica</b> - who meet these criteria must a hardcopy format. Qualifying copy of each issue, if a valid ication available on the Internet oviders who need additional This subscription includes all back issues for subscription sent upon receipt of order).	700395	\$70.00
	Physician Practitioner March 1, 2004, throug online at <i>www.connect</i> Providers who do not h Schedule contains cale items do not include th services, mammograph visions to fees may oc of the <i>Medicare B Upd</i>	Fee Schedule, effective h December 31, 2004, <i>ticutmedicare.com</i> and nave Internet access ma mandar year 2004 payment he payment rates for in my screening, or DMEF cur; these revisions with date! Nonprovider entit	Part B Physician and Non- ve for services rendered is available free of charge www.floridamedicare.com. ay purchase a hardcopy. The Fee ent rates for all localities. These jectable drugs, clinical lab POS items. Note also that re- ll be published in future editions ties or providers who need ay purchase additional copies.	700400	\$5.00 (CT) \$10.00 (FL)
Please write	legibly				
Subtotal	\$	Mail this form w	with payment to:		
ax ( <b>add % fo</b> r your area	)	Medicare Publi P.O. Box 45280			
otal	\$	Jacksonville, F	L 32232-5280		
Contact Name:					
Provider/Office	Name:				
hone:		FAX Num	ber:		
An ilin a Anlahan an	S:				
			ZIP:		





#### Index to Connecticut and Florida Medicare B Update! - Fiscal Year 2003

The following is a comprehensive index covering all r articles published the *FCSO Medicare B Update!* during fiscal year 2003 (including special electronic-only issues).

Separate Connecticut and Florida issues of the Update! were published for the First Quarter 2003. Beginning in January 2003, the Update! is consolidated into one issue for both states. In this index, content published for both Connecticut and Florida are listed first, followed by content published only for Connecticut, then content published only for Florida.

Note: Electronic issues denoted with an asterisk (\*) are *not* produced in hard copy format, and are available only on FCSO's provider education Web sites, www.connecticutmedicare.com and www.floridamedicare.com.

# **Connecticut and Florida**

### Α

Adjustments – 2003 Medicare Physician Fee Schedule,	
Cancellation of the Automatic July 2003 Mass 4th QTR 2003	15
Advance Beneficiary Notices (ABNs) 1st QTR 2003	5
	5
	6
	5
Ambulance Fee Schedule Implementation, Second	-
Clarification Regarding	7
Ambulance Fee Schedule, Third Clarification of Medicare	'
Policy Regarding the Implementation of the	19
Ambulance Transport of a Beneficiary in a PartACovered	15
Skilled Nursing Facility (SNF) Stay, Payment for Drugs	
Administered During	19
	19
Ambulatory Blood Pressure Monitoring—Revision to	28
National Coverage Determination (NCD)	20
Ambulatory Surgical Center (ASC) Not on the ASC	
Approved Procedures List—Clarification, Services	
Provided in an	23
Ambulatory Surgical Center, The List of Procedures	
Approved in an	23
Appeals Process, New Rules for the Medicare 1st QTR 2003	42CT
	44 FL
Appeal Requests Should be Submitted with Appropriate	
Supporting Documentation 4th QTR 2003	9
Appeal, Time Limit for Filing a Request for 3rd QTR 2003	11
ASC, Procedures Approved in for 2002—Correction 3rd QTR 2003	13
<b>D</b>	
B	
Beneficiary Has an Out-of-State Address, Carrier	
Jurisdiction for Medicare Payments When the 2nd QTR 2003	6
JUNSUCTION MEDICALE PAYMENTS WHEN THE 2ND QTR 2003	0
С	
0	
Carrier–Priced Codes, 2003 4th QTR 2003	15
CB, Proper Use of Modifier	51
Claim Submissions, Filing Tips for Paper 4th QTR 2003	14
Claims Mistakenly Submitted to the Local Carrier	
Will Be Returned as Unprocessable	10
Claims, Services Requiring a Mammography Certification	-
Number and a CLIA Certification Number Must Be	
Submitted on Separate	10
Clinical Diagnostic Laboratory Services Based on the	10
Negotiated Rulemaking, Claims Processing	
Requirements for	14CT
1st QTR 2003	12 FL
Clinical Diagnostic Laboratory Services, Questions	121 6
and Answers Related to Implementation of National	15CT
Coverage Determinations (NCDs) for 1st QTR 2003	13 FL
1st QTR 2003	
Clinical Laboratory Fee Schedule Jan 2003*	14CT
Jan 2003*	22 FL
CLIA Waived Tests, New	12
	26
4th QTR 2003	33
CMS Quarterly Provider Update 4th QTR 2003	50

	20
Professionals, Materials on	62
Colorectal Cancer (CRC) Screening Publications 3rd QTR 2003	61
Colorectal Cancer Screening Awareness for Health	
	58
Correct Coding Initiative	Т
	FL
	6
	10
	9

D	
Deep Brain Stimulation for Essential Tremor and	
Parkinson's Disease	31
Denial Messages, Research All Remittance Notice 2nd QTR 2003	30
Deported Medicare Beneficiaries	43
Diabetes Outpatient Self-Management Training (DSMT)	7.07
Services, Payment to Registered Dietitians for 1st QTR 2003 	7 CT 7 FL
Diabetes Outpatient Self-Management Training Services	1
(DSMT) Program and Common Working File Edits	
for DSMT & Medical Nutrition Therapy (MNT),	
Clarification Regarding Nonphysician Practitioners	
Billing on Behalf of a 2nd QTR 2003	14
Clarification, Billing on Behalf of a 3rd QTR 2003	14
Diagnostic Services Ordered with Surrogate Unique	
Physician Identification Numbers	40
(Surrogate UPINs)	10 11
Diagnostic Tests, Ordening	11
Diagnostic Tests and Purchased Interpretations of 1st QTR 2003	8CT
1st QTR 2003	8 FL
Dialysis Services, MCM Updates Pertaining to 4th QTR 2003	30
Dietitians for Diabetes Outpatient Self-Management	
Training (DSMT) Services, Payment to Registered1st QTR 2003	7CT
1st QTR 2003	7 FL
Distribution and Format of the FCSO	-
Medicare B Update!	5
Unique Physician Identification Numbers (UPIN) . 1st QTR 2003	11 CT
	11 FL
Durable Medical Equipment, Prosthetics, Orthotics,	
and Supplies (DMEPOS) Jan 2003*	27 FL
	19CT
DMEPOS Fee Schedule, April Quarterly Update	
for 2003 3rd QTR 2003	22
F	

Electrical Stimulation for the Treatment of Wounds,	
Coverage and Billing Requirements for	15
Electronic Analysis of Pacemaker System and Pacer	
Cardioverter-Defibrillator: 93724 1st QTR 2003	27 C T
	31 FL
Eligibility Benefit Inquiry and Response Transaction,	
ASCX12N 270/271—Real Time Access	39

#### F

•	
Fee Schedule, Medicare Physician Jan 2003*	8
Financial Limitation for Outpatient Rehabilitation	
Services to September 1, 2003, Delay in Implemen-	
tation of the 4th QTR 2003	34
Financial Limitation for Outpatient Rehabilitation Services—	
Clarification on Requirement to Submit Modifier	
GN, GO, or GP, Implementation of the 4th QTR 2003	34
Financial Limitation of Claims for Outpatient	
Rehabilitation Services	34
Foot and Nail Care Services, Requirements for	
Payment of Medicare Claims for 2nd QTR 2003	17
Form CMS-1500, Item 32 of 1st QTR 2003	7CT
	6 FL

### Н

Hardcopy Format, Providers Must Qualify and Register	
to Receive the Medicare B Update! in 3rd QTR 2003	7
Hardcopy Issue Registration Form,	
Medicare B Update! 3rd QTR 2003	8

# Index to Connecticut and Florida Medicare B Update! - Fiscal Year 2003

HCPCS Update, Annual Jan 2003*	2
Health Care Claim Status Request and Response	10
ASC X12N 276/277	40
(HIPAA) Transaction 835v4010 Completion Update,	
Remittance Advice Coding and	38 C T
	41 FL
Health Insurance Portability and Accountability Act—	
Administrative Simplification (HIPAA–AS), The 2nd QTR 2003	20
Health Insurance Portability and Accountability Act— Administrative Simplification (HIPAA–AS) Update 1st QTR 2003	29CT
Administrative Simplification (min AA-AS) Opdate 1st QTR 2003	32 FL
Health Insurance Portability and Accountability Act	-
(HIPAA) Standards for Privacy of Individually	
Identifiable Health Information ("Privacy Rule")	40
Business Associate Provisions	43 3
HIPAA 101 For Health Care Providers' Offices	24
HIPAA. A Letter to All Providers from CMS about 4th QTR 2003	1
HIPAA, Are Small Providers Covered Entities under? . 4th QTR 2003	41
HIPAA-AS Addenda Transactions, FCSO to Begin	
Testing and Support of	38
HIPAA-AS Transactions and Code Sets: Testing and Updates	38
4th QTR 2003	44
HIPAA Compliant for Medicare Part B, Ensuring	••
Your PC-ACE Pro32® Software Is 4th QTR 2003	49
HIPAA, Important Information for Providers about 3rd QTR 2003	41
4th QTR 2003	44
HIPAA Information, General	42
4th QTR 2003 HIPAA Information Series	44 40
HIFAA IIII0III1all0113eilles	40 48
HIPAA Makes Electronic Claims Submission the	40
Best Choice	37
HIPAA Presentations, CMS Southern Consortium's	
FREE	47
Getting Started	22
HIPAA Readiness Checklist, Provider	40
HIPAA Resources	23
	40
HIPAA Resources Updated 06/16/03	46
HIPAA Resources, Helpful	45 47
HIPAA Transactions and Code Sets after the	47
October 16, 2003, Implementation Deadline,	
Guidance on Compliance with	42
HMO for only a Portion of the Claim, Services Furn-	
ished to a Beneficiary Who is a Member of an 3rd QTR 2003	11
Home Health Consolidated Billing, Additional Remark	
Code for Claims of Therapy Services Possibly Subject to	34CT
Subject to	37 FL
Home Health Consolidated Billing Enforcement,	0=
Annual Update of Procedure Codes Used for 1st QTR 2003	32 C T
	35 FL
Home Health Consolidated Billing Enforcement,	
Quarterly Update of HCPCS Codes Used for 2nd QTR 2003	28 62
Home Health Services, Physician Certification and	02
Re-certification for	31
Home Prothrombin Time International Normalized Ratio	
(INR) Monitoring for Anticoagulation Management,	
Coverage and Billing for —Correction	12
Hospice Care Enhances Dignity and Peace As Life Nears Its End	57
Hyperbaric Oxygen Chamber, Change in Jurisdiction	57
for Topical	12CT
	12 FL
1	
	40.0-
ICD-9-CM Coding Changes, 2003 1st QTR 2003	19CT 18FL
ICD-9-CM Coding on Claims Submitted to Medicare	IOFL
Carriers—Increased Role for Physicians/Practitioners,	
Establishing New Requirements for 4th QTR 2003	7

About Medicare Physician Fee Schedule Look-up, Online Second Update to the Medicare Secondary Payer (MSP) and the Debt Collection Improvement Act of 1996 (DCIA) Medicare Stop Smoking Program	Jan 2003* 4th QTR 2003 June 2003* 3rd QTR 2003	12 8 18 1-3 45 63
About	Jan 2003* 4th QTR 2003 June 2003* 3rd QTR 2003	8 18 1-3 45
About Medicare Physician Fee Schedule Look-up, Online Second Update to the Medicare Secondary Payer (MSP) and the Debt	Jan 2003* 4th QTR 2003 June 2003*	8 18
About Medicare Physician Fee Schedule Look-up, Online	Jan 2003* 4th QTR 2003	8 18
About Medicare Physician Fee Schedule	Jan 2003*	8
	3rd QTR 2003	12
Medicare Participation for 2003, Announcement		
(MEDPARD), 2003—Revised Availability		50
Medicare Participating Physician/Supplier Director		29
Medicare Covered Drugs—Quarterly Pricing Updat	e 3rd QTR 2003	14
Medicare B Update!, New Format for Your		1CT 1FL
Madiagra P.I. Indatal Now Earmattar Your		4 1 CT
		4
		401
announces the appointment of a new Medicare B Update!, About the		3 4CT
Medical Director, FCSO Office of the Medical Direct	tor	-
Magnetic Resonance Angiography, Additional Coverage for	4th QTR 2003	37
Digital Mammography Centers, Update to the .		31
Mammography Claims, Screening and Diagnostic Mammography Quality Standards Act File for Certi		30
IVI	ard OTD 2002	20
	isiQTK2003	17 FL
Local Medical Review Policy Reconsideration Proc	ess1stQTR 2003	19CT 17 FL
in End-Stage Renal Disease (ESRD) Patients	2nd QTR 2003	11
(ADR) for Ordering Providers of Levocarnitine for use in Treatment of Carnitine Defic		24
Laboratory Services, Additional Documentation Re	quests	
Software for April 1, 2003, Changes to the	3rd QTR 2003	24
Laboratory National Coverage Determination (NCD	) Edit	
1		
Jurisdiction List, 2003		12 FL 15
Change in	1st QTR 2003	12CT 12FL
Jurisdiction for Topical Hyperbaric Oxygen Chambe	er,	10.0-
J3490 or J9999, Are You Getting the Correct Reimb ment When Billing for Drugs Using HCPCS Co	ourse- ides? Mar 2003	
•		
J	<del>-</del> ui QII \ 2003	,
Clinical Modification (ICD-9-CM)—Effective Octo 1, 2003, Annual Update of the	ber 4th OTR 2003	7
International Classification of Diseases, Ninth Revis	sion,	01
	3rd QTR 2003	51 61
Interest Rate for Medicare Overpayments and Under payments, Notice of	2nd QTR 2003	30
	1st QTR 2003	6 FL
Item 32 of Form CMS-1500	1stQTR 2003	21 FL 7 CT
Intracoronary (Intravascular) Brachytherapy	1st QTR 2003	22 CT
Injectable Drugs, Medicare Payment Allowance for		9CT 9FL
and Florida Allowances for	Jan 2003*	9
Injectable Drugs and Biologicals, 2003 Connecticu	1st QTR 2003	22 FL
Infliximab (Remicade™): J1745	1st QTR 2003	23CT
		92 92
Fiscal Year 2003		58
Health Stay Index to Connecticut and Florida Medicare B Upda	3rd QTR 2003	44
Independent Therapists and DME Suppliers— Billing for Services That May Be Part of a Hom	е	
		47 FL
to Medicare Carriers Important Addresses, Phone Numbers, and Webs	4th QTR 2003	8 44CT
ICD-9-CM Coding Requirements for Claims Submit	tted	8 FL
ICD-9-CM Coding for Diagnostic Tests—Additional Instruction to Determine the Reason for the Test		8CT

Mental Health Services, Medicare Payments for	
Part B	27
Microvolt T-wave Alternans: 93025 1st QTR 2003	27 C T
	31 FL
Modifier CB, Proper Use of	51
Modifiers and Procedure Codes Added for 2003 Jan 2003*	4
Modifiers and Procedure Codes Discontinued for 2003 Jan 2003*	7
Modifiers and Procedure Codes Revised for 2003 Jan 2003*	5
Mohs Micrographic Surgery, 17304—Multiple Surgery	
Guidelines Revised	40
Multiple Electroconvulsive Therapy (MECT),	
Noncoverage of	14
Multiple Primary Payers on Part B Claims 4th QTR 2003	63
NI	
N	
National Coverage Determination Edit Software.	

National Coverage Determination Edit Software,	
July 2003 Update to the Laboratory 4th QTR 2003	32
National Coverage Determination Edit Software,	
October 2003 Update to the Laboratory 4th QTR 2003	32
National Participating Physician Directory	50
Neuromuscular Electrical Stimulation, Coverage and	
Billing for 2nd QTR 2003	16
New Data Findings Surfaced: 76375 1st QTR 2003	25 C T
	28 FL

# 0

Ocular Photodynamic Therapy (OPT) with Verteporfin:	
67221 1st QTR 2003	24CT
1stQTR 2003	26 FL
OIG Warns against Misuse of HHS Words, Symbols,	201 L
Emblems	43
Order Form – 2003 Part B Materials 1st QTR 2003	43CT
	4301 46 FL
	63
	96
	91
Outpatient Physical or Speech Therapy Certification—	
Clarification 3rd QTR 2003	36
Outpatient Rehabilitation Services, Implementation of	
the Financial Limitation for	33
-	
Р	
PC-ACE Pro32® May Be the Solution 4th QTR 2003	49
Penal Authority, Claims for Medicare Beneficiaries in	10
State or Local Custody under a	38CT
1stQTR 2003	40 FL
Percutaneous Image-Guided Breast Biopsy, Coverage	401 L
and Billing for 1st QTR 2003	17CT
	15 FL
	13 FL 19
Clarification	
PET Scans, Expanded Coverage for	37
Place of Service (POS) Code Set, Update of the 4th QTR 2003	57
Portable X-Ray Transportation Services, Payment	
Review for 4th QTR 2003	39
Positron Emission Tomography (PET) Scans: G0030 1st QTR 2003	23 CT
	22 FL
Positron Emission Tomography (PET) Scan Code	
G0125, G0125-TC—Important Information	39
Positron Emission Tomography Scans, Expanded	
Coverage of	38
Primary Payers, How to Submit Claims to Medicare	
When There are Multiple	44
Prosthetics and Orthotics, Billing - HCPCS Updates . 1st QTR 2003	11 CT
1st QTR 2003	11 FL
Psychotropic Drug Use in Skilled Nursing Facilities	
(SNF)	36CT
(cru) /	38 FL
131 211 2000	501 L
R	
Railroad Medicare Carrier, Provider Enrollment	
	60
Information for the	63 9
	9
Remark Code for Claims of Therapy Services Possibly	
Subject to Home Health Consolidated Billing,	24 CT

Additional ...... 1st QTR 2003 34 CT 

Remittance Advice Coding and Health Insurance Portability and Accountability Act (HIPAA) Trans-	
action 835v4010 Completion Update 1st QTR 2003	38CT
	41 FL
Remittance Advice Notices, Changes to Medicare	
Provider	56
Remittance Advice Remark and Reason Code Update3rd QTR 2003	51
	50
Reviews, Widespread Probe 1st QTR 2003	18CT
	17 FL
S	

5	
Screening Pap Smear and Pelvic Examination	
Services, Diagnosis Code for 4th QTR 2003	33
Skilled Nursing Facilities (SNF), Psychotropic Drug	
Use in1stQTR 2003	36CT
1stQTR 2003	38 FL
Skilled Nursing Facility (SNF) Consolidated Billing	
(CB) to Permit Payment for Certain Diagnostic Ser- vices Furnished to Beneficiaries Receiving Treat-	
ment for End Stage Renal Disease (ESRD) at an	
Independent or Provider-Based Dialysis Facility, Rev-	
isions to Common Working File (CWF) Edits for 2nd QTR 2003	29
Skilled Nursing Facility (SNF) Consolidated Billing	
(CB), Notification of Updates to Coding Files on	
CMS Web Site for	28
Skilled Nursing Facility (SNF) Consolidated Billing,	
Quarterly Update for 4th QTR 2003	64
Skilled Nursing Facility (SNF) Stay, Physicians Ren-	
dering Services To Patients in a Covered Part A 1st QTR 2003	35CT
Smales New Demonstration Drainst Available for	37 FL
Smoke, New Demonstration Project Available for Seniors with Medicare Who	63
Specialty Codes Update	50
Stop Smoking Program, Medicare	63
Surrogate Unique Physician Identification Numbers (Surro-	00
gate UPINs), Diagnostic Services Ordered with 2nd QTR 2003	10
Surrogate Unique Physician Identification Numbers (UPIN),	
Durable Medical Equipment Ordered with 1st QTR 2003	11 CT
	11 FL
Survey, Reader — Medicare B Update! 2nd QTR 2003	31
т	

#### I

Telehealth Services, Psychatric Diagnostic Interview luna 2002\*

Examination	June 2003	3
Telehealth Update, Medicare	2nd QTR 2003	19
Temporary Codes Q4052 and Q4053, Addition of	4th QTR 2003	15
Therapy Services, New Medicare Limits on	4th QTR 2003	64
Topical Hyperbaric Oxygen Chamber, Change in		
Jurisdiction for	1st QTR 2003	12CT
	1st QTR 2003	12 FL
Tympanometry: 92567	. 1st QTR 2003	26 C T
	1st QTR 2003	31 FL

### U

50 V Vaccines, Pneumococcal Pneumonia, Hepatitis B, and Influenza Virus ...... 4th QTR 2003 10 6

# W

Weekly Radiation Therapy Management 2nd QTR 2003	19
	25 C T
	30 FL
Widespread Probe Review Results: Oral Surgery 1st QTR 2003	22 C T
	22 FL
Widespread Probe Reviews 1st QTR 2003	18CT
	17 FL

# **Connecticut Only**

# Δ

A	
Accounting Department, News from the 4th QTR 2003	61
Advance Notice Statement	34
3rd QTR 2003	65
4th QTR 2003	66
Ambulance Origin and Destination Modifiers in the	00
Ambulance Originanu Destination Mounters in the	4
MCS, Filing	4
Ambulatory Surgical Centers (ASCs) Must Submit	~
Modifier SG Jan 2003	2
Anesthesia Units Displayed on Remittance Notices Oct 2002	3
ANSI Record/Field Changes for MCS, Specific NSF/ Dec 2002	2
Antineoplastic Drugs–Additions to Policy: J9999 1st QTR 2003	23
В	
Basic Radiation Dosimetry Calculation: 77300 2nd QTR 2003	37
Beta2 Microglobulin: 82232	38
Bone Mineral Density Studies: 76075	24
	24
C	
-	
Carrier Jurisdiction for Medicare Payments Nov 2002	2
Checks and Remittance Advices, Changes to Medicare Oct 2002	2
Claim Filing Requirements, Form CMS-1500	73
Claim Filing Requirements, Multi-Carrier System	
Processing and CMS-1500 Nov 2002	3
Claim Submission Tips 4th QTR 2003	76
Clinical Laboratory Fees, 2003 Connecticut	16
Clinical Psychologists and Clinical Social Workers, 2003	10
Fee Schedule for Connecticut	13
Clinics, Provider Numbers for Professional Association	10
GroupsOct 2002	1
Comprehensive Data Analysis	'
Article Clarification: 88311	67
Clarification, Additional, 88311, 88312-88314	68
	00
Comprehensive Data Analysis Findings—	67
Eye Exams	67
Widespread Probe—Eye Exam Codes	68
Correct Payment of January and February 2003	40
Physician Services	12
Customer Service Needs Your Help Jan 2003	1
Date Last Seen, Practitioners Who Are Required	-
To Submit a Oct 2002	5
Denials Based on Local Medical Review Policy,	
Provider Notification of	36
Diabetic Testing Supplies, New Medicare Medical	
Review Guidelines for Claims for 1st QTR 2003	12
DMERC A Publications for Fiscal Year 2003,	
Changes to 2nd QTR 2003	32
DMERCA, Establishment of New P.O. Boxes for 2nd QTR 2003	32
DMERC Provider Communications (PCOM) Advisory	
Group, The Region A 2nd QTR 2003	33
DMEPOS Fees, 2003 Connecticut Jan 2003*	20
Duplicate Claim Receipts, Help us Reduce	11
_	
E	
EDI Alert, Special: Avoiding Rejects in the MCS Dec 2002	1
	1
EDI Contact Information Dec 2002	1
EDI Process Changes, Other	7
EDI Software Vendors, Billing and Clearinghouse Entities,	_
Important Information for Independent Nov 2002	7
Electronic Claim Submitters, Important Notice To All Jan 2003	3
Electronic Data Interchange (EDI) Information for Providers,	
Vendors, Clearinghouses, Billing Services, Service Bureaus,	
and In-house Programmers, Important Medicare Dec 2002	
Email Notification Service Available, Free Automatic Jan 2003	3

FDAApprovals,. Recent ...... 2nd QTR 2003

Fluorescein Angiography: 92235 ..... 1st QTR 2003

G	
Groups/Clinics, Provider Numbers for Professional	
AssociationOct 2002 Group Psychotherapy: 908532nd QTR 2003	1 39
	00
Η	
HCPCS Update, Policy Changes Related to the 20032nd QTR 2003	34
1	
ICD-9-CM Codes Will Be Date of Service Driven,	
Annual Updating ofNov2002 Important Addresses, Phone Numbers, And Web Sites—	3
Connecticut	97
	98
In Billing the Place of Service for	2
Index to Fiscal Year 2002 Connecticut	20
Medicare B Update!Jan 2003* Individual Psychotherapy: 908042nd QTR 2003	29 38
Intensity Modulated Radiation Therapy (IMRT): 773022nd QTR 2003	38
Interactive Group Psychotherapy: 90857 2nd QTR 2003	39
Interactive Individual Psychotherapy: 90810	39
Carrier System Digital	4
Internal Control Numbers (ICN) and Correspondence Control Numbers (CCN)Oct 2002	2
Investigational Device Exemption (IDE) Revised	2
Requirements	67
J	
Jurisdiction for Medicare Payments, Carrier Nov 2002	2
, , ,	-
Leuprolide Acetate (for Depot Suspension), 7.5 mg, J9217	68
Local Medical Review Policy	00
New Biopowof Brostota Lloing Imago Cuidonoo 55700 4th OTB 2002	60
Biopsy of Prostate Using Image Guidance, 55700 4th QTR 2003 Cytogenetic Studies: 88230	69 70
Darbepoetin alfa (Aranesp?) (novel erythropoiesis	
stimulating protein [NESP]), J0880:	69 69
Duplex Scan of Hemodialysis Access, 93990 4th QTR 2003	70
Duplex Scan of Lower Extremity Arteries, 93925 4th QTR 2003	70
Duplex Scan of Upper Extremity Arteries or Arterial Bypass Grafts, 93930	70
Duplex Scanning, 93975	70
G-CSF (Filgrastim, Neupogen®): J1440: 3rd QTR 2003	69
Ibritumomab Tiuxetan (Zevalin™): ZEVALIN:	69 69
Magnetic Resonance Imaging (MRI) of the Spine,	09
72141	70
Magnetic Resonance Imaging (MRI) of Upper Extremity, 73218 4th QTR 2003	70
Pegfilgrastim (Neulasta <sup>™</sup> ): J3490 3rd QTR 2003	69
Peripheral Nerve Blocks, 64400 4th QTR 2003	69
Spinal Cord Stimulation, 63650 4th QTR 2003 Revised	69
Antineoplastic Drugs, J9999 4th QTR 2003	72
Epidural, 62263	73
(formerly 62318: Implanted Catheters/Pumps for	
Intrathecal Opioid Infusions), 62311 4th QTR 2003	73
Excision of Malignant Skin Lesions, 11600	72
Greater Occipital Nerve Block/Neurolysis, 64405 4th QTR 2003 Ground Ambulance Services: A0425 3rd QTR 2003	73 70
Hyperbaric Oxygen Therapy (HBO Therapy): 99183 3rd QTR 2003	70
Implantation of Neurostimulator Electrodes (formerly	70
Deep Brain Stimulation), 61850 4th QTR 2003 Implanted Peripheral/Sacral Electrical Nerve	73
Stimulation (formerly Percutaneous Peripheral	
Electrical Nerve Stimulation), 64555 4th QTR 2003 Intercostal Nerve Blocks/Neurolysis, 64420 4th QTR 2003	73 73
Intervolative Diomo/Neuroiyaia, 04420	13

Frequently Asked Questions and Answers ...... Nov 2002

F

Iridotomy by Laser Surgery (formerly 96LMRP019CV1.0-	
Iridotomy/Iridectomy by Laser), 66761	74
Laser Trabeculoplasty (formerly 96LMRP019EV1.0-	• •
Argon Laser Trabeculoplasty), 65855	74
Luteinizing Hormone-Releasing Hormone Analogs for	14
Treatment of Malignant Neoplasm of the Prostate, J92024th QTR 200	13 71
Magnetic Resonance Angiography (MRA), 70544 4th QTR 2003	74
Magnetic Resonance Anglography (WRA), 70044 411 QTR 2003 Mammography: 98041 V1.1 FINAL	71
Medical Nutrition Therapy (MNT): 97802	71
Optical Coherence Biometry, 92136	74
Pamidronate (Aredia®, APD): J2430	70
Paravertebral Facet Joint Blocks, 64470	70
(formerly 64475)	73
Paravertebral Facet Joint, Nerve Destruction by a	15
Neurolytic Agent, 64622	74
Pegfilgrastim (Neulasta™)–formerly J3490, Q4053 4th QTR 2003	72
Peripheral Neuropathy with Loss of Protective	12
Sensation (LOPS) in People with Diabetes, G0245 4th QTR 2003	71
Physical Medicine and Rehabilitation, 97001	75
Physical Medicine and Rehabilitation: 97001	71
Policies Affected by 2003 HCPCS and ICD-9-CM	11
Updates, Additional	71
Psychiatric Diagnostic Interview Examination;	11
PSYCHAUC Diagnostic Interview Examination, PSYCH/CHRONIC PAIN: Behavioral and Psychiatric/	
Psychological Assessment and Psychotherapy in the Management of Chronic Pain, 90801	74
Sacroiliac Joint Injection, 27096 (formerly 20550) 4th QTR 2003	74
Sympathetic Blocks, 64415 (formerly 64510)	73
Treatment of Ulcers of the Feet, 94004G V1.2	75
Trigger Point Injections, 20550 (formerly 20551) 4 <sup>th</sup> QTR 2003	72
Viscosupplementation Therapy for Knee (formerly J7317: Intra-articular Injections of Hyaluronates in	
	70
the Knee Joints), VISCO 4 <sup>th</sup> QTR 2003 Retired	72
Clinical Diagnostic Laboratory Services, Retirement of	71
Local Medical Review Policies for Certain	11
	75
Open Surgical Procedures), 99.11 V1.1	75
Evaluation and Management Services, Retirement of	70
Local Medical Review Policies for	72 75
Pap Smears, Obtaining and Sending, Q0091 4th QTR 2003	
PRN Orders, 95LMRP013 V1.4	75
Treatment Benign Skin Lesions of the Feet, 11420 4th QTR 2003	75
Μ	
Mail Directory, Connecticut Medicare Part B 2nd QTR 2003	61
	0

#### MCS Pre-Pass Edits ..... Dec 2002 3 MCS Transition, First Coast Service Options, Inc., (FCSO) Answers Questions about the ...... Oct 2002 6 MCS, Multiple Months Cannot Be Grouped on Claims in .. Oct 2002 4 MCS, Special EDI Alert: Avoiding Rejects in the ..... Dec 2002 1 MCS, Specific NSF/ANSI Record/Field Changes for ...... Dec 2002 2 Medical Director, from the ...... 1st QTR 2003 3 65 66 Medicare Secondary Payer-Frequently Asked Questions ...... 1st QTR 2003 34 Medigap, Filing Your Patient's ..... Oct 2002 5 Metabolically Active Human Dermal/Epidermal Replacements: MAHD/ER ...... 2nd QTR 2003 37 Modifier Billing Errors Identified in MCS ...... Jan 2003 2 Modifier Requirements ...... Nov 2002 2 Modifier Requirements in the MCS ..... Oct 2002 3 Modifier SG, Ambulatory Surgical Centers (ASCs) Must Submit ...... Jan 2003 2 Modifiers in the MCS, Filing Ambulance Origin and Destination ......Oct 2002 Multi-Carrier System (MCS) Post Transition Issues Log ... Jan 2003 4 3 Multi-Carrier System (MCS) Seminar, Free Medicare Part B .....Oct 2002 Multi-Carrier System Digital Interactive Voice Response 7 System, The New ...... Nov 2002 4 Multi-Carrier System Processing and CMS-1500 Claim 3 Multiple Months Cannot Be Grouped on Claims in MCS ... Oct 2002 4 Ν Names, Potential Truncation of ..... Oct 2002 3

Non-Invasive Evaluation of Extremity Veins: 93965 2nd QTR 2003 Non-Invasive Physiologic Studies of the Upper or Lower	40
Evtremity Arteries: 93922 2nd OTR 2003	39
Extremity Arteries: 93922 2nd QTR 2003 NSF/ANSI Record/Field Changes for MCS, Specific Dec 2002	2
Р	
Patient Name, Address and Gender Information, Require-	
ments for Submitting	6
Nov 2002	4
Payments, Carrier Jurisdiction for Medicare Nov 2002	2
Pegfilgrastim (Neulasta <sup>™</sup> ), Coverage and Billing for 2nd QTR 2003	36
Phone Numbers, Connecticut Medicare	61
Place of Service, Change In Billing the Independent	0.
Diagnostic Testing Facilities (IDTFs) for	2
Policy Changes Related to the 2003 HCPCS Update 2nd QTR 2003	34
Portable X-Ray Equipment and Personnel to a Patient's	0.
Home or Nursing Facility, HCPCS Codes for	
Transportation of	7
Post Transition Issues Log, Multi-Carrier System (MCS) Jan 2003	3
Practitioners Who Are Required To Submit a	-
Date Last SeenOct 2002	5
Pre-Pass Edits, MCS Dec 2002	5 3
Previewâ Treatment Planning Software	36
Professional Association Groups/Clinics, Provider	
Numbers forOct 2002	1
Program Safeguards Contractor for Connecticut, Tri-	
Centurion Selected as 1st QTR 2003	32
Prostate Treatments: 53850	37
Provider Notification of Denials Based on Local Medical	-
Review Policy	36
Provider Numbers for Professional Association Groups/	
Clinics Oct 2002	1
ClinicsOct 2002 Psychiatric Diagnostic Interview Examination: 90801 2nd QTR 2003	38

# Q

Questions and Answers, Frequently Asked	Nov 2002	6
Queener and a new ore, i requering rience		•

#### R

Radiation Physics Consult: 77336 2nd QTR 2003	38
Record/Field Changes for MCS, Specific NSF/ANSI Dec 2002	2
Rejects in the MCS, Avoiding: Special EDI Alert Dec 2002	1
Remittance Advices, Changes to Medicare Checks and Oct 2002	2
Remittance Notices, Anesthesia Units Displayed on Oct 2002	3
Reviews, Telephone Jan 2003	1

#### S

3	
Self Administered Drugs (SAD) List	03 66
Seminars 2003 Medicare Made Easy Seminars On-site	
Training 2nd QTR 20	03 41
Seminars Medicare Education & Outreach Event	
Registration Form	03 43
Seminars Medicare Made Easy Seminars Five-Part	
Series for Part B Providers 2nd QTR 20	03 43
Seminars Medicare Part B Provider Communications	
Advisory Group	03 42

#### Т

•	
Telephone Reviews Jan 2003	1
Therapeutic Radiology Simulation-Aided Field Setting:	
77280	37
Treatment Devices, Design and Construction: 77332 2nd QTR 2003	38
Treprostinil (Remodulin®), Durable Medical Equipment	
Regional Carrier (DMERC) Coverage and Billing of 1st QTR 2003	13
TriCenturion Selected as Program Safeguards Contrac-	
tor for Connecticut 1st QTR 2003	32
U	
Uterine Artery Embolization	68
· · · ·	
W	
Web sites, Connecticut Medicare	61
Widespread Probe Review Results	
88311-88313	26

93922, 93923, 93924 ..... 1st QTR 2003

27

28

# Florida Only

# Α

Α	
Advance Notice Statement	45
	76
4th QTR 2003	78
Ambulance Claims, Changes in Adjudication	04
Procedures for	21 24
Antineoplastic Drugs: J9999	24
2nd QTR 2003	51
Apligraf® (Graftskin): J7340—Policy Retired	51
Arthrocentesis: 20600 1st QTR 2003	25
D	
В	
Basic Radiation Dosimetry Calculation: 77300 2nd QTR 2003	53
Beneficiary and Provider Customer Service Call	
Centers, New Telephone Hours of Operation for the	40
Medicare Parts A & B 1st QTR 2003	40
С	
Calendar of Upcoming Events, Medicare Education and	
Outreach—	45
Claims Delayed but Not Denied or Finalized	40
Clinical Diagnostic Laboratory Services, Retirement of	0
Local Medical Review Policies for Certain 2nd QTR 2003	53
Clinical Laboratory Fees, 2003 Florida Jan 2003*	24
Clinical Psychologists and Clinical Social Workers,	~ .
2003 Fee Schedule for Florida Jan 2003*	21
Comprehensive Data Analysis Article Clarification: 88311	80
Clarification, Additional, 88311, 88312-88314	81
Inappropriate Billing of Lacrimal Duct Procedures	01
Discovered Through Data Analysis 4th QTR 2003	82
Laboratory Procedures	79
Myocardial Perfusion Studies 3rd QTR 2003	78
New and Established Physician Home Visit Services	
to Undergo Widespread Probe of Multiple Providers in Florida: 99341-99350	00
Pulmonary Function Tests	82 80
Skilled Nursing Facility Admissions by Advanced	00
Registered Nurse Practitioners and Physician	
Assistants 4th QTR 2003	83
Computerized Axial Tomography of the Abdomen:	
74150	53
Computerized Tomography Scans: 70450— Correction to Policy	52
Correct Payment of January and February 2003	52
Physician Services	12
Customer Service Call Centers, New Telephone Hours	
of Operation for the Medicare Parts A & B Beneficiary	
and Provider1st QTR 2003	40
D	
	00
Deep Brain Stimulation: 61862 1st QTR 2003 Denials Based on Local Medical Review Policy,	26
Provider Notification of	49
Diabetes Outpatient Self-Management Training:	-10
G0108	50
DMEPOS Fees, 2003 Florida Jan 2003*	28
Duplex Scans, Extracranial, 93880, 93882 4th QTR 2003	81
E	
—	
Extracardiac Arteriography Associated and Billed with	05
Primary Cardiac Catheterizations: 36245 1st QTR 2003	25
Event Recording/24-Hour ECG Monitoring, 93224- 93227, 93230-93237	81
_	01
F	
Faxes, Provide Complete Cover Information on 2nd QTR 2003	44
FDAApprovals, Recent	51
G	
Group Psychotherapy: 90853 2nd QTR 2003	54
	-

н	
Hand Carried Ultrasound (Hand Held Ultrasound) 4th QTR 2003	79
HCPCS Update, Policy Changes Related to the 20032nd QTR 2003 HIV-1 Viral Load Testing: 87536	45 30
l	
I ICD 0 CM Codeo Must Bo Date of San ion Driven	
ICD-9-CM Codes Must Be Date of Service Driven, Annual Updating of	6
Important Addresses, Phone Numbers, And Web Sites – Florida	98
Important Addresses, Phone Numbers, and Web Sites – Florida	99
Incision and Drainage of Abscess of Skin, Subcutaneous	
and Accessory Structures: 10060	24
Independent Diagnostic Testing Facility (IDTF): 00001 1st QTR 2003 Index to Fiscal Year 2002 Florida Medicare B Update! Jan 2003*	24 33
Individual Psychotherapy: 90804	53
Interactive Individual Psychotherapy: 90810	54
Interferon: J9212	23
Intravenous Immune Globulin (IVIG), J1561 1st QTR 2003	22
L	
Laboratory Services, Temporary Suspension of Utilization	
Screens for	21
Corrections	
Clinical Diagnostic Laboratory Services, Retirement	
of Local Medical Review Policies for Certain-	00
Correction	90 90
Individual Psychotherapy: 90804	90 90
Interactive Individual Psychotherapy: 90810	90
New	00
Biopsy of Prostate Using Image Guidance, 55700 4th QTR 2003	84
Bone and/or Joint Imaging: 78300 3rd QTR 2003	85
Comprehensive Motion Analysis: 96000 3rd QTR 2003 Darbepoetin alfa (Aranesp™) (novel erythropoiesis	85
stimulating protein [NESP]), J0880 4th QTR 2003	83
Greater Occipital Nerve Block/Neurolysis, 64405 4th QTR 2003	84
Ibritumomab Tiuxetan (Zevalin <sup>™</sup> ) Therapy: ZEVALIN 3rd QTR 2003	84 84
Iridotomy by Laser Surgery, 66761 4th QTR 2003 Laser Trabeculoplasty, 65855 4th QTR 2003	04 84
Laser Treatment for Psoriasis: 96920	85
Leucovorin (Wellcovorin®): J0640	83
Levocarnitine (Carnitor®, L-carnitine®), J1955 4th QTR 2003	83
Magnetic Resonance Imaging of the Orbit, Face, and Neck, 70540 4th QTR 2003	84
Magnetic Resonance Imaging of Upper Extremity,	-
73218	85
Pegfilgrastim (Neulasta™): J3490	84
Sacroiliac Joint Injections, 27096	83
Specialty Care Transport: A0434	83 85
Surgical Treatment of Ingrown Nails, 11730	83
Ultrasound, Soft Tissues of Head and Neck, 76536. 4th QTR 2003	85
Revised	00
Air Ambulance Services: A0430 3rd QTR 2003	86
Antineoplastic Drugs, J9999 4th QTR 2003	86
Ambulatory Blood Pressure Monitoring, 93784 4th QTR 2003	88
Botulinum Toxin Type A (Botox): J0585 3rd QTR 2003	86
Computed Tomography of the Abdomen, 74150 3rd QTR 2003	89
Computed Tomography of the Pelvis, 72192	87 88
Diabetes Outpatient Self-Management Training (DSMT):	00
G0108	86
	85
Dysphagia/Swallowing Diagnosis and Therapy,	~~
70370	88
Excision of Malignant Skin Lesions, 11600	87
Ground Ambulance Services: A0425	87 86
H-Reflex Study, 95934	88

88 00001 ...... 3rd QTR 2003 87 

Injection of Tendon Sheath, Ligament, Trigger Points,	
or Ganglion Cvst. 20550 4th QTR 2003	87
or Ganglion Cyst, 20550	89
Interferon, J9212	87
Magnetic Resonance Angiography (MRA), 70544 4th QTR 2003	87
Magnetic Resonance Imaging (MRI) of Any Joint of the	•
Lower Extremities, 73721 3rd QTR 2003	89
Magnetic Resonance Imaging of the Brain, 70551 4th QTR 2003	87
Magnetic Resonance Imaging of the Spine, 72141 4th QTR 2003	87
Medical Nutrition Therapy (MNT), 97802 3rd QTR 2003	89
Nerve Conduction Studies, 95900 4th QTR 2003	88
Noncovered Services, The List of Medicare:	
NCSVCS	87
4th QTR 2003 86	
Optical Coherence Biometry, 92136	88
Pegfilgrastim (Neulasta <sup>™</sup> )–formerly J3490, Q4053 4th QTR 2003	86
Peripheral Neuropathy with Loss of Protective	
Sensation (LOPS) in People with Diabetes, G0245 4th QTR 2003	86
Psychiatric Diagnostic Interview Examination, 90801 4th QTR 2003	88
Physical Medicine and Rehabilitation, 97010	89
Protein A Column Apheresis, 36515 3rd QTR 2003	88
Psychiatric Diagnostic Interview Examination, 90801 3rd QTR 2003	89
Scanning Computerized Ophthalmic Diagnostic	
Imaging, 92135 3rd QTR 2003	89
Vitamin D Analogs in Chronic Renal Disease: J0636 3rd QTR 2003	86
Retired	
Insulin Injection: J1820 3rd QTR 2003	90
Nail Excision, 11765 4th QTR 2003	88
Self-Administered Drugs: J0001 3rd QTR 2003	90
Μ	
Medicare Education and Outreach—Calendar of	
Upcoming Events	45
2nd QTR 2003	55
Medicare Education and Outreach Will Hold August	
Medifest in Tampa	89
Medical Review-Table of Contents	76
4th QTR 2003	78
MEDIFEST Class Schedule 4th QTR 2003	89

Replacements: MAHD/ER	
Myocardial Perfusion Imaging: 78460	1st QTR 2003
Myocardial Perfusion Imaging, 78460,	78461,78464,
78465	4th QTR 2003
Ν	
Noncovered Services, the List of Medi	care: NCSVCS 1st QTR 2003

#### Non-Invasive Evaluation of Extremity Veins: 93965 ... 2nd QTR 2003 0 Osteogenic Stimulation: 20974 ..... 1st QTR 2003 Ρ Pamidronate (Aredia®, APD): J2430 ...... 2nd QTR 2003 Part B Mail Directory, Florida Medicare ...... 2nd QTR 2003 Pegfilgrastim (Neulasta<sup>™</sup>), Coverage and Billing for . 2nd QTR 2003 Peripheral Neuropathy with Loss of Protective Sensation (LOPS): G0245 ...... 2nd QTR 2003 Phone Numbers, Florida Medicare ...... 2nd QTR 2003 Physician's Focus, A ..... 1st QTR 2003 2nd QTR 2003 Policy Changes Related to the 2003 HCPCS Update 2nd QTR 2003 Preview Treatment Planning Software Program Safeguards Contractor for Florida, TriCenturion Proper Reporting of Electrocardiac Mapping System . 3rd QTR 2003 Proper Reporting of Quantitative Sensory Testing ...... 3rd QTR 2003 Provider Customer Service Call Center, New Changes Hours of Operation for the Medicare Parts A & B

Beneficiary and ...... 1st QTR 2003

Medifest Registration Form ...... 4th QTR 2003

Metabolically Active Human Dermal/Epidermal

ncare B Opuale! - Fiscal Teal 2003	
Provider Notification of Denials Based on Local Medical Review Policy	49 77
Q	
Qualitative Drug Screen: 80100 2nd QTR 2003	53
R	
Retirement of Local Medical Review Policies for Certain Clinical Diagnostic Laboratory Services 2nd QTR 2003	53
S	
Sedimentation Rate, Erythrocyte: 85651	30 81

Sedimentation Rate, Erythrocyte: 85651	1st QTR 2003	30
Sedimentation Rates, 85651, 85652	4th QTR 2003	81
Self Administered Drugs (SAD) List	3rd QTR 2003	77
Seminars Medifest 2003		55
Seminars Medifest Class Schedule		56
Seminars Medifest Registration Form		57
Strapping: 29540	1st QTR 2003	25
	2nd QTR 2003	52

#### т

90

52

30

81

23 52

54

25

51

62

50

51

62

3

3 45

50

35 77

77

77

52

40

Telephone Hours of Operation for the Medicare Parts A & B Beneficiary and Provider Customer Service	
Call Centers, New	40
77280 2nd QTR 2003	53
TriCenturion Selected as Program Safeguards Contractor for Florida	35
U	
Uterine Artery Embolization	80
V	
Viscosupplementation: VISCO 1st QTR 2003	23
W	
Web Cast Schedule and Registration Information 3rd QTR 2003	90
Web sites, Florida Medicare	62
Widespread Probe Review Results: 11730, 11750, 11765	24
66761	26
70450 1st QTR 2003	27
76375	28
76536 1st QTR 2003	29
78306	29 51
	01

# IMPORTANT ADDRESSES, PHONE NUMBERS, AND WEB SITES

# CONNECTICUT MEDICARE PART B MAIL DIRECTORY

Connecticut Medicare Part B welcomes any questions that you may have regarding the Medicare Part B program. Always be sure to clearly explain your question or concern. This will help our staff to know exactly what issues to address when developing a response to your inquiry.

Please submit your questions to the appropriate department. This will ensure that your concerns are handled in a proper and timely manner. This can be achieved by including an Attention Line below the address on the envelope. Listed below is a directory of departments that includes the issues that you would address to their attention.

With the exception of Reviews and Medicare EDI, please submit all correspondence with the appropriate attention line to:

> Attention: (insert dept name) First Coast Service Options, Inc. Medicare Part B P.O. Box 9000 Meriden, CT 06454-9000

#### Attention: Correspondence

The Correspondence attention line is used for inquiries pertaining to general issues regarding Medicare Part B. Some examples of these issues are deductibles, assignment, and beneficiary address changes. Do not use words such as *REVIEW* or *RECHECK* when sending general correspondence.

#### Attention: Financial Services

Use this attention line to return duplicate payments or overpayment refunds.

#### Attention: Fraud and Abuse

If you encounter what you believe is suspected, potential, or possible fraud or abuse of the Medicare program, we encourage you to contact this department.

#### Attention: Freedom of Information (FOIA)

This department handles requests for information available under the Freedom of Information Act.

#### Attention: Medical Review

Questions regarding Local Medical Review Policies and correct documentation for evaluation and management services are handled by this department. Documentation for off-label chemotherapy use should also be submitted to the Medical Review Department.

#### Attention: MSP

Write to the Medicare Secondary Payer (MSP) department when submitting an Explanation of Benefits from a primary insurance, Exhaust letters from Auto Liability claims, and MSP calculation review requests.

#### Attention: Pricing/ Provider Maintenance

Address your envelope to this department to apply for a new provider number, change a business or billing address of a provider, or to make any changes in the status of a provider. This department also handles fee schedule requests and inquiries, participation requests, and UPIN requests.

#### Attention: Resolutions

Use the Resolutions attention line when inquiring or submitting information regarding dates of death, incorrect Medicare (HIC) numbers, incorrect beneficiary information, etc.

#### Attention: Hearings

If you believe that your review determination was incorrect and want it reviewed by a Hearing Officer, send your inquiry to the attention of the Hearing Department. A request for a hearing must be made within six months of the date of the Review Department determination and at least \$100.00 must remain in controversy from this decision.

#### MAILING ADDRESS EXCEPTIONS

We have established special P.O. boxes to use when mailing your review requests, or to contact Medicare EDI:

#### Attention: Review

Please mail only your requests for reviews to this P.O. Box. *DO NOT* send new claims, general correspondence, hearings, or other documents to this location; doing so will cause a delay in the processing of that item. This P.O. Box is only for appeals.

If you believe the payment or determination is incorrect and want a claim to be reconsidered, then send it to the attention of the review department. Requests for review must be made within 120 days of the date of the Medicare Summary Notice. These requests should not include review requests on Medicare Secondary Pay calculations. Claims that are denied for return/reject need to be resubmitted and should not be sent as a review. These resubmitted claims should be sent in as new claims.

#### Post Office Box for Reviews:

Attention: Appeals First Coast Service Options, Inc. P.O. Box C-1016 Meriden, CT 06450-1016

#### Attention: EDI

The Electronic Data Interchange department handles questions and provides information on electronic claims submission (EMC).

#### Post Office Box for EDI:

Attention: CT Medicare EDI First Coast Service Options, Inc. P.O. Box 44071 Jacksonville, FL 32231-4071

# CONNECTICUT MEDICARE PHONE NUMBERS

Provider Services First Coast Service Options, Inc. Medicare Part B 1-866-419-9455 (toll-free)

Beneficiary Services First Coast Service Options, Inc. Medicare Part B 1-800-982-6819 (toll-free) 1-866-359-3614 (hearing impaired)

#### Electronic Data Interchange (EDI) Enrollment

1-203-639-3160, option 1

PC-ACE® PRO-32 1-203-639-3160, option 2

Marketing and Reject Report Issues 1-203-639-3160, option 4

Format, Testing, and Remittance Issues 1-203-639-3160, option 5

Electronic Funds Transfer Information 1-203-639-3219

#### Hospital Services

Empire Medicare Services Medicare Part A 1-800-442-8430

#### **Durable Medical Equipment**

HealthNow NY DMERC Medicare Part B 1-800-842-2052

#### Railroad Retirees

Palmetto GBA Medicare Part B 1-800-833-4455

#### Quality of Care

Peer Review Organization 1-800-553-7590

### OTHER HELPFUL NUMBERS

Social Security Administration 1-800-772-1213

American Association of Retired Persons (AARP) 1-800-523-5800

**To Report Lost or Stolen Medicare Cards** 1-800-772-1213

Health Insurance Counseling Program 1-800-994-9422

Area Agency on Aging 1-800-994-9422

Department of Social Services/ConnMap 1-800-842-1508

ConnPace/ Assistance with Prescription Drugs 1-800-423-5026

# WEB SITES

PROVIDER Connecticut www.connecticutmedicare.com Centers for Medicare & Medicaid Services www.cms.hhs.gov

BENEFICIARY Connecticut www.connecticutmedicare.com

Centers for Medicare & Medicaid Services www.medicare.gov

# IMPORTANT ADDRESSES, PHONE NUMBERS, AND WEB SITES

# FLORIDA MEDICARE PART B MAIL DIRECTORY

**CLAIMS SUBMISSIONS Routine Paper Claims** Medicare Part B P. O. Box 2525 Jacksonville, FL 32231-0019 **Participating Providers** Medicare Part B Participating Providers P. O. Box 44117 Jacksonville, FL 32231-4117 **Chiropractic Claims** Medicare Part B Chiropractic Unit P. O. Box 44067 Jacksonville, FL 32231-4067 Ambulance Claims Medicare Part B Ambulance Dept. P. O. Box 44099 Jacksonville, FL 32231-4099 Medicare Secondary Payer Medicare Part B Secondary Payer Dept. P. O. Box 44078 Jacksonville, FL 32231-4078 ESRD Claims Medicare Part B ESRD Claims P. O. Box 45236 Jacksonville, FL 32232-5236

**COMMUNICATIONS Review Requests** Medicare Part B Claims Review P. O. Box 2360 Jacksonville, FL 32231-0018 Fair Hearing Requests Medicare Part B Fair Hearings P. O. Box 45156 Jacksonville, FL 32232-5156 Administrative Law Judge Hearing Administrative Law Judge Hearing P. O. Box 45001 Jacksonville, FL 32232-5001 **Status/General Inquiries** Medicare Part B Correspondence P. O. Box 2360 Jacksonville, FL 32231-0018 **Overpayments** Medicare Part B Financial Services P. O. Box 44141 Jacksonville, FL 32231-4141

DURABLE MEDICAL EQUIPMENT (DME) DME, Orthotic or Prosthetic Claims Palmetto GBA Medicare DMERC Operations P. O. Box 100141 Columbia, SC 29202-3141

**ELECTRONIC MEDIA CLAIMS (EMC) EMC Claims, Agreements and Inquiries** Medicare EDI P. O. Box 44071 Jacksonville, FL 32231-4071 MEDICARE PART B ADDITIONAL DEVELOPMENT Within 40 days of initial request: Medicare Part B Claims P. O. Box 2537 Jacksonville, FL 32231-0020

Over 40 days of initial request: Submit the charge(s) in question, including information requested, as you would a new claim, to: Medicare Part B Claims P. O. Box 2525 Jacksonville, FL 32231-0019

MISCELLANEOUS

Provider Participation and Group Membership Issues; Written Requests for UPINs, Profiles & Fee Schedules: Medicare Registration P. O. Box 44021 Jacksonville, FL 32231-4021

**Provider Change of Address:** 

Medicare Registration P. O. Box 44021 Jacksonville, FL 32231-4021 *and* Provider Registration Department Blue Cross Blue Shield of Florida P. O. Box 41109 Jacksonville, FL 32203-1109

Provider Education: For Educational Purposes and Review of Customary/Prevailing Charges or Fee Schedule: Medicare Part B Medicare Communication and Education P. O. Box 2078 Jacksonville, FL 32231-0048 For Seminar Registration: Medicare Part B Medicare Education and Outreach P. O. Box 45157 Jacksonville, FL 32232-5157

Limiting Charge Issues: For Processing Errors: Medicare Part B P. O. Box 2360 Jacksonville, FL 32231-0048 For Refund Verification: Medicare Part B Compliance Monitoring P. O. Box 2078 Jacksonville, FL 32231-0048

Medicare Claims for Railroad Retirees: MetraHealth RRB Medicare P. O. Box 10066 Augusta, GA 30999-0001

Fraud and Abuse First Coast Service Options, Inc. P. O. Box 45087 Jacksonville, FL 32232-5087

#### FLORIDA MEDICARE PHONE NUMBERS BENEFICIARY

Toll-Free: 1-800-333-7586 Hearing Impaired: 1-800-754-7820

**Note:** The toll-free customer service lines are reserved for Medicare beneficiaries only. Use of this line by providers is not permitted and may be considered program abuse.

#### PROVIDERS

Toll-Free Customer Service: 1-866-454-9007 Interactive Voice Response (IVR): 1-877-847-4992

**For Seminar Registration Only** (*not* toll-free): 1-904-791-8103

ЕМС

Format Issues & Testing: 1-904-354-5977 option 4 Start-Up & Front-End Edits/Rejects: 1-904-791-8767 option 1 Electronic Funds Transfer 1-904-791-8016 Electronic Remittance Advice, Electronic Claim Status, & Electronic Eligibility: 1-904-791-6895 **PC-ACE Support:** 1-904-355-0313 Marketing: 1-904-791-8767 option 1 New Installations: (new electronic senders; change of address or phone number for senders): 1-904-791-8608 Help Desk: (Confirmation/Transmission):

1-904-905-8880 option 1

Printer Specifications/Test Claims: 1-904-791-8132

DME, Orthotic or Prosthetic Claims Palmetto GBA Medicare 1-803-735-1034

**MEDICARE PART A Toll-Free:** 1-877-602-8816

# WEB SITES

PROVIDER Florida www.floridamedicare.com

Centers for Medicare & Medicaid Services www.cms.hhs.gov

BENEFICIARY

Florida www.medicarefla.com

Centers for Medicare & Medicaid Services www.medicare.gov

# Medicare B Update!

FIRST COAST SERVICE OPTIONS, INC. P.O. BOX 2078 JACKSONVILLE, FL 32231-0048 P.O. BOX 9000 MERIDEN, CT 06454-9000

\* ATTENTION BILLING MANAGER \*